



(11) **EP 2 236 614 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
06.10.2010 Bulletin 2010/40

(51) Int Cl.:
C12Q 1/00 ^(2006.01) **C12Q 1/68** ^(2006.01)
C12Q 1/70 ^(2006.01) **G01N 33/53** ^(2006.01)
G01N 33/567 ^(2006.01) **G01N 33/569** ^(2006.01)

(21) Application number: **10168014.8**

(22) Date of filing: **15.08.2003**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **15.08.2002 US 403390 P**
01.04.2003 US 458978 P

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
03788531.6 / 1 576 131

(71) Applicants:
• **GENZYME CORPORATION**
Framingham,
Massachusetts 01701 (US)
• **The John Hopkins University**
Baltimore MD 21201 (US)

(72) Inventors:
• **Madden, Stephen**
Sudbury, MA 01776 (US)

- **Wang, Clarence**
Arlington, MA 02474 (US)
- **Cook, Brian**
Northboro, MA 01532 (US)
- **Lattera, John**
Baltimore, MA 21201 (US)
- **Walter, Kevin**
Pittsburgh, PA 15213 (US)

(74) Representative: **Wallis, Naomi Rachel et al**
Withers & Rogers LLP
Goldings House
2 Hays Lane
London
SE1 2HW (GB)

Remarks:

This application was filed on 30-06-2010 as a
divisional application to the application mentioned
under INID code 62.

(54) **Brain endothelial cell expression patterns**

(57) To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-

derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

EP 2 236 614 A2

Description

[0001] This application claims the benefit of provisional applications serial numbers 60/403,390 filed August 15, 2002 and 60/458,978 filed April 1, 2003. The disclosures of each are expressly incorporated herein.

TECHNICAL FIELD OF THE INVENTION

[0002] This invention is related to the area of angiogenesis and anti-angiogenesis. In particular, it relates to genes which are characteristically expressed in brain glioma endothelial cells.

BACKGROUND OF THE INVENTION

[0003] Brain cancers represent an infrequent but deadly form of cancer that has seen little improvement in survivability over the last 30 years. Tumor excision followed by therapies relying on outdated cytotoxins and radiation inevitably results in a diminished quality of life. Gliomas represent the most common brain neoplasms with highly vascular and invasive characteristics defining gliomas as one of the most aggressive tumors known. Classifications of gliomas derive from both the cellular origin and staged aggressiveness. Derived from either astrocytes or oligodendrocytes, astrocytomas and oligodendrogliomas constitute the most common types of gliomas. As is common to other tumor type classifications, glioma increases in aggressiveness from the first to third stages of disease with stage IV, glioblastoma multiforme, being the most aggressive. Moreover, glioblastoma tumors constitute one of the most vascular tumors known.

[0004] Vascular permeability within the brain is limited in comparison to other organs. Similarly, the accessibility of brain malignancies to immune surveillance was thought to be restricted as well although more recent evidence suggests the brain is not wholly immunologically privileged. This so called "blood-brain barrier" is thought to derive primarily from a combination of brain-specific capillary transport systems and astrocyte-regulated cross-talk with the endothelial cell-based vasculature (for reviews, see Bart, J., Groen, H. J., Hendrikse, N. H., van der Graaf, W. T., Vaalburg, W., and de Vries, E. G. (2000). The blood-brain barrier and oncology: new insights into function and modulation. *Cancer Treat Rev* 26, 449-62.) The presence of tight junctions and an observed high electrical resistance both contribute to restricted transvascular molecular exchange. The existence of a therapeutically impermeable vasculature has resulted in a comparatively limited amount of work aimed at intervening in brain malignancies and other CNS diseases. Defining proteins preferentially expressed on either normal or diseased brain endothelial cells holds promise for expanding CNS therapeutic regimens.

[0005] The vascular microenvironment within gliomas has been studied primarily through morphological, circulatory and perfusion based experiments (for review see Vajkoczy, P., and Menger, M. D. (2000). Vascular microenvironment in gliomas. *J Neurooncol* 50, 99-108; and Bart, J., Groen, H. J., Hendrikse, N. H., van der Graaf, W. T., Vaalburg, W., and de Vries, E. G. (2000). The blood-brain barrier and oncology: new insights into function and modulation. *Cancer Treat Rev* 26, 449-62.) These studies demonstrate profound changes in vasculature architecture associated with tumor progression. Increased fenestrations, malperfusion, hyperpermeability, and reduced leukocyte-EC interaction are all phenotypic observations linked to glioma microvasculature Bernsen, H. J., Rijken, P. F., Oostendorp, T., and van der Kogel, A. J. (1995). Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. *Br J Cancer* 71, 721-6; Vick, N. A., and Bigner, D. D. (1972). Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. *J Neurol Sci* 17, 29-39; and Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., and Jain, R. K. (1998). Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci U S A* 95, 4607-12. It is also suggested that higher grade gliomas utilize intussusceptive capillary growth to a much larger degree than earlier staged gliomas that primarily utilize both sprouting and cooption to advance vessel growth. Vajkoczy, P., Schilling, L., Ullrich, A., Schmiedek, P., and Menger, M. D. (1998). Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. *J Cereb Blood Flow Metab* 18, 510-20. The molecular characterization of glioma ECs has thus far been limited to the evaluation of common growth factors or previously defined brain EC transporters. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., and Wiegand, S. J. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. *Science* 284, 1994-8; Guerin, C., Wolff, J. E., Larterra, J., Drewes, L. R., Brem, H., and Goldstein, G. W. (1992). Vascular differentiation and glucose transporter expression in rat gliomas: effects of steroids. *Ann Neurol* 31, 481-7.

[0006] To date, global gene expression profiles from endothelial cell-specific populations is limited to normal and tumorigenic colon tissue. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. (2000). Genes expressed in human tumor endothelium. *Science* 289, 1197-202.

There is a need in the art for analysis of endothelial cells from other tissue, so that diagnostic and therapeutic for non-colonic tumors can be developed.

SUMMARY OF THE INVENTION

[0007] According to one embodiment of the invention a method is provided to aid in diagnosing glioma. An expression product of at least one gene in a first brain tissue sample suspected of being neoplastic is detected. The at least one gene is selected from the group consisting of signal sequence receptor, delta (translocon-associated protein delta); DC2 protein; KIAA0404 protein; symplekin; Huntingtin interacting protein I; plasmalemma vesicle associated protein; KIAA0726 gene product; latexin protein; transforming growth factor, beta 1; hypothetical protein FLJ22215; Rag C protein; hypothetical protein FLJ23471; N-myristoyltransferase 1; hypothetical protein dJ1181N3.1; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonectin); Hs 111988; Hs 112238; laminin, alpha 5; protective protein for beta-galactosidase (galactosialidosis); Melanoma associated gene; Melanoma associated gene; E3 ubiquitin ligase SMURF1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; gene predicted from cDNA with a complete coding sequence; Thy-1 cell surface antigen; Hs 127824; GTP binding protein 2; Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918); cutaneous T-cell lymphoma-associated tumor antigen se20-4; differentially expressed nucleolar TGF-beta1 target protein (DENTT); dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); smoothelin; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); putative translation initiation factor; retinoic acid induced 14; matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase); Lutheran blood group (Auberger b antigen included); stanniocalcin 2; nuclear factor (erythroid-derived 2)-like 2; protein tyrosine phosphatase, non-receptor type 1; integrin, alpha 10; collagen, type VI, alpha 2; chromosome 21 open reading frame 25; CDC37 (cell division cycle 37, *S. cerevisiae*, homolog); Hs 16450; Rho guanine nucleotide exchange factor (GEF) 7; creatine kinase, brain; hypothetical protein FLJ10297; hypothetical protein FLJ10350; TNF-induced protein; tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein); cofilin 1 (non-muscle); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); v-ets avian erythroblastosis virus E26 oncogene homolog 1; protease, cysteine, 1 (legumain); ribosomal protein L13; chromosome 22 open reading frame 5; zinc finger protein 144 (Mel-18); degenerative spermatocyte (homolog *Drosophila*; lipid desaturase); eukaryotic translation initiation factor 2C, 2; mitochondrial ribosomal protein L45; prostate tumor over expressed gene 1; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a); glioma endothelial marker 1 precursor; NS1-binding protein; ribosomal protein L38; tuftelin-interacting protein; HLA class II region expressed gene KE2; translocase of inner mitochondrial membrane 17 homolog A (yeast); sudD (suppressor of bimD6, *Aspergillus nidulans*) homolog; heparan sulfate proteoglycan 2 (perlecan); SEC24 (*S. cerevisiae*) related gene family, member A; NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase); DNA segment on chromosome X and Y (unique) 155 expressed sequence; annexin A2; Homo sapiens clone 24670 mRNA sequence; hypothetical protein; matrix metalloproteinase 10 (stromelysin 2); KIAA1049 protein; G protein-coupled receptor; hypothetical protein FLJ20401; matrix metalloproteinase 14 (membrane-inserted); KIAA0470 gene product; solute carrier family 29 (nucleoside transporters), member 1; stanniocalcin 1; stanniocalcin 1; stanniocalcin 1; tumor suppressor deleted in oral cancer-related 1; tumor suppressor deleted in oral cancer-related 1; apolipoprotein C-I; glutathione peroxidase 4 (phospholipid hydroperoxidase); Hs 272106; transcription factor binding to IGHM enhancer 3; hypothetical protein DKFZp762A227; hypothetical protein FLJ22362; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); PRO0628 protein; melanoma-associated antigen recognised by cytotoxic T lymphocytes; LOC88745; Homo sapiens beta-1,3-galactosyltransferase-6 (B3GALT6) mRNA, complete cds; sprouty (*Drosophila*) homolog 4; sprouty (*Drosophila*) homolog 4; Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone DKFZp434E1515); coactosin-like protein; hypothetical protein FLJ21865; Hs296234; KIAA0685 gene product; hypothetical protein FLJ10980; ribosomal protein L10; ribosomal protein S19; Hs 299251; Huntingtin interacting protein K; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 50374; Hs 311780; Hs 212191; v-akt murine thymoma viral oncogene homolog 2; Hs 328774; transducin-like enhancer of split 2, homolog of *Drosophila* E(sp1); KIAA1870 protein; ribosomal protein L10a; peptidylprolyl isomerase A (cyclophilin A); Hs 344224; hypothetical protein FLJ23239; hypothetical protein DKFZp761H221; KIAA1887 protein; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 701679; Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453; Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035904; hypothetical protein LOC57333; myosin ID; plexin B2; lectin, galactoside-binding, soluble, 8 (galectin 8); double ring-finger protein, Dorfin; DKFZP434B168 protein; LIM domain binding 2; integrin beta 4 binding protein; synaptopodin; Hs 54828; insulin induced gene 1; acetyl LDL receptor; SREC; excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); hypothetical protein FLJ22329; schwannomin-interacting protein 1; PTEN induced putative kinase 1; myosin X; Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97; golgi phosphoprotein 1; splicing factor, arginine/serine-rich 6; laminin, gamma 3; cysteine-rich protein 2; U6 snRNA-associated Sm-like protein LSM7; hypothetical protein FLJ10707; Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene, clone IMAGE:3342825, mRNA, partial cds; macrophage migration inhibitory factor (glycosylation-inhibiting factor); ubiquinol-cytochrome c re-

ductase hinge protein; gap junction protein, alpha 1, 43kD (connexin 43); dihydropyrimidinase-like 3; aquaporin 1 (channel-forming integral protein, 28kD); protein expressed in thyroid; macrophage myristoylated alanine-rich C kinase substrate; procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI); protease, serine, 11 (IGF binding); 24-dehydrocholesterol reductase; collagen, type IV, alpha 2; profilin 1; apolipoprotein D; hyaluronoglucosaminidase 2; hypothetical protein FLJ22678; quiescin Q6; ras homolog gene family, member A; ras homolog gene family, member A; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; uridine phosphorylase; KIAA0638 protein; B7 homolog 3; lamin A/C; lamin A/C; lamin A/C; regulator of G-protein signalling 12; proteasome (prosome, macropain) 26S subunit, non-ATPase, 8; Homo sapiens, Similar to RIKEN cDNA 5730528L13 gene, clone MGC:17337 IMAGE:4213591, mRNA, complete cds; prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy); laminin, alpha 4; transcription elongation factor A (SII), 1; lectin, galactoside-binding, soluble, 3 binding protein; ribosomal protein 516; glycophorin C (Gerbich blood group); endothelin receptor type B; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; small nuclear ribonucleoprotein polypeptide B"; transmembrane 4 superfamily member 2; TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD; lysyl oxidase-like 2; SRY (sex determining region Y)-box 4; SOX4 SRY (sex determining region Y)-box 4; SRY (sex determining region Y)-box 4; actin related protein 2/3 complex, subunit 2 (34 kD); Homo sapiens cDNA: FLJ23507 fis, clone LNG03128; hypothetical protein FLJ12442; Fas (TNFRSF6)-associated via death domain; mitogen-activated protein kinase kinase kinase 11; TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); insulin receptor; cell membrane glycoprotein, 110000M(r) (surface antigen); Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926; jagged 1 (Alagille syndrome); KIAA0304 gene product; pre-B-cell leukemia transcription factor 2; Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864; p53-induced protein; complement component 1, q subcomponent, receptor 1; complement component 1, q subcomponent, receptor 1; apolipoprotein E; chemokine (C-C motif) ligand 3; coagulation factor II (thrombin) receptor-like 3; coagulation factor III (thromboplastin, tissue factor); collagen, type I, alpha 1; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 9; cystatin C (amyloid angiopathy and cerebral hemorrhage); endoplasmic reticulum associated protein 140 kDa; ESTs; ESTs; ESTs, Highly similar to hypothetical protein FLJ10350 [Homo sapiens] [H.sapiens]; ESTs, Highly similar to ITB1_HUMAN Integrin beta-1 precursor (Fibronectin receptor beta subunit) (CD29) (Integrin VLA-4 beta subunit) [H.sapiens]; ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]; ESTs, Weakly similar to T17346 hypothetical protein DKFZp586O1624.1 - human (fragment) [H.sapiens]; ESTs, Weakly similar to T21371 hypothetical protein F25H8.3 - Caenorhabditis elegans [C.elegans]; eukaryotic translation initiation factor 4A, isoform 1; heme oxygenase (decycling) 1; Hermansky-Pudlak syndrome 4; Homo sapiens cDNA FLJ34888 fis, clone NT2NE2017332; Homo sapiens cDNA FLJ39848 fis, clone SPLEN2014669; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059; Homo sapiens, clone IMAGE:4845226, mRNA; hypothetical protein FLJ22329; hypothetical protein FLJ32205; hypothetical protein MGC4677; inhibin, beta B (activin AB beta polypeptide); insulin-like growth factor binding protein 5; junction plakoglobin; KIAA0620 protein; KIAA0943 protein; likely ortholog of rat vacuole membrane protein 1; Lysosomal-associated multispinning membrane protein-5; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; matrix Gla protein; matrix metalloproteinase 1 (interstitial collagenase); microtubule-associated protein 1 light chain 3 beta; nerve growth factor receptor (TNFR superfamily, member 16); ribosomal protein S9; ring finger protein 40; 5100 calcium binding protein, beta (neural); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B; SPARC-like 1 (mast9, hevin); tumor necrosis factor, alpha-induced protein 3; UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5; von Willebrand factor; v-akt murine thymoma viral oncogene homolog 2; cyclin-dependent kinase (cdc2-like) 10; ortholog mouse myocytic induction/differentiation originator; brain-specific angiogenesis inhibitor 1; EGF-TM7 latrophilin-related protein; sema domain; integrin, alpha 5; likely ortholog of mouse fibronectin type III; Lutheran blood group (Auberger b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16); insulin-like growth factor binding protein; leukemia inhibitory factor; protein tyrosine phosphatase, nonreceptor type I;

and Homo sapiens, clone IMAGE:3908182, mRNA, partial cds. Expression of the at least one gene in the first brain tissue sample is compared to expression of the at least one gene in a second brain tissue sample which is normal. Increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample identifies the first brain tissue sample as likely to be neoplastic.

According to another embodiment of the invention a method is provided of treating a glioma. Cells of the glioma are contacted with an antibody. The antibody specifically binds to an extracellular epitope of a protein selected from the group consisting of plasmalemma associated protein; KIAA0726 gene product; osteonectin; laminin, alpha 5; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; Thy-1 cell surface antigen; dysferlin, limb girdle muscular dystrophy 2B; integrin, alpha 5; matrix metalloproteinase 9; Luthjheran blood group, integrin, alpha 10, collagen, type VI, alpha 2; glioma endothelial marker 1 precursor; translocase of inner mitochondrial membrane 17 homolog A; heparan sulfate proteoglycan 2; annexin A2; matrix metalloproteinase 10; G protein-coupled receptor; matrix metalloproteinase

14; solute carrier family 29, member 1; CD59 antigen p18-20; KIAA 1870 protein; plexin B2; lectin, galactoside-binding, soluble, 8; integrin beta 4 binding protein; acetyl LDL receptor; laminin, gamma 3; macrophage migration inhibitory factor; gap junction protein, alpha 1, 43 kD; aquaporin 1; protease, serine, 11; collagen, type IV, alpha 2; apolipoprotein D; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; regulator of G-protein signaling 12; prosaposin; laminin, alpha 4; lectin, galactoside-binding, soluble, 3 binding protein; glycophorin C; endothelin receptor type B; biglycan; transmembrane 4 superfamily member 2; lysyl oxidase-like 2; TEK tyrosine kinase, endothelial; insulin receptor; cell membrane glycoprotein, 110000M(r); jagged 1; plasmalemma vesicle associated protein; TEM13, Thy-1 cell surface antigen; coagulation factor II (thrombin) receptor-like 3; dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); likely ortholog of rat vacuole membrane protein 1; nerve growth factor receptor (TNFR superfamily, member 16); degenerative spermatocyte homolog, lipid desaturase (Drosophila); TEM1, endosialin; heme oxygenase (decycling) 1; G protein-coupled receptor; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 9; matrix metalloproteinase 14 (membrane-inserted); solute carrier family 29 (nucleoside transporters), member 1; likely ortholog of mouse embryonic epithelial gene 1; major histocompatibility complex, class I, C; likely ortholog of mouse fibronectin type III repeat containing protein 1; sprouty homolog 4 (Drosophila); KIAA0620 protein; coagulation factor III (thromboplastin, tissue factor); aquaporin 1 (channel-forming integral protein, 28kDa); major histocompatibility complex, class I, B; Lysosomal-associated multispinning membrane protein-5; endothelin receptor type B; insulin receptor; complement component 1, q subcomponent, receptor 1; brain-specific angiogenesis inhibitor 1; EGF-TM7 latrophilin-related protein; sema domain; integrin, alpha 5; likely ortholog of mouse fibronectin type III; Lutheran blood group (Auberger b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16) and complement component 1, q subcomponent, receptor 1. Immune destruction of cells of the glioma is thereby triggered.

[0008] According to still another embodiment of the invention a method is provided for identifying a test compound as a potential anti-cancer or anti-glioma drug. A test compound is contacted with a cell which expresses at least one gene selected from the group consisting of: signal sequence receptor, delta (translocon-associated protein delta); DC2 protein; KIAA0404 protein; symplekin; Huntingtin interacting protein I; plasmalemma vesicle associated protein; KIAA0726 gene product; latexin protein; transforming growth factor, beta 1; hypothetical protein FLJ22215; Rag C protein; hypothetical protein FLJ23471; N-myristoyltransferase 1; hypothetical protein dJ1181N3.1; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonectin); Hs 111988; Hs 112238; laminin, alpha 5; protective protein for beta-galactosidase (galactosialidosis); Melanoma associated gene; Melanoma associated gene; E3 ubiquitin ligase SMURF1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; gene predicted from cDNA with a complete coding sequence; Thy-1 cell surface antigen; Hs 127824; GTP binding protein 2; Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918); cutaneous T-cell lymphoma-associated tumor antigen se20-4; differentially expressed nucleolar TGF-beta1 target protein (DENTT); dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); smoothelin; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); putative translation initiation factor; retinoic acid induced 14; matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase); Lutheran blood group (Auberger b antigen included); stanniocalcin 2; nuclear factor (erythroid-derived 2)-like 2; protein tyrosine phosphatase, non-receptor type 1; integrin, alpha 10; collagen, type VI, alpha 2; chromosome 21 open reading frame 25; CDC37 (cell division cycle 37, *S. cerevisiae*, homolog); Hs 16450; Rho guanine nucleotide exchange factor (GEF) 7; creatine kinase, brain; hypothetical protein FLJ10297; hypothetical protein FLJ10350; TNF-induced protein; tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein); cofilin 1 (non-muscle); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); v-ets avian erythroblastosis virus E26 oncogene homolog 1; protease, cysteine, 1 (legumain); ribosomal protein L13; chromosome 22 open reading frame 5; zinc finger protein 144 (Mel-18); degenerative spermatocyte (homolog *Drosophila*; lipid desaturase); eukaryotic translation initiation factor 2C, 2; mitochondrial ribosomal protein L45; prostate tumor over expressed gene 1; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a); glioma endothelial marker 1 precursor; NS1-binding protein; ribosomal protein L38; tuftelin-interacting protein; HLA class II region expressed gene KE2; translocase of inner mitochondrial membrane 17 homolog A (yeast); sudD (suppressor of bimD6, *Aspergillus nidulans*) homolog; heparan sulfate proteoglycan 2 (perlecan); SEC24 (*S. cerevisiae*) related gene family, member A; NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase); DNA segment on chromosome X and Y (unique) 155 expressed sequence; annexin A2; Homo sapiens clone 24670 mRNA sequence; hypothetical protein; matrix metalloproteinase 10 (stromelysin 2); KIAA1049 protein; G protein-coupled receptor; hypothetical protein FLJ20401; matrix metalloproteinase 14 (membrane-inserted); KIAA0470 gene product; solute carrier family 29 (nucleoside transporters), member 1; stanniocalcin 1; stanniocalcin 1; stanniocalcin 1; tumor suppressor deleted in oral cancer-related 1; tumor suppressor deleted in oral cancer-related 1; apolipoprotein C-I; glutathione peroxidase 4 (phospholipid hydroperoxidase); Hs 272106; transcription factor binding to IGHM enhancer 3; hypothetical protein DKFZp762A227; hypothetical protein FLJ22362; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30,

EL32 and G344); PRO0628 protein; melanoma-associated antigen recognised by cytotoxic T lymphocytes; LOC88745; Homo sapiens beta-1,3-galactosyltransferase-6 (B3GALT6) mRNA, complete cds; sprouty (Drosophila) homolog 4; sprouty (Drosophila) homolog 4; Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone DKFZp434E1515); coactosin-like protein; hypothetical protein FLJ21865; Hs296234; KIAA0685 gene product; hypothetical protein FLJ10980; 5 ribosomal protein L10; ribosomal protein S19; Hs 299251; Huntingtin interacting protein K; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 50374; Hs 311780; Hs 212191; v-akt murine thymoma viral oncogene homolog 2; Hs 328774; transducin-like enhancer of split 2, homolog of Drosophila E(spl); KIAA1870 protein; ribosomal protein L10a; peptidylprolyl isomerase A (cyclophilin A); Hs 344224; hypothetical protein FLJ23239; hypothetical protein DKFZp761H221; KIAA1887 protein; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 701679; Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453; Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035904; 10 hypothetical protein LOC57333; myosin ID; plexin B2; lectin, galactoside-binding, soluble, 8 (galectin 8); double ring-finger protein, Dorfin; DKFZP434B168 protein; LIM domain binding 2; integrin beta 4 binding protein; synaptopodin; Hs 54828; insulin induced gene 1; acetyl LDL receptor; SREC; excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); hypothetical protein FLJ22329; schwannomin-interacting protein 1; PTEN induced putative kinase 1; myosin X; Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97; golgi phosphoprotein 1; splicing factor, arginine/serine-rich 6; laminin, gamma 3; cysteine-rich protein 2; U6 snRNA-associated Sm-like protein LSM7; 20 hypothetical protein FLJ10707; Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene, clone IMAGE:3342825, mRNA, partial cds; macrophage migration inhibitory factor (glycosylation-inhibiting factor); ubiquinol-cytochrome c reductase hinge protein; gap junction protein, alpha 1, 43kD (connexin 43); dihydropyrimidinase-like 3; aquaporin 1 (channel-forming integral protein, 28kD); protein expressed in thyroid; macrophage myristoylated alanine-rich C kinase substrate; procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI); protease, serine, 11 (IGF binding); 24-dehydrocholesterol reductase; collagen, type IV, alpha 2; profilin 1; apolipoprotein 25 D; hyaluronoglucosaminidase 2; hypothetical protein FLJ22678; quiescin Q6; ras homolog gene family, member A; ras homolog gene family, member A; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; uridine phosphorylase; KIAA0638 protein; B7 homolog 3; lamin A/C; lamin A/C; lamin A/C; regulator of G-protein signalling 12; proteasome (prosome, macropain) 26S subunit, non-ATPase, 8; Homo sapiens, Similar to RIKEN cDNA 5730528L13 gene, clone MGC:17337 IMAGE:4213591, mRNA, complete cds; prosaposin (variant Gaucher disease and variant 30 metachromatic leukodystrophy); laminin, alpha 4; transcription elongation factor A (SII), 1; lectin, galactoside-binding, soluble, 3 binding protein; ribosomal protein S16; glycophorin C (Gerbich blood group); endothelin receptor type B; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; small nuclear ribonucleoprotein polypeptide B"; transmembrane 4 superfamily member 2; TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD; lysyl oxidase-like 2; SRY (sex determining region Y)-box 4; 35 SOX4 SRY (sex determining region Y)-box 4; SRY (sex determining region Y)-box 4; actin related protein 2/3 complex, subunit 2 (34 kD); Homo sapiens cDNA: FLJ23507 fis, clone LNG03128; hypothetical protein FLJ12442; Fas (TNFRSF6)-associated via death domain; mitogen-activated protein kinase kinase kinase 11; TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); insulin receptor; cell membrane glycoprotein, 110000M(r) (surface antigen); Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926; jagged 1 (Alagille syndrome); 40 KIAA0304 gene product; pre-B-cell leukemia transcription factor 2; Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864; p53-induced protein; complement component 1, q subcomponent, receptor 1; complement component 1, q subcomponent, receptor 1; apolipoprotein E; chemokine (C-C motif) ligand 3; coagulation factor II (thrombin) receptor-like 3; coagulation factor III (thromboplastin, tissue factor); collagen, type I, alpha 1; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); C-type (calcium dependent, carbohydrate-recognition domain) lectin, 45 superfamily member 9; cystatin C (amyloid angiopathy and cerebral hemorrhage); endoplasmic reticulum associated protein 140 kDa; ESTs; ESTs; ESTs, Highly similar to hypothetical protein FLJ10350 [Homo sapiens] [H.sapiens]; ESTs, Highly similar to ITB1_HUMAN Integrin beta-1 precursor (Fibronectin receptor beta subunit) (CD29) (Integrin VLA-4 beta subunit) [H.sapiens]; ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]; ESTs, Weakly similar to T17346 hypothetical protein DKFZp586O1624.1 - human (fragment) [H.sapiens]; ESTs, Weakly similar 50 to T21371 hypothetical protein F25H8.3 - Caenorhabditis elegans [C.elegans]; eukaryotic translation initiation factor 4A, isoform 1; heme oxygenase (decycling) 1; Hermansky-Pudlak syndrome 4; Homo sapiens cDNA FLJ34888 fis, clone NT2NE2017332; Homo sapiens cDNA FLJ39848 fis, clone SPLEN2014669; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059; Homo sapiens, clone IMAGE:4845226, mRNA; hypothetical protein FLJ22329; hypothetical protein FLJ32205; hypothetical protein MGC4677; inhibin, beta B (activin AB beta polypeptide); insulin-like growth factor binding protein 5; junction plakoglobin; KIAA0620 protein; KIAA0943 protein; likely ortholog of rat vacuole membrane protein 1; Lysosomal-associated multispinning membrane protein-5; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; matrix Gla protein; matrix metalloproteinase 1 (interstitial collagenase); microtubule-associated protein 1 light chain 3 beta; nerve growth factor receptor (TNFR superfamily, member 16);

ribosomal protein S9; ring finger protein 40; S100 calcium binding protein, beta (neural); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B; SPARC-like 1 (mast9, hevin); tumor necrosis factor, alpha-induced protein 3; UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5; von Willebrand factor; v-akt murine thymoma viral oncogene homolog 2; cyclin-dependent kinase (cdc2-like) 10; ortholog mouse myocytic induction/differentiation originator; brain-specific angiogenesis inhibitor 1; EGF-TM7 latrophilin-related protein; sema domain; integrin, alpha 5; likely ortholog of mouse fibronectin type III; Lutheran blood group (Auberger b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16); insulin-like growth factor binding protein; leukemia inhibitory factor; protein tyrosine phosphatase, nonreceptor type I; and Homo sapiens, clone IMAGE:3908182, mRNA, partial cds. An expression product of the at least one gene is monitored. The test compound is identified as a potential anti-cancer drug if it decreases the expression of the at least one gene.

[0009] According to yet another embodiment of the invention a method is provided to aid in diagnosing glioma. An mRNA of at least one gene in a first brain tissue sample suspected of being neoplastic is detected. The at least one gene is identified by a tag selected from the group consisting of SEQ ID NO: 1-32. Expression of the at least one gene in the first brain tissue sample is compared to expression of the at least one gene in a second brain tissue sample which is normal. If increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is found, the first brain tissue sample is identified as likely to be neoplastic.

[0010] Another embodiment of the invention is a method of identifying a test compound as a potential anti-cancer or anti-glioma drug. A test compound is contacted with a cell. The cell expresses an mRNA of at least one gene identified by a tag selected from the group consisting of SEQ ID NO: 1-32. An mRNA of the at least one gene is monitored. The test compound is identified as a potential anti-cancer drug if it decreases the expression of at least one gene.

[0011] Still another embodiment of the invention is a method to induce an immune response to glioma. A protein or nucleic acid encoding a protein is administered to a mammal, preferably a human. The protein is selected from the group consisting of: signal sequence receptor, delta (translocon-associated protein delta); DC2 protein; KIAA0404 protein; symplekin; Huntingtin interacting protein I; plasmalemma vesicle associated protein; KIAA0726 gene product; latexin protein; transforming growth factor, beta 1; hypothetical protein FLJ22215; Rag C protein; hypothetical protein FLJ23471; N-myristoyltransferase 1; hypothetical protein dJ1181N3.1; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonection); Hs 111988; Hs 112238; laminin, alpha 5; protective protein for beta-galactosidase (galactosialidosis); Melanoma associated gene; Melanoma associated gene; E3 ubiquitin ligase SMURF1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; gene predicted from cDNA with a complete coding sequence; Thy-1 cell surface antigen; Hs 127824; GTP binding protein 2; Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918); cutaneous T-cell lymphoma-associated tumor antigen se20-4; differentially expressed nucleolar TGF-beta1 target protein (DENTT); dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); smoothelin; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); putative translation initiation factor; retinoic acid induced 14; matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase); Lutheran blood group (Auberger b antigen included); stanniocalcin 2; nuclear factor (erythroid-derived 2)-like 2; protein tyrosine phosphatase, non-receptor type 1; integrin, alpha 10; collagen, type VI, alpha 2; chromosome 21 open reading frame 25; CDC37 (cell division cycle 37, *S. cerevisiae*, homolog); Hs 16450; Rho guanine nucleotide exchange factor (GEF) 7; creatine kinase, brain; hypothetical protein FLJ10297; hypothetical protein FLJ10350; TNF-induced protein; tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein); cofilin 1 (non-muscle); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); v-ets avian erythroblastosis virus E26 oncogene homolog 1; protease, cysteine, 1 (legumain); ribosomal protein L13; chromosome 22 open reading frame 5; zinc finger protein 144 (Mel-18); degenerative spermatocyte (homolog *Drosophila*; lipid desaturase); eukaryotic translation initiation factor 2C, 2; mitochondrial ribosomal protein L45; prostate tumor over expressed gene 1; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a); glioma endothelial marker 1 precursor; NS1-binding protein; ribosomal protein L38; tuftelin-interacting protein; HLA class II region expressed gene KE2; translocase of inner mitochondrial membrane 17 homolog A (yeast); sudD (suppressor of bimD6, *Aspergillus nidulans*) homolog; heparan sulfate proteoglycan 2 (perlecan); SEC24 (*S. cerevisiae*) related gene family, member A; NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase); DNA segment on chromosome X and Y (unique) 155 expressed sequence; annexin A2; Homo sapiens clone 24670 mRNA sequence; hypothetical protein; matrix metalloproteinase 10 (stromelysin 2); KIAA1049 protein; G protein-coupled receptor; hypothetical protein FLJ20401; matrix metalloproteinase 14 (membrane-inserted); KIAA0470 gene product; solute carrier family 29 (nucleoside transporters), member 1; stanniocalcin 1; stanniocalcin 1; stanniocalcin 1; tumor suppressor deleted in oral cancer-related 1; tumor suppressor deleted in oral cancer-related 1; apolipoprotein C-I; glutathione peroxidase 4 (phospholipid hydroperoxidase); Hs 272106; transcription factor binding to IGHM enhancer 3; hypothetical protein DKFZp762A227; hypothetical protein FLJ22362; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); PRO0628 protein; melanoma-associated antigen recognised by cytotoxic T lymphocytes; LOC88745; Homo sapiens

beta-1,3-galactosyltransferase-6 (B3GALT6) mRNA, complete cds; sprouty (Drosophila) homolog 4; sprouty (Drosophila) homolog 4; Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone DKFZp434E1515); coactosin-like protein; hypothetical protein FLJ21865; Hs296234; KIAA0685 gene product; hypothetical protein FLJ10980; ribosomal protein L10; ribosomal protein S19; Hs 299251; Huntingtin interacting protein K; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 50374; Hs 311780; Hs 212191; v-akt murine thymoma viral oncogene homolog 2; Hs 328774; transducin-like enhancer of split 2, homolog of Drosophila E(sp1); KIAA1870 protein; ribosomal protein L10a; peptidylprolyl isomerase A (cyclophilin A); Hs 344224; hypothetical protein FLJ23239; hypothetical protein DKFZp761H221; KIAA1887 protein; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 701679; Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453; Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035904; hypothetical protein LOC57333; myosin ID; plexin B2; lectin, galactoside-binding, soluble, 8 (galectin 8); double ring-finger protein, Dorfin; DKFZP434B168 protein; LIM domain binding 2; integrin beta 4 binding protein; synaptopodin; Hs 54828; insulin induced gene 1; acetyl LDL receptor; SREC; excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); hypothetical protein FLJ22329; schwannomin-interacting protein 1; PTEN induced putative kinase 1; myosin X; Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97; golgi phosphoprotein 1; splicing factor, arginine/serine-rich 6; laminin, gamma 3; cysteine-rich protein 2; U6 snRNA-associated Sm-like protein LSm7 hypothetical protein FLJ10707; Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene, clone IMAGE:3342825, mRNA, partial cds; macrophage migration inhibitory factor (glycosylation-inhibiting factor); ubiquinol-cytochrome c reductase hinge protein; gap junction protein, alpha 1, 43kD (connexin 43); dihydropyrimidinase-like 3; aquaporin 1 (channel-forming integral protein, 28kD); protein expressed in thyroid; macrophage myristoylated alanine-rich C kinase substrate; procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI); protease, serine, 11 (IGF binding); 24-dehydrocholesterol reductase; collagen, type IV, alpha 2; profilin 1; apolipoprotein D; hyaluronoglucosaminidase 2; hypothetical protein FLJ22678; quiescin Q6; ras homolog gene family, member A; ras homolog gene family, member A; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; uridine phosphorylase; KIAA0638 protein; B7 homolog 3; lamin A/C; lamin A/C; lamin A/C; regulator of G-protein signalling 12; proteasome (prosome, macropain) 26S subunit, non-ATPase, 8; Homo sapiens, Similar to RIKEN cDNA 5730528L13 gene, clone MGC:17337 IMAGE:4213591, mRNA, complete cds; prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy); laminin, alpha 4; transcription elongation factor A (SII), 1; lectin, galactoside-binding, soluble, 3 binding protein; ribosomal protein S16; glycoporphin C (Gerbich blood group); endothelin receptor type B; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; small nuclear ribonucleoprotein polypeptide B"; transmembrane 4 superfamily member 2; TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD; lysyl oxidase-like 2; SRY (sex determining region Y)-box 4; SOX4 SRY (sex determining region Y)-box 4; SRY (sex determining region Y)-box 4; actin related protein 2/3 complex, subunit 2 (34 kD); Homo sapiens cDNA: FLJ23507 fis, clone LNG03128; hypothetical protein FLJ12442; Fas (TNFRSF6)-associated via death domain; mitogen-activated protein kinase kinase kinase 11; TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); insulin receptor; cell membrane glycoprotein, 110000M(r) (surface antigen); Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926; jagged 1 (Alagille syndrome); KIAA0304 gene product; pre-B-cell leukemia transcription factor 2; Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864; p53-induced protein; complement component 1, q subcomponent, receptor 1; complement component 1, q subcomponent, receptor 1; apolipoprotein E; chemokine (C-C motif) ligand 3; coagulation factor II (thrombin) receptor-like 3; coagulation factor III (thromboplastin, tissue factor); collagen, type I, alpha 1; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 9; cystatin C (amyloid angiopathy and cerebral hemorrhage); endoplasmic reticulum associated protein 140 kDa; ESTs; ESTs; ESTs, Highly similar to hypothetical protein FLJ10350 [Homo sapiens] [H.sapiens]; ESTs, Highly similar to ITB1_HUMAN Integrin beta-1 precursor (Fibronectin receptor beta subunit) (CD29) (Integrin VLA-4 beta subunit) [H.sapiens]; ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]; ESTs, Weakly similar to T17346 hypothetical protein DKFZp586O1624.1 - human (fragment) [H.sapiens]; ESTs, Weakly similar to T21371 hypothetical protein F25H8.3 - Caenorhabditis elegans [C.elegans]; eukaryotic translation initiation factor 4A, isoform 1; heme oxygenase (decycling) 1; Hermansky-Pudlak syndrome 4; Homo sapiens cDNA FLJ34888 fis, clone NT2NE2017332; Homo sapiens cDNA FLJ39848 fis, clone SPLEN2014669; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059; Homo sapiens, clone IMAGE:4845226, mRNA; hypothetical protein FLJ22329; hypothetical protein FLJ32205; hypothetical protein MGC4677; inhibin, beta B (activin AB beta polypeptide); insulin-like growth factor binding protein 5; junction plakoglobin; KIAA0620 protein; KIAA0943 protein; likely ortholog of rat vacuole membrane protein 1; Lysosomal-associated multispinning membrane protein-5; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; matrix Gla protein; matrix metalloproteinase 1 (interstitial collagenase); microtubule-associated protein 1 light chain 3 beta; nerve growth factor receptor (TNFR superfamily, member 16); ribosomal protein S9; ring finger protein 40; S100 calcium binding protein, beta (neural); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B;

SPARC-like 1 (mast9, hevin); tumor necrosis factor, alpha-induced protein 3; UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5; von Willebrand factor; v-akt murine thymoma viral oncogene homolog 2; cyclin-dependent kinase (cdc2-like) 10; ortholog mouse myocytic induction/differentiation originator; brain-specific angiogenesis inhibitor 1 ; EGF-TM7 latrophilin-related protein; sema domain ; integrin, alpha 5 ; likely ortholog of mouse fibronectin type III; Lutheran blood group (Aubergier b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16); insulin-like growth factor binding protein; leukemia inhibitory factor; protein tyrosine phosphatase, nonreceptor type I; and Homo sapiens, clone IMAGE: 3908182, mRNA, partial cds. An immune response to the protein is thereby induced.

[0012] The present invention thus provides the art with methods of diagnosing and treating gliomas and other brain tumors.

DETAILED DESCRIPTION OF THE INVENTION

[0013] Using SAGE (Serial Analysis of Gene Expression) profiling, this study was able to identify previously unrecognized, angiogenesis-specific markers that discriminate between non-proliferative and pathologic endothelial cells. We identified 255 human genes that were expressed at significantly higher levels in brain tumor endothelium than in normal brain endothelium. See Table 1. We have named these markers GEMs (glioma endothelial markers). Any of the GEMs disclosed in any of the tables can be used in the methods of the present invention, according to the discretion of the skilled artisan.

[0014] ECs represent only a minor fraction of the total cells within normal or tumor tissues, and only those EC transcripts expressed at the highest levels would be expected to be represented in libraries constructed from unfractionated tissues. The genes described in the current study should therefore provide a valuable resource for basic and clinical studies of human brain angiogenesis in the future. Genes which have been identified as expressed more in glioma endothelial cells than in normal brain endothelial cells (GEMs) include those which correspond to tags shown in SEQ ID NOS: 1-32. The tags correspond to the segment of the cDNA that is 3' of the 3' most restriction endonuclease site for the restriction enzyme NlaIII which was used as the anchoring enzyme. The tag shown is the same strand as the mRNA. Other such genes are listed in Tables 1 and 2.

Table 1

StdTag	SEQ	LongTag	SEQ ID	Function
AAACCATTCT	1	AAACCATTCTCCTCCGC	256	
AAGGCAGGGA	2	AAGGCAGGGAGGGAGG	257	
ACACAGCAAG	3	ACACAGCAAGACGAGAA	258	
AGCTGGAGTC	4	AGCTGGAGTCCTAGGCA	259	
AGCTGGCACC	5	AGCTGGCACCAGAGCCC	260	
ATAAATGAGG	6	ATAAATGAGGTAAGGTC	261	
CAAGCACCCC	7	CAAGCACCCCCGTTCCA	262	
CACTACCCAC	8	CACTACCCACCAGACGC	263	
CACTACTCAC	9	CACTACTCACCAGGCGC	264	
CCCACCTCCA	10	CCCACCTCCAGTCCAGC	265	
CCCGCCTCTT	11	CCCGCCTCTTCACGGGC	266	
CCTCAGA TGT	12	CCTCAGATGTTTGAAAA	267	
CGCTACTCAC	13	CGCTACTCACCAGACGC	268	
CTAAGACCTC	14	CTAAGACCTCACCAGTC	269	
CTAAGACTTC	15	CTAAGACTTCACCGGTC	270	
GAGTGGGTGC	16	GAGTGGGTGCAGCCTCC	271	
GGGACAGCTG	17	GGGACAGCTGTCTGTGG	272	
GGGTTGGCTT	18	GGGTTGGCTTGAAACCA	273	
GTAAGTGATC	19	GTAAGTGATCTGGAAGT	274	

EP 2 236 614 A2

(continued)

	StdTag	SEQ	LongTag	SEQ ID	Function
5	GTAAGTGTAC	20	GTAAGTGTACTGGTAAG	275	
	GTAGGGGTAA	21	GTAGGGGTAAAAGGAGG	276	
	TAACCACTGC	22	TAACCACTGCACTTTCC	277	
	TACTGCTCGG	23	TACTGCTCGGAGGTCGG	278	
10	TCAGGCTGAA	24	TCAGGCTGAAGTCAGGC	279	
	TCCATACACC	25	TCCATACACCTATCCCC	280	
	TCCTTTTAAA	26	TCCTTTTAAAACAAAAC	281	
15	TGATTAAGGT	27	TGATTAAGGTCGGCGCT	282	
	TGGTATCACA	28	TGGTATCACACAAGGGG	283	
	TGGTGTATGC	29	TGGTGTATGCATCGGGG	284	
	TGTCAGTGGG	30	TGTCAGTGGGCAGGCGG	285	
20	TGTGGGAGGC	31	TGTGGGAGGCTGATGGG	286	
	TTTAACGGCC	32	TTTAACGGCCGCGGTAC	287	
	GCTCTCTATG	33	GCTCTCTATGCTGACGT	288	signal sequence receptor, delta (translocon-associated protein delta)
25	AGAATGAAAC	34	AGAATGAAACTGCCGGG	289	DC2 protein
	AAGTGAATAH	35	AGTGAATAAACTGCC	290	KIAA0404 protein
	GATGACGACT	36	GATGACGACTCGGGGCT	291	symplesin; Huntingtin interacting protein I
30	CCCTTTCACA	37	CCCTTTCACACACACTT	292	plasmalemma vesicle associated protein
	TCCTGGGGCA	38	TCCTGGGGCAGGGGCG	293	KIAA0726 gene product
	TCTATTGATG	39	TCTATTGATGTGTATGC	294	latexin protein
	GGGGCTGTAT	40	GGGGCTGTATTTAAGGA	295	transforming growth factor, beta 1
35	CCCAGGACAC	41	CCCAGGACACCAGCTGG:	296	hypothetical protein FLJ22215
	GGAGCTGCTG	42	GGAGCTGCTGCTTGTGG	297	Rag C protein
	TGGACAGCAG	43	TGGACAGCAGGGACCTG	298	hypothetical protein FLJ23471
40	TCTGGGAACAH	44	TCTGGGAACAGGGACGG	299	N-myristoltransferase 1
	CCTGTGTATG	45	CCTGTGTATGTGTGTAA	300	hypothetical protein dJ1181N3.1
	GGCAAGAAGA	46	GGCAAGAAGAAGATCGC	301	ribosomal protein L27
45	AAATGCTTGG	47	AAATGCTTGGAGGTGAA	302	secreted protein, acidic, cysteine-rich (osteonectin)
	CTAAAAACCT	48	CTAAAAACCTTATGACA	303	secreted protein, acidic, cysteine-rich (osteonectin)
50	GAGCATTGCA	49	GAGCATTGCACCACCCG	304	secreted protein, acidic, cysteine-rich (osteonectin)
	GGTGGACACG	50	GGTGGACACGGATCTGC	305	secreted protein, acidic, cysteine-rich (osteonectin)
55	GCTCCTGAGC	51	GCTCCTGAGCCCCGGCC	306	ESTs, Weakly similar to 165992 gene MLL protein [H.sapiens]
	AAGAAGTGGAAH	52	AAGAAGTGGAGATTGTC	307	ESTs
	TGGGAAGTGG	53	TGGGAAGTGGGCTCCTT	308	maternally expressed 3

EP 2 236 614 A2

(continued)

	StdTag	SEQ	LongTag	SEQ ID	Function
5	ACTCGCTCTG	54	ACTCGCTCTGTGGAGGT	309	laminin, alpha 5
	TTTCAGGGGA	55	TTTCAGGGGAGGGGGAA	310	protective protein for beta-galactosidase (galactosialidosis)
	ACAACGTCCA	56	ACAACGTCCAGCTGGTG	311	Melanoma associated gene
10	GTCTCAGTGC	57	GTCTCAGTGCTGAGGCG	312	Melanoma associated gene
	CCCCCTGCC	58	CCCCCTGCCCTCTGCC	313	E3 ubiquitin ligase SMURF1
	AGAAACCACG	59	AGAAACCACGGAAATGG	314	collagen, type IV, alpha 1
	GACCGCAGGA	60	GACCGCAGGAGGGCAGA	315	collage type IV, alpha 1
15	GTGCTACTTC	61	GTGCTACTTCTTCTTCT	316	collagen, type IV, alpha 1
	GATAACTACA	62	GATAACTACATTACCTG	317	Nnsulin-iike growth factor binding protein
	TGGCTGTGAC	63	TGGCTGTGACTGTGACT	318	gene predicted from cDNA with a complete coding sequence
20	GAGTGAGACC	64	GAGTGAGACCCAGGAGC	319	Tthy-1 cell surface antigen
	GAGTGGCTAC	65	GAGTGGCTACCCGCCGC	320	ESTs, Weakly similar to T28770 hypothetical protein W03D2.1- <i>Caenorhabditis elegans</i>
25	GA CTCAGGGA	66	GA CTCAGGGATTGTG	321	GTP binding protein 2
	GTTATATGCC	67	GTTATATGCCCGGGAGA	322	Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918)
30	GAGGCGCTGC	68	GAGGCGCTGCTGCCACC	323	cutaneous T-cell lymphoma-associated tumor antigen se20-4; differentially expressed nucleolar TGF-beta1 target protein (DENTT)
35	GAGCTCTGAG	69	GAGCTCTGAGATCACCC	324	dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive)
	GCCAGCCAGT	70	GCCAGCCAGTGGAAGC	325	Smoothelin
40	ATGGCAACAG	71	ATGGCAACAGATCTGGA	326	integrin, alpha 5 (fibronectin receptor, alpha polypeptide)
	AAGGAGTTAC	72	AAGGAGTTACACTAGTC	327	putative translation initiation factor
	TCCCACAAGG	73	TCCCACAAGGCTGCTTG	328	retinoic acid induced 14
45	TAAATCCCCA	74	TAAATCCCCACTGGGAC	329	matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)
	CCCGCCCCCG	75	CCCGCCCCCGCCTTCCC	330	Lutheran blood group (Auberger b antigen included)
50	CCCGAGGCAG	76	CCCGAGGCAGAGTCGGG	331	stanniocalcin 2
	CTACGTGATG	77	CTACGTGATGAAGATGG	332	nuclear factor (erythroid-derived 2)-like 2
	ATGGGTTTGC	78	ATGGGTTTGCATTTTAG	333	protein tyrosine phosphatase, non-receptor type 1
55	GGCATTGTCT	79	GGCATTGTCTCTGTTTC	334	integrin, alpha 10
	GTGCTAAGCG	80	GTGCTAAGCGGGCCCGG	335	Collagen, type alpha 2

EP 2 236 614 A2

(continued)

	StdTag	SEQ	LongTag	SEQ ID	Function
5	ACCGTTTGCA	81	ACCGTTTGCAATTCGAAA	336	chromosome 21 open reading frame 25
	CAGCGCTGCA	82	CAGCGCTGCATTGACTC	337	CDC37 (cell division cycle 37, S. cerevisiae, homolog)
	GAAGACACTT	83	GAAGACACTTGGTTTGA	338	ESTs
10	CGCTGGGCGT	84	CGCTGGGCGTCTGGGAC	339	Rho guanine nucleotide exchange factor (GEF) 7
	CACCCCTGAT	85	CACCCCTGATGTTTCGCC	340	creatine kinase, brain
	GCCCCCCTGC	86	GCCCCCCTGCCCCGTGC	341	hypothetical protein FLJ10297
15	CCCCCTGCC	87	CCCCCTGCCCTCGCCTG	342	hypothetical protein FLJ10350
	AGCATAAAAA	88	AGCATAAAAAATGCGTGC	343	TNF-induced protein
20	GGGCTGGACG	89	GGGCTGGACGGCTGCGT	344	tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein)
	CTGCCAACTT	90	CTGCCAACTTCTAACCG	345	cofilin 1 (non-muscle)
25	AAGTGGATAG	91	AAGTGGATAGATACTTC	346	splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated)
	CGTACTGAGC	92	CGTACTGAGCGCTTTGG	347	splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated)
30	CCGCTTACTC	93	CCGCTTACTCTGTTGGG	348	v-ets avian erythroblastosis virus E26 oncogene homolog 1
	GGGGCTTCTG	94	GGGGCTTCTGTAGCCCC	349	protease, cysteine, 1 (legumain)
	CCCGTCCGGA	95	CCCGTCCGGAACGTCTA	350	ribosomal protein L13
35	AGTTCCACCA	96	AGTTCCACCAGAAAGCC	351	chromosome 22 open reading frame 5
	GGCCTCCAGC	97	GGCCTCCAGCCACCCAC	352	zinc finger protein 144 (Mel-18)
	GGAGGCTGAG	98	GGAGGCTGAGGTGGGA	353	degenerative spermatocyte (homolog Drosophila; lipid desaturase)
40	CAGAGGCGTC	99	CAGAGGCGTCCGCAGGT	354	eukaryotic translation initiation factor 2C, 2
	GACCAGCCTT	100	GACCAGCCTTCAGATGG	355	mitochondrial ribosomal protein L45
	GAGGATGGTG	101	GAGGATGGTGTCTGAG	356	prostate tumor over expressed gene 1
45	TCGTGCGAGA	102	TCGTGCGAGAAGGCGCT	357	NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a)
	GGGGCTGCCC	103	GGGGCTGCCCAGCTGGA	358	tumor endothelial marker 1 precursor
50	CTGTACATAC	104	CTGTACATACTTTTGG	359	NS1-binding protein
	GCGACGAGGC	105	GCGACGAGGCGCGCTG	360	ribosomal protein L38
	GCCAAGTGAA	106	GCCAAGTGAAGTGTGGC	361	protein
	AAGATAAACT	107	AAGATAAACTCTGGGCC	362	HLA class II region expressed gene KE2
55	GAGAGTGTAC	108	GAGAGTGTACTGGCACT	363	of inner mitochondrial membrane 17 homolog A (yeast)

EP 2 236 614 A2

(continued)

	StdTag	SEQ	LongTag	SEQ ID	Function
5	CCACTGCACT	109	CCACTGCACTCCGGCCT	364	sudD (suppressor of bimD6, Aspergillus nidulans) homolog
	CCACCCTCAC	110	CCACCCTCACACACACA	365	heparan sulfate proteoglycan 2 (perlecan)
10	CAGACCATTG	111	CAGACCATTGTTTGATC	366	SEC24 (S. cerevisiae) related gene family, member A
	GGGAGCTGCG	112	GGGAGCTGCGCCAACGG	367	NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase)
15	GGGATTTCTG	113	GGGATTTCTGTGTCTGC	368	DNA segment on chromosome X and Y (unique) 155 expressed sequence
	CTTCCAGCTA	114	CTTCCAGCTAACAGGTC	369	annexin A2
	CAGAAACAGA	115	CAGAAACAGACTGGGGG	370	Homo sapiens clone 24670 mRNA sequence
20	TCTGTGCTCA	116	TCTGTGCTCAGGAAGAG	371	hypothetical protein
	TGCAATAGGT	117	TGCAATAGGTGAGAGAA	372	matrix metalloproteinase 10 (stromelysin 2)
25	ATGGCCAACT	118	ATGGCCAACTTCCACCT	373	KIAA 1049 protein
	TCACACAGTG	119	TCACACAGTGCCGTGTCG	374	G protein-coupled receptor
	GGCTTAGGAT	120	GGCTTAGGATGTGAATG	375	hypothetical protein FLJ20401
	GGGAGGGGTG	121	GGGAGGGGTGGGGGTG	376	matrix metalloproteinase 14 (membrane-inserted)
30	GAAGTAGAAG	122	GAAGTAGAAGGTAAGGA	377	KIAA0470 gene product
	CACCCTGTAC	123	CACCCTGTACAGTTGCC	378	solute carrier family 29 (nucleoside transporters), member 1
35	ATGTTTACAA	124	ATGTTTACAAGATGGCG	379	stanniocalcin 1
	CAAACCTGGTC	125	CAAACCTGGTCTAGGTCA	380	stanniocalcin 1
	GTAATGACAG	126	GTAATGACAGATGCAAG	381	stanniocalcin 1
40	ACCTGCCGAC	127	ACCTGCCGACAGTGTTG	382	tumor suppressor deleted in oral cancer-related 1
	TGATGCGCGC	128	TGATGCGCGCTTTGTTG	383	tumor suppressor deleted in oral cancer-related 1
45	TGGCCCCAGG	129	TGGCCCCAGGTGCCACC	384	apolipoprotein C-1
	GCCTGCTGGG	130	GCCTGCTGGGCTTGGCT	385	glutathione peroxidase 4 (phospholipid hydroperoxidase)
	TGCCTGTGGT	131	TGCCTGTGGTCCCAGCT	386	ESTs
50	GAGGGTATAC	132	GAGGGTATACTGAGGGG	387	transcription factor binding to IGHM enhancer 3
	GGAGCCAGCT	133	GGAGCCAGCTGACCTGC	388	hypothetical protein DKFZp762A227
	GAGCCTCAGG	134	GAGCCTCAGGTGCTCCC	389	hypothetical protein FLJ22362
55	TACTTCACAT	135	TACTTCACATACAGTGC	390	CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)

EP 2 236 614 A2

(continued)

	StdTag	SEQ	LongTag	SEQ ID	Function
5	TAATCCCAGC	136	TAATCCCAGCACTTTGG	391	PRO0628 protein
	CACCTTCCAG	137	CACCTTCCAGCCCGGGG	392	melanoma-associated antigen recognised by cytotoxic T lymphocytes
	GAGTCTGTTC	138	GAGTCTGTTCGTGACTC	393	LOC88745
10	GGATTTTGGT	139	GGATTTTGGTCTCTGTC	394	Homo sapiens beta-1,3-galactosyltransferase-6 (B3GALT6) mRNA,
	TGCCTGTAGT	140	TGCCTGTAGTCCTAGTT	395	sprouty (Drosophila) homolog 4
15	TTACAAACAG	141	TTACAAACAGAAAAGCT	396	sprouty (Drosophila) homolog 4
	TCTTCTTTCA	142	TCTTCTTTCAGAAATGGG	397	Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone
	AGCACATTTG	143	AGCACATTTGATATAGC	398	coactosin-like protein
20	CAGGGCTCGC	144	CAGGGCTCGCGTGCGG	399	hypothetical protein FLJ21865
	GCTGGTCCCA	145	GCTGGTCCCAGGGCCAG	400	ESTs, Weakly similar to T31613 hypothetical protein Y50E8A.i- Caenorhabditis elegans [C.elegans]
25	TCCACGCCCT	146	TCCACGCCCTTCCTGGC	401	KIAA0685 gene product
	TTGCAATAGC	147	GCAATAGCAAAACCC	402	hypothetical protein FLJ10980
	AGGGCTTCCA	148	AGGGCTTCCAATGTGCT	403	ribosomal protein L10
	CTGGGTAAAT	149	CTGGGTAAATAAATTGC	404	ribosomal in S19
30	AACCTGGGAG	150	AACCTGGGAGGTGGAGG	405	ESTs
	GGCAACGTGG	151	GGCAACGTGGTAGAGGC	406	Huntingtin interacting protein K
	GGATGCGCAG	152	GGATGCGCAGGGGAGG	407	Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 50374
35	CACCTGTAGT	153	CACCTGTAGTCCTAGCT	408	EST
	GTGGTGCGCG	154	GTGGTGCGCGCCTGTAG	409	EST
	GCAGGGTGGG	155	GCAGGGTGGGGAGGGG	410	v-akt murine thymoma viral oncogene homolog 2
40	CAAGCATCCC	156	CAAGCATCCCCGTTCCA	411	EST
	TGGGGGCCGA	157	TGGGGGCCGATGGGCA	412	transducin-like enhancer of split 2, homolog of Drosophila E(sp1)
45	TCAGTGTATT	158	TCAGTGTATTAACCC	413	KIAA1870 protein
	GGCAAGCCCC	159	GGCAAGCCCCAGCGCCT	414	ribosomal protein L10a
	CCTAGCTGGA	160	CCTAGCTGGATTGCAGA	415	peptidylprolyl isomerase A (cyclophilin A)
50	GCAAAACCCT	161	GCAAAACCCTGCTCTCC	416	ESTs, Weakly similar to ubiquitous TPR motif, Y isoform [H.sapiens]
	GCTGGTTCCT	162	GCTGGTTCCTGAGTGGC	417	hypothetical protein FLJ23239
	GCACCTCAGC	163	GCACCTCAGCCAGGGGT	418	hypothetical protein DKFZp761H221
55	ACCAGCTGTC	164	ACCAGCTGTCCAGGGGC	419	KIAA1887 protein
	TTTGAATCAG	165	TTTGAATCAGTGCTAGA	420	Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 701679

EP 2 236 614 A2

(continued)

	StdTag	SEQ	LongTag	SEQ ID	Function
5	AGACTAGGGG	166	AGACTAGGGGCCGGAGC	421	Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453
	AGCTCAGTGA	167	AGCTCAGTGAGAAGGGC	422	Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84
10	GGCCAACATT	168	GGCCAACATTTGGTCCA	423	Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035904
	TTTGTGGGCA	169	TTTGTGGGCAGTCAGGC	424	hypothetical protein LOC57333
	ATTGTAGACA	170	ATTGTAGACAATGAGGG	425	myosin ID
15	CCCTAGGTTG	171	CCCTAGGTTGGGCCCT	426	plexin B2
	AAATCACCAA	172	AAATCACCAATCAAGGC	427	lectin, galactoside-binding, soluble, 8 (galectin 8)
	GGCTGCAGTC	173	GGCTGCAGTCTTCTTCC	428	double ing-finger protein, Dorfin
20	GTGGCAGDCG	174	GTGGCAGGCGCCTGTAG	429	DKFZP434B168 protein
	TAAAGGCACA	175	TAAAGGCACAGTGGCTC	430	LIM domain binding 2
	GGCTCCTGGC	176	GGCTCCTGGCTCTGGAC	431	integrin beta 4 binding protein
25	ATATTAGGAA	177	ATATTAGGAAGTCGGGG	432	Synaptopodin
	GCTTCAGTGG	178	GCTTCAGTGGGGGAGAG	433	ESTs
	TGATTAAC	179	TGATTAACAAAGTTGC	434	insulin induced gene
	ASGCCACCACG	180	AGCCACCACGCCTGGTC	435	acetyl LDL receptor; SREC
30	GGCGGCTGCA	181	GGCGGCTGCAGAGCCTG	436	excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)
	TGTTTGGGGG	182	TGTTTGGGGGCTTTAG	437	hypothetical protein FLJ22329
35	CCTGCCTCGT	183	CCTGCCTCGTAGTGAAG	438	schwannomin-interacting protein 1
	AGGCCTGGGC	184	AGGCCTGGGCCTCTGCG	439	PTEN induced putative kinase 1
	CAAACTGTT	185	CAAACTGTTTGTGGC	440	myosin X
40	GAGAGGACAT	186	GAGAGGACATTGGAGGG	441	Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97
	GAGTTAGGCA	187	GAGTTAGGCACTTCCTG	442	golgi phosphoprotein 1
45	CCGTAGTGCC	188	CCGTAGTGCCTTTATGG	443	splicing factor, arginine/serine-rich 6
	CATAAACGGG	189	CATAAACGGGCACACCC	444	laminin, gamma 3
	TCCCTGGCAG	190	TCCCTGGCAGAGGGCTT	445	cysteine-rich proteins 2
50	GAGGCCATCC	191	GAGGCCATCCCCAACCC	446	U6 snRNA-associated Sm-like protein LSm7
	TTGCCTGGGA	192	TTGCCTGGGATGCTGGT	447	hypothetical protein FLJ10707
55	CTGTCAGCGG	193	CTGTCAGCGGCTGCCCC	448	Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene, clone IMAGE: 3342825, mRNA, partial cds

EP 2 236 614 A2

(continued)

	StdTag	SEQ	LongTag	SEQ ID	Function
5	AACGCGGCCA	194	AACGCGGCCAATGTGGG	449	macrophage migration inhibitory factor (glycosylation-inhibiting factor)
	GGTTTGGCTT	195	GGTTTGGCTTAGGCTGG	450	ubiquinol-cytochrome c reductase hinge protein
10	GATTTTTGTG	196	ATTTTTGTGGTGTGGG	451	gap junction protein, alpha 1, 43kD (connexin 43)
	GGCTGCCCTG	197	GGCTGCCCTGGGCAGCC	452	dihydropyrimidinase-like 3
	ATGGCAACAG	198	ATGGCAACAGAAACCAA	453	aquaporin 1 (channel-forming integral protein, 28kD)
15	CGCTGTGGGG	199	CGCTGTGGGGTGCAGAC	454	protein expressed in thyroid
	GGCAGCCAGA	200	GGCAGCCAGAGCTCCAA	455	macrophage myristoylated alanine-rich C kinase substrate
20	AGAGCAAACC	201	AGAGCAAACCGTAGTCC	456	procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI)
	TTCCCTCAA	202	TTCCCTCAAAGACTCT	457	protease, serine, 11 (IGF binding)
	TCCCCGTGGC	203	TCCCCGTGGCTGTGGGG	458	24-dehydrocholesterol reductase
25	TTCTCCCAAA	204	TTCTCCCAAATACCGTT	459	collagen, type IV, alpha 2
	GGCTGGGGGC	205	GGCTGGGGGCCAGGGC	460	profilin 1
	CCCTACCCTG	206	CCCTACCCTGTTACCTT	461	apolipoprotein D
30	TAGGACCCTG	207	TAGGACCCTGCAGGGGG	462	hyaluronoglucosaminidase 2
	GTTTTTGCTT	208	GTTTTTGCTTCAGCGGC	463	hypothetical protein FLJ22678
	CTTGATTCCC	209	CTTGATTCCCACGCTAC	464	quiescin Q6
	GCTTGGCTCC	210	GCTTGGCTCCCAAAGGG	465	ras homolog gene family, member A
35	GGTGGCACTC	211	GGTGGCACTCAGTCTCT	466	ras homolog gene family, member A
	ACCTGTGACC	212	ACCTGTGACCAGCACTG	467	plasminogen activator, urokinase
	ACTGAGGAAA	213	ACTGAGGAAAGGAGCTC	468	insulin-like growth factor binding protein 3
40	TGCAGCGCCT	214	TGCAGCGCCTGCGGCCT	469	uridine phosphorylase
	CTGGGGGGAA	215	CTGGGGGGAAGGGACTG	470	KIAA0638 protein
	GTGCTATTCT	216	GTGCTATTCTGGGGCTG	471	B7 homolog 3
	GGAGGGGGCT	217	GGAGGGGGCTTGAAGCC	472	lamin A/C
45	GTGCCTGAGA	218	GTGCCTGAGAGGCAGGC	473	lamin A/C
	TCACAGGGTC	219	TCACAGGGTCCCCGGGG	474	lamin A/C
	GGGCTCCCTG	220	GGGCTCCCTGGCCCTGG	475	regulator of G-protein signalling 12
50	GCCCCAGGTA	221	GCCCCAGGTAGGGGGAC	476	proteasome (prosome, macropain) 26S subunit, non-ATPase, 8
	GAAAGTGGCT	222	GAAAGTGGCTGTCCTGG	477	Homo sapiens, Similar to RIKEN cDNA 5730528L 13 gene, clone MGC:17337 IMAGE:4213591, mRNA, complete cds
55	TCCCTGGCTG	223	TCCCTGGCTGTTGAGGC	478	prosaposin (variant Gaucher disease and variant metachromatic

EP 2 236 614 A2

(continued)

	StdTag	SEQ	LongTag	SEQ ID	Function
5	ACAGAGCACA	224	ACAGAGCACAGCTGCCC	479	laminin, alpha 4
	CTTTGCACTC	225	CTTTGCACTCTCCTTTG	480	transcription elongation factor A (SII), 1
	ATGCTCCCTG	226	ATGCTCCCTGAGGAGCT	481	lectin, galactoside-binding, soluble, 3 binding protein
10	CCGTCCAAGG	227	CCGTCCAAGGGTCCGCT	482	ribosomal protein S16
	GGGCCCCCTG	228	GGGCCCCCTGGGCAGTG	483	glycophorin C (Gerbich blood group)
	CTTATGCTGC	229	CTTATGCTGCTGGTGCC	484	endothelin receptor type B
15	GGTTATTTTG	230	GGTTATTTTGAGTGTA	485	serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
	GCCTGTCCCT	231	GCCTGTCCCTCCAAGAC	486	Biglycan
20	AAGATGAGGG	232	AAGATGAGGGGGCAGGC	487	small nuclear ribonucleoprotein polypeptide B"
	CCAACAAGAA	233	CCAACAAGAATGCATTG	488	transmembrane 4 superfamily member 2
	AAGGATGCGG	234	AAGGATGCGGTGATGGC	489	TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD
25	TGTCATCACA	235	TGTCATCACAGACACTT	490	lysyl oxidase-like 2
	CAGGCTTTTT	236	CAGGCTTTTTGGCTTCC	491	SRY (sex determining region Y)-box 4
	TCAAGTTCAC	237	TCAAGTTCAGTGCCTGT	492	SOX4 SPY (sex determining region Y)-box 4
30	TCCCTGGGCA	238	TCCCTGGGCAGCTTCAG	493	SRY (sex determining region Y)-box 4
	CAGGAGTTCA	239	CAGGAGTTCAAAGAAGG	494	actin related protein 2/3 complex, subunit 2 (34 kD)
35	CAGGTGGTTC	240	CAGGTGGTTCTGCCATC	495	Homo sapiens cDNA: FLJ23507 fis, clone LNG03128
	GCCCACATCC	241	GCCCACATCCGCTGAGG	496	hypothetical protein FLJ12442
40	GCTGGGGTGG	242	GCTGGGGTGGGGGTGG	497	Fas (TNFRSF6)-associated via death domain
	GACCTCCTGC	243	GACCTCCTGCCCTGGGG	498	mitogen-activated protein kinase kinase kinase 11
45	AGTGAATAAA	244	AGTGAATAAATGTCTTG	499	TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)
	AAGGTTCTTC	245	AAGGTTCTTCTCAAGGG	500	insulin receptor
50	AGCCTGGACT	246	AGCCTGGACTGAGCCAC	501	cell membrane glycoprotein, 110000M(r) (surface antigen)
	CAACCCAGAT	247	CAACCCAGATTGGGGTG	502	Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926
	TGCTTCTGCC	248	TGCTTCTGCCACCCTGC	503	jagged 1 (Alagille syndrome)
55	CAGGTGACAA	249	CAGGTGACAAGGGCCCT	504	KIAA0304 gene product
	GGCCGGGGGC	250	GGCCGGGGGCAGTTCTC	505	pre-B-cell leukemia transcription factor 2

EP 2 236 614 A2

(continued)

StdTag	SEQ	LongTag	SEQ ID	Function
GTGCGCTAGG	251	GTGCGCTAGGGCCCCCGG	506	Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864
AGGCTGTCCA	252	AGGCTGTCCAGGCTCTG	507	p53-induced protein
TGTTATGTCC	253	TGTTATGTCCATTTTGC	508	complement component 1, q subcomponent, receptor 1
TTTCCCAAAC	254	TTTCCCAAACGTGAGG	509	complement component 1, q subcomponent, receptor 1
GGGGATGGGG	255	GGGGATGGGGTACTGCC	510	Homo sapiens, clone IMAGE:3908182, mRNA, partial cds

Table 2.

SEQ ID NO:	Unigene ID	OMIMID	gene symbol	locuslink id	Cellular Component
33	Hs.102135	300090	SS	6748	endoplasmic reticulum, membrane
34	Hs.103180				
35	Hs.105850		KIAA0404	23130	
36	Hs.107019	602388	SPK	8189	cytoplasm, nucleoplasm
37	Hs.107125				membrane
38	Hs.107809		KIAA0726	9746	membrane
39	Hs.109276				
40	Hs.1103	190180	TGFB1	7040	
41	Hs.110443				
42	Hs.110950				
43	Hs.110964				
44	Hs.111039	160993	NMT1	4836	
45	Hs.11114		DJ1181N3	58476	
46	Hs.111611		RPL27	6155	intracellular, ribosome
47	Hs.111779	182120	SPARC	6678	basement membrane
48	Hs.111779	182120	SPARC	6678	basement membrane
49	Hs.111779	182120	SPARC	6678	basement membrane
50	Hs.111779	182120	SPARC	6678	basement membrane
51	Hs.111988				
52	Hs.112238				
53	Hs.112844				
54	Hs.11669	601033	LAMA5	3911	basement lamina
55	Hs.118126	256540	PPGB	5476	endoplasmic reticulum, lysosome
56	Hs.118893	600134	D2S448	7837	cellular_component unknown
57	Hs.118893	600134	D2S44	7837	cellular_component unknown
58	Hs.119120	605568	SMURF1	57154	intracellular
59	Hs.119129	120130	COL4A1	1282	collagen

EP 2 236 614 A2

(continued)

SEQ ID NO:	Unigene ID	OMIMID	gene symbol	locuslink id	Cellular Component
60	Hs.119129	120130	COL4A1	1282	collagen
61	Hs.119129	120130	COL4A1	1282	collagen
62	Hs.119206	602867	IGFBP7	3490	extracellular
63	Hs.124				
64	Hs.125359	188230	THY1	7070	integral plasma membrane protein
65	Hs.127824				
66	Hs.13011		GTPBP2	54676	
67	Hs.13350				
68	Hs.136164				
69	Hs.143897	603009	DYSF	8291	plasma membrane
70	Hs.149098	602127	SMTN	6525	actin cytoskeleton
71	Hs.149609	135620	ITGA5	3678	cytoskeleton, extracellular matrix,
72	Hs.150580		SUI1	10209	cellular_component unknown
73	Hs.15165				
74	Hs.151738	120361	MMP9	4318	extracellular matrix, extracellular
75	Hs.155048	111200	LU	4059	integral plasma membrane protein,
76	Hs.155223	603665	STC2	8614	
77	Hs.155396	600492	NFE2L2	4780	nucleus
78	Hs.155894	176885	PTPN1	5770	cytoplasm, soluble fraction
79	Hs.158237	604042	ITGA10	8515	cytoskeleton, extracellular matrix,
80	Hs.159263	120240	COL6A2	1292	extracellular matrix
81	Hs.16007				
82	Hs.160958	605065	CDC37	11140	
83	Hs.16450				
84	Hs.172813	605477	P85SPR	8874	
85	Hs.173724	123280	CKB	1152	cytoplasm
86	Hs.173739				
87	Hs.177596				
88	Hs.17839		GG2	25816	
89	Hs.180338	603366	TNFRSF12	8718	integral plasma membrane protein,
90	Hs.180370	601442	CFL1	1072	cytoskeleton, nucleus
91	Hs.180610	605199	SFPQ	6421	nucleus
92	Hs.180610	605199	SFPQ	6421	nucleus
93	Hs.18063	164720	ETS1	2113	nucleus
94	Hs.18069	602620	PRSC1	5641	
95	Hs.180842	113703	RPL13	6137	cytosolic ribosome, intracellular
96	Hs.182626				
97	Hs.184669	600346	ZNF144	7703	nucleus

EP 2 236 614 A2

(continued)

	SEQ ID NO:	Unigene ID	OMIMID	gene symbol	locuslink id	Cellular Component
5	98	Hs.185973		DEGS	8560	endoplasmic reticulum, integral
	99	Hs.193053	606229	EIF2C2	27161	cellular_component unknown
	100	Hs.19347		MRPL45	84311	mitochondrion
	101	Hs.19555				
10	102	Hs.19561	602139	NDUFA7	4701	membrane fraction mitochondrion,
	103	Hs.195727	606064	TEM1	57124	extracellular matrix
	104	Hs.197298		NS1	10625	spliceosome, transcription factor
	105	Hs.2017	604182	RPL38	6169	60S ribosomal subunit, intracellular,
15	106	Hs.20225				
	107	Hs.205736	605660	HKE2	10471	prefoldin
	108	Hs.20716	605057	TIM17	10440	integral plasma membrane protein,
	109	Hs.209061	603579	SUDD	8780	
20	110	Hs.211573	14246	HSPG2	3339	basement membrane, extracellular
	111	Hs.211612		SEC24A	10802	COPII vesicle coat, endoplasmic
	112	Hs.211914	601825	NDUFS7	4727	mitochondrion, NADH dehydrogenase
	113	Hs.21595	312095	DXYS155E	8227	cellular_component unknown
25	114	Hs.217493	151740	ANXA2	302	plasma membrane, soluble fraction
	115	Hs.21906				
	116	Hs.22129				
	117	Hs.2258	185260	MMP10	4319	extracellular matrix, extracellular
30	118	Hs.227835				
	119	Hs.23016		RDC1	57007	integral membrane protein, membrane
	120	Hs.233955				
	121	Hs.2399	600754	MMP14	4323	extracellular matrix, integral plasma
35	122	Hs.25132				
	123	Hs.25450	602193	SLC29A1	2030	integral plasma membrane protein,
	124	Hs.25590	601185	STC1	6781	
	125	Hs.25590	601185	STC1	6781	
40	126	Hs.25590	601185	STC1	6781	
	127	Hs.25664		DOC	10263	
	128	Hs.25664		DOC	10263	
	129	Hs.268571	107710	APOC1	341	
45	130	Hs.2706	138322	GPX4	2879	mitochondrion
	131	Hs.272106				
	132	Hs.274184	314310	TFE3	7030	nucleus
	133	Hs.274453				
50	134	Hs.27836				
	135	Hs.278573	107271	CD59	966	membrane fraction, plasma membrane

EP 2 236 614 A2

(continued)

SEQ ID NO:	Unigene ID	OMIMID	gene symbol	locuslink id	Cellular Component
136	Hs.278941				
137	Hs.279869	604853	MAAT1	10573	
138	Hs.283636				
139	Hs.284284				
140	Hs.285814				
141	Hs.285814				
142	Hs.287830				
143	Hs.289092		CLP	23406	intracellular
144	Hs.29288				
145	Hs.296234				
146	Hs.296406				
147	Hs.29716				
148	Hs.29797	312173	RPL10	6134	60S ribosomal subunit, intracellular,
149	Hs.298262	603474	RPS19	6223	40S ribosomal subunit, intracellular, ribosome
150	Hs.299257				
151	Hs.300954				
152	Hs.302741				
153	Hs.311780				
154	Hs.312191				
155	Hs.326445	164731	AKT2	208	
156	Hs.327884				
157	Hs.332173	601041	TLE2	7089	nucleus
158	Hs.334604		KIAA1870	85301	collagen
159	Hs.334895		RPL10A	4736	60S ribosomal subunit, intracellular,
160	Hs.342389	123840	PPIA	5478	cytoplasm
161	Hs.344224				
162	Hs.34516				
163	Hs.347297				
164	Hs.348428				
165	Hs.348967				
166	Hs.350065				
167	Hs.351706				
168	Hs.36353				
169	Hs.39619		LOC57333	57333	
170	Hs.39871	606539	MYO1D	4642	myosin
171	Hs.3989	604293	PLXNB2	23654	membrane
172	Hs.4082	606099	LGALS8	3964	extracellular space

EP 2 236 614 A2

(continued)

SEQ ID NO:	Unigene ID	OMIMID	gene symbol	locuslink id	Cellular Component
173	Hs.48320		DORFIN	25897	centrosome
174	Hs.48604				
175	Hs.4980	603450	LDB2	9079	nucleus
176	Hs.5215	602912	ITGB4BP	3692	extrinsic membrane protein,
177	Hs.5307				
178	Hs.54828				
179	Hs.56205	602055	INSIG1	3638	
180	Hs.57735		SREC	8578	membrane
181	Hs.59544	126380	ERCC1	2067	nucleus
182	Hs.61478				
183	Hs.61490				
184	Hs.6163		PINK1	65018	
185	Hs.61638				
186	Hs.61661				
187	Hs.6831				
188	Hs.6891	601944	SFRS6	6431	nucleus
189	Hs.69954	604349	LAMC3	10319	extracellular matrix, membrane
190	HS.70327	601183	CRIP2	1397	
191	Hs.70830		LOC51690	51690	nucleus, small nucleolar
192	Hs.7187				
193	Hs.7247				
194	Hs.73798	153620	MIF	4282	extracellular space
195	Hs.73818		UQCRH	7388	mitochondrial electron transport chain
196	Hs.74471	121014	GJA1	2697	connexon, integral plasma membrane
197	Hs.74566	601168	DPYSL3	1809	
198	Hs.74602	107776	AQP1	358	integral plasma membrane protein,
199	Hs.7486				
200	Hs.75061		MLP	65108	
201	Hs.75093	153454	PLOD	5351	endoplasmic reticulum
202	Hs.75111	602194	PRSS11	5654	extracellular space
203	Hs.75616				
204	Hs.75617	120090	COL4A2	1284	collagen, collagen type IV
205	Hs.75721	176610	PFN1	5216	actin cytoskeleton
206	Hs.75736	107740	APOD	347	extracellular space
207	Hs.76873	603551	HYAL2	8692	lysosome
208	Hs.7718				
209	Hs.77266	603120	QSCN6	5768	
210	Hs.77273	165390	ARHA	387	cytoskeleton

EP 2 236 614 A2

(continued)

SEQ ID NO:	Unigene ID	OMIMID	gene symbol	locuslink id	Cellular Component
211	Hs.77273	165390	ARHA	387	cytoskeleton
212	Hs.77274	191840	PLAU	5328	extracellular space
213	Hs.77326	146732	IGFBP3	3486	extracellular space
214	Hs.77573	191730	UP	7378	
215	Hs.77864				
216	Hs.77873	605715	B7	80381	cellular_component unknown
217	Hs.77886	150330	LMNA	4000	lamin , nuclear lamina, nucleus
218	Hs.77886	150330	LMNA	4000	lamin, nuclear lamina, nucleus
219	Hs.77886	150330	LMNA	4000	lamin, nuclear lamina, nucleus
220	Hs.78281	602512	RGS12	6002	extrinsic plasma membrane protein,
221	Hs.78466		PSMD8	5714	19S proteasome regulatory particle
222	Hs.78531				
223	Hs.78575	176801	PSAP	5660	extracellular space, integral membrane
224	Hs.78672	600133	LAMA4	3910	basement lamina
225	Hs.78869	601425	TCEA1	6917	nucleus
226	Hs.79339	600626	LGALS3BP	3959	extracellular space, membrane
227	Hs.80617	603675	RPS16	6217	40S ribosomal subunit, intracellular,
228	Hs.81994	110750	GYPC	2995	integral plasma membrane protein,
229	Hs.82002	131244	EDNRB	1910	integral plasma membrane protein,
230	Hs.82085	173360	SERPINE1	5054	
231	Hs.821	301870	BGN	633	extracellular matrix
232	Hs.82575	603520	SNRNPB2	6629	nucleus, snRNP U2e
233	Hs.82749	300096	TM4SF2	7102	integral plasma membrane protein,
234	Hs.83126	600772	TAF2I	6882	nucleus, TFIID complex
235	Hs.83354		LOXL2	4017	extracellular space, membrane
236	Hs.83484	184430	SOX4	6659	nucleus
237	Hs.83484				
238	Hs.83484	184430	SOX4	6659	nucleus
239	Hs.83583	604224	ARPC2	10109	actin cytoskeleton, Arp2/3 protein
240	Hs.84063				
241	Hs.84753				
242	Hs.86131	602457	FADD	8772	cytoplasm
243	Hs.89449	600050	MAP3K11	4296	
244	Hs.89640	600221	TEK	7010	integral plasma membrane protein,
245	Hs.89695	147670	INSR	3643	integral plasma membrane protein,
246	Hs.90107		GP110	11047	integral plasma membrane protein,
247	Hs.9096				
248	Hs.91143	601920	JAG1	182	membrane

(continued)

SEQ ID NO:	Unigene ID	OMIMID	gene symbol	locuslink id	Cellular Component
249	Hs.92236		KIAA0304	9757	nucleus
250	Hs.93728	176311	PBX2	5089	nucleus
251	Hs.9408				
252	Hs.96908		PIG11	9537	
253	Hs.97199	120577	C1QR	22918	integral plasma membrane protein,
254	Hs.97199	120577	C1QR	22918	integral plasma membrane protein,
255	Hs.99093				

[0015] Isolated and purified nucleic acids, according to the present invention are those which are not linked to those genes to which they are linked in the human genome. Moreover, they are not present in a mixture such as a library containing a multitude of distinct sequences from distinct genes. They may be, however, linked to other genes such as vector sequences or sequences of other genes to which they are not naturally adjacent. Tags disclosed herein, because of the way that they were made, represent sequences which are 3' of the 3' most restriction enzyme recognition site for the tagging enzyme used to generate the SAGE tags. In this case, the tags are 3' of the most 3' most NlaIII site in the cDNA molecules corresponding to mRNA. Nucleic acids corresponding to tags may be RNA, cDNA, or genomic DNA, for example. Such corresponding nucleic acids can be determined by comparison to sequence databases to determine sequence identities. Sequence comparisons can be done using any available technique, such as BLAST, available from the National Library of Medicine, National Center for Biotechnology Information. Tags can also be used as hybridization probes to libraries of genomic or cDNA to identify the genes from which they derive. Thus, using sequence comparisons or cloning, or combinations of these methods, one skilled in the art can obtain full-length nucleic acid sequences. Genes corresponding to tags will contain the sequence of the tag at the 3' end of the coding sequence or of the 3' untranslated region (UTR), 3' of the 3' most recognition site in the cDNA for the restriction endonuclease which was used to make the tags. The nucleic acids may represent either the sense or the anti-sense strand. Nucleic acids and proteins although disclosed herein with sequence particularity, may be derived from a single individual. Allelic variants which occur in the population of humans are included within the scope of such nucleic acids and proteins. Those of skill in the art are well able to identify allelic variants as being the same gene or protein. Given a nucleic acid, one of ordinary skill in the art can readily determine an open reading frame present, and consequently the sequence of a polypeptide encoded by the open reading frame and, using techniques well known in the art, express such protein in a suitable host. Proteins comprising such polypeptides can be the naturally occurring proteins, fusion proteins comprising exogenous sequences from other genes from humans or other species, epitope tagged polypeptides, etc. Isolated and purified proteins are not in a cell, and are separated from the normal cellular constituents, such as nucleic acids, lipids, etc. Typically the protein is purified to such an extent that it comprises the predominant species of protein in the composition, such as greater than 50, 60 70, 80, 90, or even 95% of the proteins present.

[0016] Using the proteins according to the invention, one of ordinary skill in the art can readily generate antibodies which specifically bind to the proteins. Such antibodies can be monoclonal or polyclonal. They can be chimeric, humanized, or totally human. Any functional fragment or derivative of an antibody can be used including Fab, Fab', Fab2, Fab'2, and single chain variable regions. So long as the fragment or derivative retains specificity of binding for the endothelial marker protein it can be used. Antibodies can be tested for specificity of binding by comparing binding to appropriate antigen to binding to irrelevant antigen or antigen mixture under a given set of conditions. If the antibody binds to the appropriate antigen at least 2, 5, 7, and preferably 10 times more than to irrelevant antigen or antigen mixture then it is considered to be specific.

[0017] Techniques for making such partially to fully human antibodies are known in the art and any such techniques can be used. According to one particularly preferred embodiment, fully human antibody sequences are made in a transgenic mouse which has been engineered to express human heavy and light chain antibody genes. Multiple strains of such transgenic mice have been made which can produce different classes of antibodies. B cells from transgenic mice which are producing a desirable antibody can be fused to make hybridoma cell lines for continuous production of the desired antibody. See for example, Nina D. Russel, Jose R. F. Corvalan, Michael L. Gallo, C. Geoffrey Davis, Liise-Anne Pirofski. Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci Infection and Immunity April 2000, p. 1820-1826; Michael L. Gallo, Vladimir E. Ivanov, Aya Jakobovits, and C. Geoffrey Davis. The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans European Journal of Immunology 30: 534-540, 2000; Larry L. Green. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human

monoclonal antibodies *Journal of Immunological Methods* 231 11-23, 1999; Yang X-D, Corvalan JRF, Wang P, Roy CM-N and Davis CG. Fully Human Anti-interleukin-8 Monoclonal Antibodies: Potential Therapeutics for the Treatment of Inflammatory Disease States. *Journal of Leukocyte Biology* Vol. 66, pp401-410 (1999); Yang X-D, Jia X-C, Corvalan JRF, Wang P, CG Davis and Jakobovits A. Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy. *Cancer Research* Vol. 59, Number 6, pp1236-1243 (1999); Jakobovits A. Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci. *Advanced Drug Delivery Reviews* Vol. 31, pp: 33-42 (1998); Green L and Jakobovits A. Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. *J. Exp. Med.* Vol. 188, Number 3, pp: 483-495 (1998); Jakobovits A. The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. *Exp. Opin. Invest. Drugs* Vol. 7 (4), pp : 607-614 (1998); Tsuda H, Maynard-Currie K, Reid L, Yoshida T, Edamura K, Maeda N, Smithies O, Jakobovits A. Inactivation of Mouse HPRT locus by a 203-bp retrotransposon insertion and a 55-kb gene-targeted deletion: establishment of new HPRT-Deficient mouse embryonic sGEM cell lines. *Genomics* Vol. 42, pp: 413-421 (1997); Sherman-Gold, R. Monoclonal Antibodies: The Evolution from '80s Magic Bullets To Mature, Mainstream Applications as Clinical Therapeutics. *Genetic Engineering News* Vol. 17, Number 14 (August 1997); Mendez M, Green L, Corvalan J, Jia X-C, Maynard-Currie C, Yang X-d, Gallo M, Louie D, Lee D, Erickson K, Luna J, Roy C, Abderrahim H, Kirschenbaum F, Noguchi M, Smith D, Fukushima A, Hales J, Finer M, Davis C, Zsebo K, Jakobovits A. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. *Nature Genetics* Vol. 15, pp: 146-156 (1997); Jakobovits A. Mice engineered with human immunoglobulin YACs: A new technology for production of fully human antibodies for autoimmunity therapy. *Weir's Handbook of Experimental Immunology, The Integrated Immune System* Vol. IV, pp: 194.1-194.7 (1996); Jakobovits A. Production of fully human antibodies by transgenic mice. *Current Opinion in Biotechnology* Vol. 6, No. 5, pp: 561-566 (1995); Mendez M, Abderrahim H, Noguchi M, David N, Hardy M, Green L, Tsuda H, Yeast S, Maynard-Currie C, Garza D, Gemmill R, Jakobovits A, Klapholz S. Analysis of the structural integrity of YACs comprising human immunoglobulin genes in yeast and in embryonic sGEM cells. *Genomics* Vol. 26, pp: 294-307 (1995); Jakobovits A. YAC Vectors: Humanizing the mouse genome. *Current Biology* Vol. 4, No. 8, pp: 761-763 (1994); Arbones M, Ord D, Ley K, Ratech H, Maynard-Curry K, Otten G, Capon D, Tedder T. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. *Immunity* Vol. 1, No. 4, pp: 247-260 (1994); Green L, Hardy M, Maynard-Curry K, Tsuda H, Louie D, Mendez M, Abderrahim H, Noguchi M, Smith D, Zeng Y, et. al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. *Nature Genetics* Vol. 7, No. 1, pp: 13-21 (1994); Jakobovits A, Moore A, Green L, Vergara G, Maynard-Curry K, Austin H, Klapholz S. Germ-line transmission and expression of a human-derived yeast artificial chromosome. *Nature* Vol. 362, No. 6417, pp: 255-258 (1993); Jakobovits A, Vergara G, Kennedy J, Hales J, McGuinness R, Casentini-Borocz D, Brenner D, Otten G. Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production. *Proceedings of the National Academy of Sciences USA* Vol. 90, No. 6, pp: 2551-2555 (1993); Kucherlapati et al., U.S. 6,1075,181.

[0018] Antibodies can also be made using phage display techniques. Such techniques can be used to isolate an initial antibody or to generate variants with altered specificity or avidity characteristics. Single chain Fv can also be used as is convenient. They can be made from vaccinated transgenic mice, if desired. Antibodies can be produced in cell culture, in phage, or in various animals, including but not limited to cows, rabbits, goats, mice, rats, hamsters, guinea pigs, sheep, dogs, cats, monkeys, chimpanzees, apes.

[0019] Antibodies can be labeled with a detectable moiety such as a radioactive atom, a chromophore, a fluorophore, or the like. Such labeled antibodies can be used for diagnostic techniques, either *in vivo*, or in an isolated test sample. Antibodies can also be conjugated, for example, to a pharmaceutical agent, such as chemotherapeutic drug or a toxin. They can be linked to a cytokine, to a ligand, to another antibody. Suitable agents for coupling to antibodies to achieve an anti-tumor effect include cytokines, such as interleukin 2 (IL-2) and Tumor Necrosis Factor (TNF); photosensitizers, for use in photodynamic therapy, including aluminum (III) phthalocyanine tetrasulfonate, hematoporphyrin, and phthalocyanine; radionuclides, such as iodine-131 (¹³¹I), yttrium-90 (⁹⁰Y), bismuth-212 (²¹²Bi), bismuth-213 (²¹³Bi), technetium-99m (^{99m}Tc), rhenium-186 (¹⁸⁶Re), and rhenium-188 (¹⁸⁸Re); antibiotics, such as doxorubicin, adriamycin, daunorubicin, methotrexate, daunomycin, neocarzinostatin, and carboplatin; bacterial, plant, and other toxins, such as diphtheria toxin, pseudomonas exotoxin A, staphylococcal enterotoxin A, abrin-A toxin, ricin A (deglycosylated ricin A and native ricin A), TGF-alpha toxin, cytotoxin from chinese cobra (*naja naja atra*), and gelonin (a plant toxin); ribosome inactivating proteins from plants, bacteria and fungi, such as restrictocin (a ribosome inactivating protein produced by *Aspergillus restrictus*), saporin (a ribosome inactivating protein from *Saponaria officinalis*), and RNase; tyrosine kinase inhibitors; ly207702 (a difluorinated purine nucleoside); liposomes containing antitumor agents (e.g., antisense oligonucleotides, plasmids which encode for toxins, methotrexate, etc.); and other antibodies or antibody fragments, such as F(ab).

[0020] Those of skill in the art will readily understand and be able to make such antibody derivatives, as they are well known in the art. The antibodies may be cytotoxic on their own, or they may be used to deliver cytotoxic agents to particular locations in the body. The antibodies can be administered to individuals in need thereof as a form of passive

immunization.

[0021] Characterization of extracellular regions for the cell surface and secreted proteins from the protein sequence is based on the prediction of signal sequence, transmembrane domains and functional domains. Antibodies are preferably specifically immunoreactive with membrane associated proteins, particularly to extracellular domains of such proteins or to secreted proteins. Such targets are readily accessible to antibodies, which typically do not have access to the interior of cells or nuclei. However, in some applications, antibodies directed to intracellular proteins may be useful as well. Moreover, for diagnostic purposes, an intracellular protein may be an equally good target since cell lysates may be used rather than a whole cell assay.

[0022] Computer programs can be used to identify extracellular domains of proteins whose sequences are known. Such programs include SMART software (Schultz et al., Proc. Natl. Acad. Sci. USA 95: 5857-5864, 1998) and Pfam software (BaGEMan et al., Nucleic acids Res. 28: 263-266, 2000) as well as PSORTII. Typically such programs identify transmembrane domains; the extracellular domains are identified as immediately adjacent to the transmembrane domains. Prediction of extracellular regions and the signal cleavage sites are only approximate. It may have a margin of error + or - 5 residues. Signal sequence can be predicted using three different methods (Nielsen et al, Protein Engineering 10: 1-6, 1997, Jagla et. al, Bioinformatics 16: 245-250, 2000, Nakai, K and Horton, P. Trends in Biochem. Sci. 24:34-35, 1999) for greater accuracy. Similarly transmembrane (TM) domains can be identified by multiple prediction methods. (Pasquier, et. al, Protein Eng. 12:381-385, 1999, Sonnhammer et al., In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p. 175-182, Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998, Klein, et.al, Biochim. Biophys. Acta, 815:468, 1985, Nakai and Kanehisa Genomics, 14: 897-911, 1992). In ambiguous cases, locations of functional domains in well characterized proteins are used as a guide to assign a cellular localization.

[0023] Putative functions or functional domains of novel proteins can be inferred from homologous regions in the database identified by BLAST searches (Altschul et. al. Nucleic Acid Res. 25: 3389-3402, 1997) and/or from a conserved domain database such as Pfam (BaGEMan et.al, Nucleic Acids Res. 27:260-262 1999) BLOCKS (Henikoff, et. al, Nucl. Acids Res. 28:228-230, 2000) and SMART (Ponting, et. al, Nucleic Acid Res. 27,229-232, 1999). Extracellular domains include regions adjacent to a transmembrane domain in a single transmembrane domain protein (out-in or type I class). For multiple transmembrane domains proteins, the extracellular domain also includes those regions between two adjacent transmembrane domains (in-out and out-in). For type II transmembrane domain proteins, for which the N-terminal region is cytoplasmic, regions following the transmembrane domain is generally extracellular. Secreted proteins on the other hand do not have a transmembrane domain and hence the whole protein is considered as extracellular.

[0024] Membrane associated proteins can be engineered to delete the transmembrane domains, thus leaving the extracellular portions which can bind to ligands. Such soluble forms of transmembrane receptor proteins can be used to compete with natural forms for binding to ligand. Thus such soluble forms act as inhibitors. and can be used therapeutically as anti-angiogenic agents, as diagnostic tools for the quantification of natural ligands, and in assays for the identification of small molecules which modulate or mimic the activity of a GEM:ligand complex.

[0025] Alternatively, the endothelial markers themselves can be used as vaccines to raise an immune response in the vaccinated animal or human. For such uses, a protein, or immunogenic fragment of such protein, corresponding to the intracellular, extracellular or secreted GEM of interest is administered to a subject. The immunogenic agent may be provided as a purified preparation or in an appropriately expressing cell. The administration may be direct, by the delivery of the immunogenic agent to the subject, or indirect, through the delivery of a nucleic acid encoding the immunogenic agent under conditions resulting in the expression of the immunogenic agent of interest in the subject. The GEM of interest may be delivered in an expressing cell, such as a purified population of glioma endothelial cells or a populations of fused glioma endothelial and dendritic cells. Nucleic acids encoding the GEM of interest may be delivered in a viral or non-viral delivery vector or vehicle. Non-human sequences encoding the human GEM of interest or other mammalian homolog can be used to induce the desired immunologic response in a human subject. For several of the GEMs of the present invention, mouse, rat or other ortholog sequences are described herein or can be obtained from the literature or using techniques well within the skill of the art.

[0026] Endothelial cells can be identified using the markers which are disclosed herein as being endothelial cell specific. These include the human markers identified by SEQ ID NOS: 1-510. Antibodies specific for such markers can be used to identify such cells, by contacting the antibodies with a population of cells containing some endothelial cells. The presence of cross-reactive material with the antibodies identifies particular cells as endothelial. Similarly, lysates of cells can be tested for the presence of cross-reactive material. Any known format or technique for detecting cross-reactive material can be used including, immunoblots, radioimmunoassay, ELISA, immunoprecipitation, and immunohistochemistry. In addition, nucleic acid probes for these markers can also be used to identify endothelial cells. Any hybridization technique known in the art including Northern blotting, RT-PCR, microarray hybridization, and in situ hybridization can be used.

[0027] One can identify glioma endothelial cells for diagnostic purposes, testing cells suspected of containing one or more GEMs. One can test both tissues and bodily fluids of a subject. For example, one can test a patient's blood for

evidence of intracellular and membrane associated GEMS, as well as for secreted GEMS. Intracellular and/or membrane associated GEMs may be present in bodily fluids as the result of high levels of expression of these factors and/or through lysis of cells expressing the GEMs.

[0028] Populations of various types of endothelial cells can also be made using the antibodies to endothelial markers of the invention. The antibodies can be used to purify cell populations according to any technique known in the art, including but not limited to fluorescence activated cell sorting. Such techniques permit the isolation of populations which are at least 50, 60, 70, 80, 90, 92, 94, 95, 96, 97, 98, and even 99 % the type of endothelial cell desired, whether normal, tumor, or pan-endothelial. Antibodies can be used to both positively select and negatively select such populations. Preferably at least 1, 5, 10, 15, 20, or 25 of the appropriate markers are expressed by the endothelial cell population.

[0029] Populations of endothelial cells made as described herein, can be used for screening drugs to identify those suitable for inhibiting the growth of tumors by virtue of inhibiting the growth of the tumor vasculature.

[0030] Populations of endothelial cells made as described herein, can be used for screening candidate drugs to identify those suitable for modulating angiogenesis, such as for inhibiting the growth of tumors by virtue of inhibiting the growth of endothelial cells, such as inhibiting the growth of the tumor or other undesired vasculature, or alternatively, to promote the growth of endothelial cells and thus stimulate the growth of new or additional large vessel or microvasculature.

[0031] Inhibiting the growth of endothelial cells means either regression of vasculature which is already present, or the slowing or the absence of the development of new vascularization in a treated system as compared with a control system. By stimulating the growth of endothelial cells, one can influence development of new (neovascularization) or additional vasculature development (revascularization). A variety of model screening systems are available in which to test the angiogenic and/or anti-angiogenic properties of a given candidate drug. Typical tests involve assays measuring the endothelial cell response, such as proliferation, migration, differentiation and/or intracellular interaction of a given candidate drug. By such tests, one can study the signals and effects of the test stimuli. Some common screens involve measurement of the inhibition of heparanase, endothelial tube formation on Matrigel, scratch induced motility of endothelial cells, platelet-derived growth factor driven proliferation of vascular smooth muscle cells, and the rat aortic ring assay (which provides an advantage of capillary formation rather than just one cell type).

[0032] Drugs can be screened for the ability to mimic or modulate, inhibit or stimulate, growth of tumor endothelium cells and/or normal endothelial cells. Drugs can be screened for the ability to inhibit tumor endothelium growth but not normal endothelium growth or survival. Similarly, human cell populations, such as normal endothelium populations or glioma endothelial cell populations, can be contacted with test substances and the expression of glioma endothelial markers and/or normal endothelial markers determined. Test substances which decrease the expression of glioma endothelial markers (GEMs) are candidates for inhibiting angiogenesis and the growth of tumors. In cases where the activity of a GEM is known, agents can be screened for their ability to decrease or increase the activity.

[0033] For those glioma endothelial markers identified as containing transmembrane regions, it is desirable to identify drug candidates capable of binding to the GEM receptors found at the cell surface. For some applications, the identification of drug candidates capable of blocking the GEM receptor from its native ligand will be desired. For some applications, the identification of a drug candidate capable of binding to the GEM receptor may be used as a means to deliver a therapeutic or diagnostic agent. For other applications, the identification of drug candidates capable of mimicking the activity of the native ligand will be desired. Thus, by manipulating the binding of a transmembrane GEM receptor:ligand complex, one may be able to promote or inhibit further development of endothelial cells and hence, vascularization.

[0034] For those glioma endothelial markers identified as being secreted proteins, it is desirable to identify drug candidates capable of binding to the secreted GEM protein. For some applications, the identification of drug candidates capable of interfering with the binding of the secreted GEM to its native receptor. For other applications, the identification of drug candidates capable of mimicking the activity of the native receptor will be desired. Thus, by manipulating the binding of the secreted GEM:receptor complex, one may be able to promote or inhibit further development of endothelial cells, and hence, vascularization.

[0035] Expression can be monitored according to any convenient method. Protein or mRNA can be monitored. Any technique known in the art for monitoring specific genes' expression can be used, including but not limited to ELISAs, SAGE, microarray hybridization, Western blots. Changes in expression of a single marker may be used as a criterion for significant effect as a potential pro-angiogenic, anti-angiogenic or anti-tumor agent. However, it also may be desirable to screen for test substances which are able to modulate the expression of at least 5, 10, 15, or 20 of the relevant markers, such as the tumor or normal endothelial markers. Inhibition of GEM protein activity can also be used as a drug screen. Human and mouse GEMS can be used for this purpose.

[0036] Test substances for screening can come from any source. They can be libraries of natural products, combinatorial chemical libraries, biological products made by recombinant libraries, etc. The source of the test substances is not critical to the invention. The present invention provides means for screening compounds and compositions which may previously have been overlooked in other screening schemes. Nucleic acids and the corresponding encoded proteins of the markers of the present invention can be used therapeutically in a variety of modes. GEMs can be used to stimulate the growth of vasculature, such as for wound healing or to circumvent a blocked vessel. The nucleic acids and encoded

proteins can be administered by any means known in the art. Such methods include, using liposomes, nanospheres, viral vectors, non-viral vectors comprising polycations, etc. Suitable viral vectors include adenovirus, retroviruses, and sindbis virus. Administration modes can be any known in the art, including parenteral, intravenous, intramuscular, intraperitoneal, topical, intranasal, intrarectal, intrabronchial, etc.

[0037] Specific biological antagonists of GEMs can also be used to therapeutic benefit. For example, antibodies, T cells specific for a GEM, antisense to a GEM, and ribozymes specific for a GEM can be used to restrict, inhibit, reduce, and/or diminish tumor or other abnormal or undesirable vasculature growth. Such antagonists can be administered as is known in the art for these classes of antagonists generally. Anti-angiogenic drugs and agents can be used to inhibit tumor growth, as well as to treat diabetic retinopathy, rheumatoid arthritis, psoriasis, polycystic kidney disease (PKD), and other diseases requiring angiogenesis for their pathologies.

[0038] Mouse counterparts to human GEMs can be used in mouse cancer models or in cell lines or *in vitro* to evaluate potential anti-angiogenic or anti-tumor compounds or therapies. Their expression can be monitored as an indication of effect. Mouse GEMs can be used as antigens for raising antibodies which can be tested in mouse tumor models. Mouse GEMs with transmembrane domains are particularly preferred for this purpose. Mouse GEMs can also be used as vaccines to raise an immunological response in a human to the human ortholog.

[0039] The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1

[0040] In this study we employ SAGE transcript profiling to derive the transcriptomes from normal and neoplastic brain tissue. Moreover, we have employed a new version of SAGE, long SAGE, allowing for the derivation of 21 bp SAGE tags. These longer tags allow for the direct interrogation of genomic DNA, identifying unique locations of cell-specific transcription. Endothelial cells from normal brain and different stages of gliomas were expression profiled and compared to each other and to the colon endothelial cell data. Distinct sets of genes define global tumor and normal endothelial cell markers as well as defining glioma-specific endothelial markers. This expanded tumor endothelial cell database will likely provide further insights into the complex regulatory mechanisms governing tumor angiogenesis.

EXAMPLE 2

[0041] Tissue procurement and endothelial cell isolation. Five separate brain tissue samples (Table 1) were resected and immediately subjected to endothelial cell isolation with slight modifications to the protocol described previously. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. (2000). Genes expressed in human tumor endothelium. *Science* 289, 1197-202.

[0042] Briefly, samples were surgically excised and submerged in DMEM. The samples were minced into 2 centimeter cubes and subjected to tissue digestion with a collagenase cocktail. Samples were mixed at 37°C until dissolved. Cells were spun down and washed two times with PBSBSA and filtered through successive nylon mesh filters of 250, 100 and 40 microns. Samples were resuspended in PBS/BSA and applied to a 30% Percoll gradient centrifuging for 15 minutes at 800g. 5 ml off the top of the percoll gradient was diluted in 50 ml DMEM and cells pelleted, washed with PBS and resuspended in 3 ml PBSBSA. Cells were filtered through falcon blue top filter tubes, spun down and resuspended in 1 ml PBS/BSA. 100 microliters of prewashed anti-CD45 magnetic beads (Dyna) were added and the solution allowed to gently mix for ten minutes. Bead-bound cells were discarded and the supernatant transferred to a fresh microcentrifuge tube. 10 microliters of P1H12 mAb (1:100) (Brain N1, T1, and T2 samples) or UEA-I lectin (Brain N2 and T3 samples) was added and the samples were mixed gently at 4°C for 45 minutes. Cells were pelleted and washed 3 times in PBSBSA and resuspended in 500 microliters PBS/BSA. Prewashed goat anti-mouse M450 dynabeads were added to each tube and allowed to mix for 15 minutes at 4°C. Bead-bound cells were washed 8 times with PBS/BSA and resuspended in a final volume of 500 microliters PBS. Cells were counted and frozen at -70°C prior to RNA extraction.

EXAMPLE 3

[0043] RNA isolation and SAGE library generation. RNA was isolated from the selected cells and initially subjected to RT-PCR analysis to determine the relative abundance of specific, known endothelial cell markers. The microSAGE protocol St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. (2000). Genes expressed in human tumor endothelium. *Science* 289, 1197-202 (server www.sagenet.org, directory [sage_protocol](http://sagenet.org/sage_protocol)) was used to generate high-quality long-SAGE libraries employing the tagging enzyme MmeI instead of BsmFI. 21 base tags were defined by capillary sequencing using a combination of an ABI 3700 and ABI 3100. The sample descriptions and sequencing depth are shown in Table 3.

EXAMPLE 4

[0044] Data analysis. Long SAGE tags derived from the brain endothelial samples were reduced to short tags to allow for the integration of colon endothelial SAGE data. Aggregate short tags were derived from the long tags. Any short tag counts that had more than one corresponding long tag representative were summed and the counts represented as one short tag. Both sequencing errors and legitimate long tag derivatives contribute to the generation of multiple long tags. For transcript and genome mapping, differential long tags were employed. Differential gene expression was evaluated as follows: For the two normal brain samples, either the maximum or minimum value was used for determining tumor/normal and normal/tumor ratios, respectively. For the three brain tumor samples, the median value was used for the tumor/normal whereas the maximum value was used for the normal/tumor ratios. A two parameter family of beta distributions was used to assess the probability of observing two fold differences in the observed SAGE tag abundances. Chen, H., Centola, M., Altschul, S. F., and Metzger, H. (1998). Characterization of gene expression in resting and activated mast cells. *J Exp Med* 188, 1657-68.

EXAMPLE 5

[0045] The following provides a detailed protocol useful for isolating brain endothelial cells. All steps were done at 4° C in cold room and in centrifuge except digestion.

1) Take sample from operating room and submerge in known volume of DMEM+ in 50 ml conical tube to measure tumor volume by displacement. Cut off 2 small pieces of tumor on dry ice and store at -70° C for mRNA extraction/immunohistochemistry/in situ analysis.

2) Take sample from conical and place in small amount of DMEM+ in 10 cm Tissue Culture dish in hood. Mince specimen into 2 mm cubes with sterile scalpel.

3) Transfer minced specimen to small autoclaved erlenmeyer flask and add 5X volume of digestion cocktail. Sample volumes > 5 ml should be split into multiple flasks.

4) Mix in bacterial shaker or in 37° C room on rotating shaker for 45 minutes or until sample is dissolved. Titrate with 10 ml piper every 15 minutes. Once a good cell suspension is obtained, remove and transfer to 50 ml conical.

Remainder of protocol done at 4°C.

5) Spin down at 1500 RPM (600xg) at 4° C for 5 minutes.

6) Wash 2X with PBS/BSA and spin down again. Pool samples.

7) Filter through Nylon Mesh (250, 100, 40 micron).

8) Spin down.

9) Resuspend in PBS/BSA at 1/2 the original tumor volume.

10) Apply sample in 500 ul aliquots to preformed 30% Percoll gradient (Gradients needed = volume of original sample).

11) Spin at 1750 RPM (800g) for 15 minutes.

12) Remove top 5 ml Percoll from each tube and dilute with DMEM to 50 ml volume.

13) Pellet cells in centrifuge at 1500 RPM. Pool pelleted cells.

14) Wash 2X with PBS/BSA and resuspend in 3 ml PBS/BSA.

15) Filter through Falcon Blue Top Filter tube.

16) Spin down and resuspend in 1 ml PBS/BSA in a 1.5 ml microcentrifuge tube.

EP 2 236 614 A2

17) Add 100 μ l of prewashed anti-CD45 beads (hematopoietic depletion) to solution and rotate end over end in cold room for ten minutes. [For brain tissue isolation, an additional negative selection with BerEP4 epithelial depletion is not needed]

18) Remove bead-bound cells and transfer supernatant to a fresh microcentrifuge tube. Save bead-bound sample by freezing at -70° C. Repeat extraction to ensure complete removal of all beads.

19) Add 10 μ l of P1H12 mAb (1:100) to cells and mix in cold room with end-over-end rotation for 45 minutes. [As an alternative, selection using UEA1 lectin also provides quality endothelial cell selection.] 20) Pellet cells and wash 3X with PBS/BSA.

21) Resuspend cells in 500 μ l of PBS/BSA.

22) Divide sample into four 1.5 ml microcentrifuge tubes (125 μ l per tube) and bring volume up to 800 μ l. Add 50 μ l of prewashed goat anti-mouse M450 dynabeads to each tube.

23) Rotate tubes in cold room for 15 minutes.

24) Separate with magnet and save supernatant as staining control, tumor/brain fraction.

25) Rinse 8X with PBS/BSA.

26) Pool beads into single microcentrifuge tube.

27) Resuspend final cells in 500 μ l plain PBS.

28) Take 5 μ l of solution and combine with 5 μ l of Magic DAPI and count on hemacytometer.

29) Remove 10k cells for staining for quality control based on hemacytometer results

30) Separate beads again and freeze remainder at -70° C for mRNA extraction.

EXAMPLE 6

[0046] This example describes the preparation of SAGE tags from mRNA extracted from brain endothelial cells. The preparation is described with reference to standard SAGE tag preparation procedures as are known in the art.

All of the template was used in the PCR SAGE ditag step. Usually we take only a small portion of our template, dilute it and perform ~300 PCR reactions. For these libraries we used all of our material, diluted it and performed ~ 1200 PCR reactions.

* During the post-amplified PCR product purification step we normally do a standard large volume phenol/chloroform extraction and remove the aqueous layer which contains the product of interest. For these libraries we used Eppendorf's Phase Lock product which creates a physical barrier between the aqueous and organic layers thereby decreasing the amount of product you leave behind. This product was used for all P/C extractions in the second half of the protocol.

* Digesting the amplified PCR products with NlaIII to release the ditag of interest is usually done in one reaction. For these libraries I divided the material into thirds and performed 3 NlaIII reactions in the hopes of yielding more released ditag.

* Due to the low amount of material, upon entering the concatemer and digested pZERO ligation reaction, I modified the recipe for this reaction to accommodate this. Standard reaction calls for 6 μ l of concatemers, 2 μ l of 5x ligase buffer, 1 μ l digested pZERO vector, and 1 μ l of high concentrate ligase. I modified it to 6 μ l of concatemers, 2 μ l of 5x ligase buffer, 0.3-0.5 μ l of digested pZERO vector, 1 μ l high concentrate ligase and filled

the missing volume with water. My intention was to favor the concatemer to pZERO ligation reaction relative to the competing pZERO to pZERO ligation reaction.
 Most gels during the procedure showed weak amounts of product for
 5 visualization and the concatemer gels showed no visible product via the naked eye (we cut out certain fractions regardless).

EXAMPLE 7

10 **[0047]** Microarray Analysis. Custom 50 nucleotide oligomer arrays were constructed containing 606 unique gene elements. The 606 genes were derived from tumor and normal induced genes from both colon and brain data (328 genes), as well as 278 genes from both literature reviews and housekeeping genes. Arrays were interrogated with Cy3 and Cy5 dye-swapped labelled aRNA samples comparing HMVECs grown on plastic, collagen, fibrin, or Matrigel.

EXAMPLE 8

15 **[0048]** In situ Hybridizations and Immunohistochemistry. In situ hybridizations for PV I, VEGFR2 and vWF were carried out as described previously (10). Co-staining of PV1 and CD31 was carried out as follows: Four 500 nucleotide riboprobe fragments specific for PV1 were transcribed and used to probe formalin fixed 5 micron tissue sections. Final detection
 20 of the bound riboprobes were delayed until after the CD31 IHC staining. After PV1 hybridization and washing, tissue sections were fixed for 20 minutes in 4% formaldehyde. After a brief rinse in TBS, antigen retrieval was carried out using DAKO target retrieval solution (DAKO, Cat#S 1699) according to manufacturer's instructions. After a five minute wash in TBS, slides were digested with Proteinase K at 20 ng/ml in TBS for 20 minutes at 37T, then blocked for 20 minutes
 25 at room temperature in block (10% Goat serum/0.5% Casein/0.05% Tween-20/PBS). Slides were incubated with DAKO CD31 (Cat#M0823) at a final concentration of 1 microgram/slide in block solution, for 60 minutes at room temperature. After two 5 minute TBST (DAKO, Cat#S3306) washes at room temperature, PV1 riboprobe and CD31 antibody were detected with Streptavidin-Cy2 (Jackson ImmunoResearch, Cat#016-220-084) at 5 micrograms/slide for the PV1 ribo-
 30 probe, and goat anti-mouse-Cy3 (Jackson ImmunoResearch, Cat# 115-165 -146) at 2.5 micrograms/slide for CD3 1, for 60 minutes at room temperature. After three Ywashes in TBST, the slides were mounted with antifade medium containing DAPI nuclear counter-stain, cover-slipped and stored at -20°C until viewing. Single images of DAPI, Cy2 and
 Cy3 images were acquired separately on a Zeiss Axioplan at 40x with a Hammamatsu camera, then merged together to form a composite image using universal imaging metamorph software, and stored at -20C until viewing.

EXAMPLE 9

35 **[0049]** Capillary-like tubule formation assay. The formation of capillary-like tubular structures was assessed in Matrigel-coated multiwell plates essentially as described previously (12). Briefly, 300 microliters of Matrigel (BD, Bedford, MA) was added to each well of a 24well plate and allowed to polymerize at 37 °C for 30 minutes. HMVECs (BioWhittaker)
 40 were infected with adenovirus harboring Tem.1 or GFP gene or empty vector (EV) for 67 hours at 300 MOI (Multiplicity Of Infection). Cells were then seeded at a density of 30 x 103 cells/well in 500 microliters EGM-2 medium with supplements (BioWhittaker) in Matrigel-coated plates and incubated at 37 °C for 24 hours and viewed using a Nikon Eclipse TE200 microscope under a phase contrast and photographed. Images were analyzed using software Scion Image (Scion Corporation, Frederick, MD) under the mode of integrated density.

EXAMPLE 9

45 **[0050]** Cell Proliferation Assay. HMVEC proliferation was assessed by the Cell Titer-Glo Luminescent Cell Viability Assay (Promega, Madison, WI) in 96-well cell culture plates. HMVECs were seeded at 2,000 cells per well in 100 microliters medium and plates were incubated at 37 °C for 48 hours. Reagent was added to each well according to
 50 manufacture's instruction, and fluorescence was measured using the Millipore CytoFluor2350.

EXAMPLE 10

55 **[0051]** Five independent endothelial cell populations were purified from glioma tumor tissue and normal brain tissue. In this study, the tissue defined as normal is derived from patients with epilepsy who have undergone a temporal lobectomy. The samples are summarized in Table 3. Samples N1, T1 and T2 were ultimately P1H12-selected and samples N2 and T3 were UEA-I selected. Prior to SAGE analysis, each sample was assessed for the relative mRNA abundance for vWF, Glial fibrillary acidic protein (GFAP) and EF1 by RT-PCR. Abundant levels of vWF and the control

housekeeper EF1, and low levels of the glial cell-specific gene GFAP suggested the cell population was primarily endothelial (data not shown). SAGE analysis was performed to a depth of approximately 50,000 tags (Table 3). For data analysis, each SAGE project was normalized to exactly 50,000 tags. Pairwise comparisons between expression data derived from tumor samples selected with P1H12 or UEA-I showed correlation coefficients around 80%, slightly higher than a comparison between two tumor samples both selected with P1H12. This suggests that selecting endothelial cells with either P1H12 or UEA-I results in highly similar cell populations. Moreover, nearly half of the tumor specific markers revealed in this study are induced 4 fold in each of the normal samples used, suggesting the normal samples are similar populations as well. With this in mind, we felt that combining data for the two normal samples and for the three tumor samples was appropriate.

Table 3. Samples used in this study.

Sample	Description	Tags Generated	EC Selection
Brain N1	Normal temporal lobectomy ECs	43,000	P1H12
Brain N2	Normal temporal lobectomy ECs	49,000	UEA-I
Brain T1	Grade IV Glioma Ecs	46,000	P1H12
Brain T2	Grade III Glioma Ecs	50,000	P1H12
Brain T3	Grade IV Glioma Ecs	58,000	UEA-I
Colon N*	Normal colon Ecs	96,000	P1H12
Colon T*	Tumor colon Ecs	96,000	P1H12
Fetal Brain	Normal bulk	204,000	-
Fetal Kidney	Normal bulk	50,000+	-

[0052] Genes specific for endothelial cells showed expression levels consistent with the previously examined colon endothelial SAGE data (Table 4). Additionally, markers specific for epithelial, hematopoietic or glial cells showed limited or no expression in the brain endothelial libraries suggesting little contamination from non-endothelial cell populations (Table 4). Finally, the data generated here allow for the derivation of a 12 gene EC prediction class of which 6 have been previously described as EC-specific (Huminiemi, L., and Bicknell, R. (2000). In silico cloning of novel endothelial-specific genes. Genome Res 10, 1796-806.) (data not shown). This provides further evidence of pure EC populations used for this study.

Table 4. Cell specificity markers.

Gene	Specificity	Colon N	Colon T	Brain N1	Brain N2	Brain T1	Brain T2	Brain T3
Hevin	EC	161	69	51	99	223	121	48
VWF	EC	35	33	12	53	37	51	110
Tie2/Tek	EC	4	2	2	4	1	4	3
CD34	EC	5	2	3	10	12	4	11
CD14	Hematopoietic	1	1	1	2	0	0	1
CK8	Epithelial	1	2	0	0	2	1	1
GLUT1	Brain EC	0	1	8	37	2	25	8
GFAP	Glial	0	0	0	0	0	0	0

[0053] Genes expressed preferentially in glioma derived endothelial cells as opposed to normal endothelial cells are potentially involved in regulating angiogenesis-dependent tumor growth. Specific parameters for the sorting of SAGE data and the layering of additional statistical filters allowed for a conservative estimate of legitimate differentially expressed

genes (see Methods). Excluding mitochondrial genes, 131 genes were observed to be induced in the glioma endothelial cells based on a four fold induction ratio. Only 14 genes can be entertained as glioma-specific when additional statistical filters are applied (Table 5). In this case, a two fold parameter family of distributions was used to establish a 90% probability of observing at least a 2 fold difference in values. Only one of these twelve genes, apolipoprotein D, shows higher expression in the stage III glioma than at least one of the stage IV tumors. This suggests that many of the highly induced glioma endothelial genes revealed in this analysis may be involved in later stages of angiogenesis where the initiation of vascular sprouting has already occurred or are glioma type specific showing representation in the astrocytoma and not oligodendroglioma-derived ECs.. Less highly induced genes, or genes primarily induced in the less aggressive tumor stage, may be more reflective of angiogenesis initiation. Several genes regulating extracellular matrix architecture are revealed as highly induced in this study. HSPG2 (perlecan), several type IV collagen transcript variants, and matrix metalloprotease 14 (MMP14) have all been shown to play a role in remodeling the extracellular matrix. Interestingly, other genes that play roles in either cellular signaling or cell-cell communication are also highly expressed exclusively in glioma-associated endothelial cells. Melanoma associated antigen (MG50), endothelin receptor, the G-protein coupled receptor RDC-1, and integrin αV are all cell surface proteins previously demonstrated to play a role in signaling cascades. Although the endothelin receptor, RDC-1 and integrin αV have previously been shown to regulate angiogenesis, MG50 does not have an association with angiogenesis. Moreover, MG50 was previously shown to be selectively associated with several types of tumor cells with a function yet to be defined. It is noteworthy that the p53-induced, brain-specific angiogenesis inhibitor (BAI-1) was expressed to significant levels but restricted to the earlier stage tumor present in this study (data not shown). It is possible that the loss of expression of BAI-1 in the later tumor stages reflects the need to more aggressively advance vascular development. Other than the detection of a differential HEYL SAGE tag, no other colon endothelial markers were observed to be preferentially expressed in the grade III tumor. In total, of the 14 tumor induced genes listed, 12 are either present on the cell surface or secreted. The localization of the remaining two gene products has yet to be determined as these genes remain uncharacterized. Finally, it is noteworthy that only a select few genes show significant (>2 tags) expression in a fetal brain library where angiogenesis is expected to be robust.

[0054] In contrast to the highly biased localization of glioma-induced endothelial cell gene expression defined above, genes that are induced in the normal endothelial cells relative to glioma endothelial cells show a radically different cellular distribution. Twenty-one genes are induced 4 fold or greater in the normal endothelial cells. Filtering for genes with a 50% or greater chance of having greater than 2 fold difference in transcript abundance reduces this list to 14 genes (Table 6). Protein products predicted for these 14 genes show a range of cellular localizations with 4 gene products being intracellular, 5 being integral membrane proteins, 3 extracellular, and one each either secreted, on the cell surface or a nuclear membrane receptor. Several of these genes have functions consistent with either tumor suppressor or anti-angiogenic functions. These anti-proliferative functions have been ascribed to the early growth response gene 1 (EGR1), BTG2, Fruppel-like factor 4 (KLF4), and the serine protease inhibitor SPINT2 although associations with angiogenesis are limited to SPINT2. The down-regulation of these genes in each of the three glioma tumors suggests that these genes may function to encode proteins with anti-angiogenic properties. Both SPINT2 and BTG2 are secreted and may act via paracrine mechanisms. Also noteworthy is the preferential expression of the secreted protein MT1A as this metallothionein may serve as an antioxidant potentially attenuating DNA damage within adjacent cells. Interestingly, EGR1 and KLF4 encode transcription factors suggesting that some part of the anti-angiogenic pathway revealed here may be initiated by these gene products. With the exception of MT1A, none of the above genes show differential expression in colon tumor ECs and may therefore be glioma-specific EC markers.

[0055] The specificity of gene expression for tumor EC subtypes is important to define and can be addressed with the glioma EC data integrated with data obtained previously for colon EC populations. A limited number of genes are preferentially expressed in both brain and colon normal EC populations. In contrast, 16 genes were induced at least 4 fold in both colon and brain tumor EC fractions. 12 of these genes also met the criteria of having a greater than 50% chance of being at least 2 fold differential (Table 7). The majority of these genes (7) are collagen transcripts. However, tumor endothelial marker 1 (TEM1), THY1, and RDC-1 also show consistent induction in the different tumor EC cells. This limited conservation of tumor-induced EC expression suggests highly specific EC expression profiles dependent on the tissue source. TEM1 expression has been validated on tissue arrays harboring tissue slices from astrocytomas (data not shown).

[0056] Defining the specificity of gene expression to particular cell types can assist in determining function and designing therapeutics. Our non-endothelial cell SAGE database currently contains 76 libraries encoding 255,000 unique SAGE transcripts. The epithelial cell lines derive from lung, ovary, kidney, prostate, breast, colon, pancreas. Additional non-epithelial sources include cardiomyocytes, melanocytes, glioblastoma and monocytes. Genes which show induction in glioma ECs and demonstrate a restricted expression in non-EC cells may be ideal targets for anti-angiogenic therapies. Allowing for 1 or fewer tags in any non-EC library and at least a four-fold induction in glioma ECs yielded only 5 genes (Table 8). Some of these genes are likely not EC-specific due to the relatively limited number of cell types included within the non-EC database. However, both PV-1 and Plexin A2 (PLXNA2) are interesting genes with potential functional relevance to angiogenesis regulation.

[0057] The SAGE tag that defines PLXNA2 falls outside of the current mRNA boundaries residing 3' of the ultimate exon. RT-PCR results, however, have confirmed transcription of mRNA containing this tag in the tumor samples used to derive the SAGE data. Plexins share homology with the scatter factor/hepatocyte growth factor (SF/HGF) family of receptors encoded by the MET gene family [Tamagnone, L., Artigiani, S., Chen, H., He, Z., Ming, G. I., Song, H., Chedotal, A., Winberg, M. L., Goodman, C. S., Poo, M., Tessier-Lavigne, M., and Comoglio, P. M. (1999). Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. *Cell* 99, 71-80.] Earlier results have demonstrated a link between SF/HGF expression and increase tumorigenicity [Bowers, D. C., Fan, S., Walter, K. A., Abounader, R., Williams, J. A., Rosen, E. M., and Lattera, J. (2000). Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. *Cancer Res* 60, 4277-83.] Moreover, SF/HGF promotes this increased tumorigenicity with concordant stimulation in angiogenesis [Lamszus, K., Lattera, J., Westphal, M., and Rosen, E. M. (1999). Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. *Int J Dev Neurosci* 17, 517-30.] In vivo targeting of SF/HGF was demonstrated to inhibit glioma growth and angiogenesis [Abounader, R., Lal, B., Luddy, C., Koe, G., Davidson, B., Rosen, E. M., and Lattera, J. (2002). In vivo targeting of SF/HGF and c-met expression via UlsnRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. *Faseb J* 16, 108-10.]. Plexins are known to function as coreceptors with neuropilin 1 functioning as a receptor for semaphorin and, in turn, regulating neuronal guidance and cell association [Tamagnone, 1999, *supra*]. As neuropilin-1 and Plexin association can serve to receive signals from semaphorins to guide neuronal growth, it is conceivable that a Plexin-neuropilin association may regulate angiogenic growth in a manner analogous to KDR-neuropilin complexes signaling VEGF responses. Plexin A2 shows very low level expression in colon ECs and is not differentially induced in colon tumor ECs. It is noteworthy that another plexin, plexin B2 (PLXNB2), also showed a five fold increase in glioma EC expression but did not make the statistical threshold demanded for Table 8. Plexin B2 was previously shown to be differentially induced in brain tumors [Shinoura, N., Shamraj, O. I., Hugenholz, H., Zhu, J. G., McBlack, P., Warnick, R., Tew, J. J., Wani, M. A., and Menon, A. G. (1995). Identification and partial sequence of a cDNA that is differentially expressed in human brain tumors. *Cancer Lett* 89, 215-21.] The upregulation of plexins in glioma ECs allows for a hypothesis whereby SF/HGF directly stimulates EC migration and proliferation. The novel discovery of a consistently upregulated level of Plexin A2 in gliomas requires further evidence for a functional link between tumor levels of plexin A2 and angiogenesis regulation, particularly in the brain.

[0058] PV-1 (also called PLVAP for plasmallema vesicle associated protein), is a recently discovered type II integral membrane glycoprotein shown to colocalize with caveolin-1. Stan, R. V., Arden, K. C., and Palade, G. E. (2001). cDNA and protein sequence, genomic organization, and analysis of cis regulatory elements of mouse and human PLVAP genes. *Genomics* 72, 304-13. Interestingly, this protein was the first to be shown to localize to the stomatal diaphragms and transendothelial channels within caveolae. The specific function of PV-1 remains unknown. PV-1 is expressed at substantial levels in colon ECs but is not expressed differentially between normal and tumor colon ECs. The upregulation of this caveolae-associated protein in gliomas may provide a means for specifically targeting glioma-associated endothelial cells as well as potentially providing a therapeutic delivery mechanism to the underlying tumorigenic cells (Marx, J. (2001). Caveolae: a once-elusive structure gets some respect. *Science* 294, 1862-5.))

[0059] From this study there is also the potential to define brain EC specific genes irrespective of function or differential expression in normal or tumor tissue. Applying the same criteria as that applied for defining EC restricted glioma induced genes, only two genes, TNF α -induced protein 3 and JCTNB, show consistent expression in the brain EC samples but severely limited expression in non-EC databases.

[0060] The blood brain barrier within brain capillary endothelial cells results in a restricted diffusion of both small and large molecules as compared to non-brain EC junction complexes. As a result of this, brain capillary ECs facilitate molecular exchange via a tightly regulated, or catalyzed transport system. Any differential expression of catalyzed membrane transporters between normal and tumor tissue may provide a means to selectively deliver therapies to tumor cells. The insulin receptor (IR) has been known for some time to be a marker for brain capillary ECs and to facilitate delivery of drugs. One of the most highly induced, glioma-specific genes in this study is the IR (Table 8). The high induction of IR transcripts in gliomas was not previously recognized and may provide a selective delivery mechanism to cancer cells as these receptors are also proposed to reside within caveolae structures [Smith, R. M., Jarret, L. (1988). *Lab. Invest.* 58, 613-629.] Overall, very few transporters showed a differential induction in glioma-associated ECs as compared to their normal counterpart (Table 9). This is counter to previous suggestions linking altered expression of transporters with histologic grade of CNS tumors [Guerin, C., Wolff, J. E., Lattera, J., Drewes, L. R., Brem, H., and Goldstein, G. W. (1992). Vascular differentiation and glucose transporter expression in rat gliomas: effects of steroids. *Ann Neurol* 31, 481-7.] Only one other gene, SLC1A5 Solute carrier family 1 member 5 (neutral amino acid transporter), showed a greater than 4 fold induction in glioma-derived ECs. It should be stated, however, that the standard SAGE tag for integrin α V is shared with aquaporin. Long tag derivations of these two genes revealed that both integrin α V and aquaporin are induced in glioma ECs. Aquaporin may play a role in caveolae swelling that accompanies VEGF stimulated EC growth [Roberts, W. G., and Palade, G. E. (1997). Neovasculture induced by vascular endothelial growth factor is

fenestrated. Cancer Res 57, 765-72.] Only one membrane transporter, Na⁺/K⁺ transporting ATP1A2 ATPase, was reciprocally repressed in glioma-derived ECs. It remains possible that certain transporters were missed in this analysis due to incorrect functional assignment. Nonetheless, the low number of differentially regulated transport facilitators suggests a small number of these genes need to be transcriptionally activated to accommodate any necessary increase in protein abundance required for tumor growth.

Table 10 shows genes induced in glioma endothelial cells but not in colon tumor or breast tumor endothelial cells.

Table 11 shows genes which encode transporters which are repressed in glioma endothelial cells.

Table 12 shows genes which encode proteins which are localized to the nucleus of both brain and colon tumor endothelial cells.

Table 13 shows genes which encode proteins which are localized to the cytoplasm of both brain and colon tumor endothelial cells.

Table 14 shows genes which encode proteins which are extracellular from both brain and colon tumor endothelial cells.

Table 15 shows genes which encode proteins which are localized to the membrane of both brain and colon tumor endothelial cells.

Table 16 shows genes which encode proteins which are induced in both brain and colon tumor endothelial cells.

Table 17 shows additional tumor endothelial markers in brain.

Table 18 shows tumor endothelial markers in the brain which are cytoplasmic.

Table 19 shows tumor endothelial markers in the brain which are nuclear.

Table 20 shows tumor endothelial markers in the brain which are membrane associated.

Table 21 shows tumor endothelial markers in the brain which are extracellular.

Table 22 shows tumor endothelial markers in the brain which are unsorted with respect to cellular localization.

References

[0061]

Abounader, R., Lal, B., Luddy, C., Koe, G., Davidson, B., Rosen, E. M., and Laterra, J. (2002). In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. *Faseb J* 16, 108-10.

Bart, J., Groen, H. J., Hendrikse, N. H., van der Graaf, W. T., Vaalburg, W., and de Vries, E. G. (2000). The blood-brain barrier and oncology: new insights into function and modulation. *Cancer Treat Rev* 26, 449-62.

Bernsen, H. J., Rijken, P. F., Oostendorp, T., and van der Kogel, A. J. (1995). Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. *Br J Cancer* 71, 721-6.

Bowers, D. C., Fan, S., Walter, K. A., Abounader, R., Williams, J. A., Rosen, E. M., and Laterra, J. (2000). Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT- dependent pathways. *Cancer Res* 60, 4277-83.

Chen, H., Centola, M., Altschul, S. F., and Metzger, H. (1998). Characterization of gene expression in resting and activated mast cells. *J Exp Med* 188, 1657-68.

Guerin, C., Wolff, J. E., Laterra, J., Drewes, L. R., Brem, H., and Goldstein, G. W. (1992). Vascular differentiation

and glucose transporter expression in rat gliomas: effects of steroids. *Ann Neurol* 31, 481-7.

Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., and Jain, R. K. (1998). Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci U S A* 95, 4607-12.

Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., and Wiegand, S. J. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. *Science* 284, 1994-8.

Huminiecki, L., and Bicknell, R. (2000). In silico cloning of novel endothelial-specific genes. *Genome Res* 10, 1796-806.

Lamszus, K., Laterra, J., Westphal, M., and Rosen, E. M. (1999). Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. *Int J Dev Neurosci* 17, 517-30.

Marx, J. (2001). Caveolae: a once-elusive structure gets some respect. *Science* 294, 1862-5.

Roberts, W. G., and Palade, G. E. (1997). Neovasculature induced by vascular endothelial growth factor is fenestrated. *Cancer Res* 57, 765-72.

Shinoura, N., Shamraj, O. I., Hugenholz, H., Zhu, J. G., McBlack, P., Warnick, R., Tew, J. J., Wani, M. A., and Menon, A. G. (1995). Identification and partial sequence of a cDNA that is differentially expressed in human brain tumors. *Cancer Lett* 89, 215-21.

Smith, R. M., Jarret, L. (1988). *Lab. Invest.* 58, 613-629.

St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. (2000). Genes expressed in human tumor endothelium. *Science* 289, 1197-202.

Stan, R. V., Arden, K. C., and Palade, G. E. (2001). cDNA and protein sequence, genomic organization, and analysis of cis regulatory elements of mouse and human PLVAP genes. *Genomics* 72, 304-13.

Tamagnone, L., Artigiani, S., Chen, H., He, Z., Ming, G. I., Song, H., Chedotal, A., Winberg, M. L., Goodman, C. S., Poo, M., Tessier-Lavigne, M., and Comoglio, P. M. (1999). Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. *Cell* 99, 71-80.

Vajkoczy, P., and Menger, M. D. (2000). Vascular microenvironment in gliomas. *J Neurooncol* 50, 99-108.

Vajkoczy, P., Schilling, L., Ullrich, A., Schmiedek, P., and Menger, M. D. (1998). Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. *J Cereb Blood Flow Metab* 18, 510-20.

Vick, N. A., and Bigner, D. D. (1972). Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. *J Neurol Sci* 17, 29-39.

[0062] Clauses:

1. A method to aid in diagnosing glioma, comprising the steps of:

detecting an expression product of at least one gene in a first brain tissue sample suspected of being neoplastic wherein said at least one gene is selected from the group consisting of signal sequence receptor, delta (translocon-associated protein delta); DC2 protein; KIAA0404 protein; symplekin; Huntingtin interacting protein I; plasmalemma vesicle associated protein; KIAA0726 gene product; latexin protein; transforming growth factor, beta 1; hypothetical protein FLJ22215; Rag C protein; hypothetical protein FLJ23471; N-myristoyltransferase 1; hypothetical protein dJ1181N3.1; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonection); Hs 111988; Hs 112238; laminin, alpha 5; protective protein for beta-galactosidase (galactosialidosis); Melanoma associated gene; Melanoma associated gene; E3 ubiquitin ligase SMURF1; collagen, type IV, alpha 1; collagen,

type IV, alpha 1; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; gene predicted from cDNA with a complete coding sequence; Thy-1 cell surface antigen; Hs 127824; GTP binding protein 2; Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918); cutaneous T-cell lymphoma-associated tumor antigen se20-4; differentially expressed nucleolar TGF-beta1 target protein (DENTT); dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); smoothelin; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); putative translation initiation factor; retinoic acid induced 14; matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase); Lutheran blood group (Aubergier b antigen included); stanniocalcin 2; nuclear factor (erythroid-derived 2)-like 2; protein tyrosine phosphatase, non-receptor type 1; integrin, alpha 10; collagen, type VI, alpha 2; chromosome 21 open reading frame 25; CDC37 (cell division cycle 37, *S. cerevisiae*, homolog); Hs 16450; Rho guanine nucleotide exchange factor (GEF) 7; creatine kinase, brain; hypothetical protein FLJ10297; hypothetical protein FLJ10350; TNF-induced protein; tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein); cofilin 1 (non-muscle); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); v-ets avian erythroblastosis virus E26 oncogene homolog 1; protease, cysteine, 1 (legumain); ribosomal protein L13; chromosome 22 open reading frame 5; zinc finger protein 144 (Mel-18); degenerative spermatocyte (homolog *Drosophila*; lipid desaturase); eukaryotic translation initiation factor 2C, 2; mitochondrial ribosomal protein L45; prostate tumor over expressed gene 1; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a); glioma endothelial marker 1 precursor; NS1-binding protein; ribosomal protein L38; tuftelin-interacting protein; HLA class II region expressed gene KE2; translocase of inner mitochondrial membrane 17 homolog A (yeast); sudD (suppressor of bimD6, *Aspergillus nidulans*) homolog; heparan sulfate proteoglycan 2 (perlecan); SEC24 (*S. cerevisiae*) related gene family, member A; NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase); DNA segment on chromosome X and Y (unique) 155 expressed sequence; annexin A2; Homo sapiens clone 24670 mRNA sequence; hypothetical protein; matrix metalloproteinase 10 (stromelysin 2); KIAA1049 protein; G protein-coupled receptor; hypothetical protein FLJ20401; matrix metalloproteinase 14 (membrane-inserted); KIAA0470 gene product; solute carrier family 29 (nucleoside transporters), member 1; stanniocalcin 1; stanniocalcin 1; stanniocalcin 1; tumor suppressor deleted in oral cancer-related 1; tumor suppressor deleted in oral cancer-related 1; apolipoprotein C-I; glutathione peroxidase 4 (phospholipid hydroperoxidase); Hs 272106; transcription factor binding to IGHM enhancer 3; hypothetical protein DKFZp762A227; hypothetical protein FLJ22362; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); PR00628 protein; melanoma-associated antigen recognised by cytotoxic T lymphocytes; LOC88745; Homo sapiens beta-1,3-galactosyltransferase-6 (B3GALT6) mRNA, complete cds; sprouty (*Drosophila*) homolog 4; sprouty (*Drosophila*) homolog 4; Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone DKFZp434E1515); coactosin-like protein; hypothetical protein FLJ21865; Hs296234; KIAA0685 gene product; hypothetical protein FLJ10980; ribosomal protein L10; ribosomal protein S19; Hs 299251; Huntingtin interacting protein K; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 50374; Hs 311780; Hs 212191; v-akt murine thymoma viral oncogene homolog 2; Hs 328774; transducin-like enhancer of split 2, homolog of *Drosophila* E(spl); KIAA1870 protein; ribosomal protein L10a; peptidylprolyl isomerase A (cyclophilin A); Hs 344224; hypothetical protein FLJ23239; hypothetical protein DKFZp761H221; KIAA1887 protein; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 701679; Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453; Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035904; hypothetical protein LOC57333; myosin ID; plexin B2; lectin, galactoside-binding, soluble, 8 (galectin 8); double ring-finger protein, Dorfin; DKFZP434B168 protein; LIM domain binding 2; integrin beta 4 binding protein; synaptopodin; Hs 54828; insulin induced gene 1; acetyl LDL receptor; SREC; excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); hypothetical protein FLJ22329; schwannomin-interacting protein 1; PTEN induced putative kinase 1; myosin X; Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97; golgi phosphoprotein 1; splicing factor, arginine/serine-rich 6; laminin, gamma 3; cysteine-rich protein 2; U6 snRNA-associated Sm-like protein LSM7; hypothetical protein FLJ10707; Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene, clone IMAGE:3342825, mRNA, partial cds; macrophage migration inhibitory factor (glycosylation-inhibiting factor); ubiquinol-cytochrome c reductase hinge protein; gap junction protein, alpha 1, 43kD (connexin 43); dihydropyrimidinase-like 3; aquaporin 1 (channel-forming integral protein, 28kD); protein expressed in thyroid; macrophage myristoylated alanine-rich C kinase substrate; procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI); protease, serine, 11 (IGF binding); 24-dehydrocholesterol reductase; collagen, type IV, alpha 2; profilin 1; apolipoprotein D; hyaluronoglucosaminidase 2; hypothetical protein FLJ22678; quiescin Q6; ras homolog gene family, member A; ras homolog gene family, member A; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; uridine phos-

phorylase; KIAA0638 protein; B7 homolog 3; lamin A/C; lamin A/C; lamin A/C; regulator of G-protein signalling 12; proteasome (prosome, macropain) 26S subunit, non-ATPase, 8; Homo sapiens, Similar to RIKEN cDNA 5730528L13 gene, clone MGC:17337 IMAGE:4213591, mRNA, complete cds; prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy); laminin, alpha 4; transcription elongation factor A (SII), 1; lectin, galactoside-binding, soluble, 3 binding protein; ribosomal protein S16; glycophorin C (Gerbich blood group); endothelin receptor type B; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; small nuclear ribonucleoprotein polypeptide B"; transmembrane 4 super-family member 2; TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD; lysyl oxidase-like 2; SRY (sex determining region Y)-box 4; SOX4 SRY (sex determining region Y)-box 4; SRY (sex determining region Y)-box 4; actin related protein 2/3 complex, subunit 2 (34 kD); Homo sapiens cDNA: FLJ23507 fis, clone LNG03128; hypothetical protein FLJ12442; Fas (TNFRSF6)-associated via death domain; mitogen-activated protein kinase kinase kinase 11; TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); insulin receptor; cell membrane glycoprotein, 110000M(r) (surface antigen); Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926; jagged 1 (Alagille syndrome); KIAA0304 gene product; pre-B-cell leukemia transcription factor 2; Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864; p53-induced protein; complement component 1, q subcomponent, receptor 1; complement component 1, q subcomponent, receptor 1; apolipoprotein E; chemokine (C-C motif) ligand 3; coagulation factor II (thrombin) receptor-like 3; coagulation factor III (thromboplastin, tissue factor); collagen, type I, alpha 1; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 9; cystatin C (amyloid angiopathy and cerebral hemorrhage); endoplasmic reticulum associated protein 140 kDa; ESTs; ESTs; ESTs, Highly similar to hypothetical protein FLJ10350 [Homo sapiens] [H.sapiens]; ESTs, Highly similar to ITB1_HUMAN Integrin beta-1 precursor (Fibronectin receptor beta subunit) (CD29) (Integrin VLA-4 beta subunit) [H.sapiens]; ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]; ESTs, Weakly similar to T17346 hypothetical protein DKFZp586O1624.1 - human (fragment) [H.sapiens]; ESTs, Weakly similar to T21371 hypothetical protein F25H8.3 - *Caenorhabditis elegans* [C.elegans]; eukaryotic translation initiation factor 4A, isoform 1; heme oxygenase (decycling) 1; Hermansky-Pudlak syndrome 4; Homo sapiens cDNA FLJ34888 fis, clone NT2NE2017332; Homo sapiens cDNA FLJ39848 fis, clone SPLEN2014669; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059; Homo sapiens, clone IMAGE:4845226, mRNA; hypothetical protein FLJ22329; hypothetical protein FLJ32205; hypothetical protein MGC4677; inhibin, beta B (activin AB beta polypeptide); insulin-like growth factor binding protein 5; junction plakoglobin; KIAA0620 protein; KIAA0943 protein; likely ortholog of rat vacuole membrane protein 1; Lysosomal-associated multispansing membrane protein-5; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; matrix Gla protein; matrix metalloproteinase 1 (interstitial collagenase); microtubule-associated protein 1 light chain 3 beta; nerve growth factor receptor (TNFR superfamily, member 16); ribosomal protein S9; ring finger protein 40; S100 calcium binding protein, beta (neural); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B; SPARC-like 1 (mast9, hevin); tumor necrosis factor, alpha-induced protein 3; UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5; von Willebrand factor; v-akt murine thymoma viral oncogene homolog 2; cyclin-dependent kinase (cdc2-like) 10; ortholog mouse myocytic induction/differentiation originator; brain-specific angiogenesis inhibitor 1; EGF-TM7 latrophilin-related protein; sema domain; integrin, alpha 5; likely ortholog of mouse fibronectin type III; Lutheran blood group (Auberger b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16); insulin-like growth factor binding protein; leukemia inhibitory factor; protein tyrosine phosphatase, nonreceptor type I; and Homo sapiens, clone IMAGE:3908182, mRNA, partial cds; and

comparing expression of the at least one gene in the first brain tissue sample with expression of the at least one gene in a second brain tissue sample which is normal, wherein increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample identifies the first brain tissue sample as likely to be neoplastic.

2. The method of clause 1 wherein the increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is at least two-fold higher.
3. The method of clause 1 wherein the increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is at least five-fold higher.
4. The method of clause 1 wherein the increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is at least ten-fold higher.
5. The method of clause 1 wherein the expression product is RNA.
6. The method of clause 1 wherein the expression product is protein.

7. The method of clause 1 wherein the first and second tissue samples are from a human.
8. The method of clause 1 wherein the first and second tissue samples are from the same human.
9. The method of clause 6 wherein the step of detecting is performed using a Western blot.
10. The method of clause 6 wherein the step of detecting is performed using an immunoassay.
11. The method of clause 6 wherein the step of detecting is performed using an immunohistochemical assay.
12. The method of clause 5 wherein the step of detecting is performed using SAGE.
13. The method of clause 5 wherein the step of detecting is performed using hybridization to a microarray.
14. A method of treating a glioma, comprising the step of:

contacting cells of the glioma with an antibody, wherein the antibody specifically binds to an extracellular epitope of a protein selected from the group consisting of plasmalemma vesicle associated protein; KIAA0726 gene product; osteonectin: laminin, alpha 5; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; Thy-1 I cell surface antigen; dysferlin, limb girdle muscular dystrophy 2B; integrin, alpha 5; matrix metalloproteinase 9; Lütjheran blood group, integrin, alpha 10, collagen, type VI, alpha 2; glioma endothelial marker 1 precursor; translocase of inner mitochondrial membrane 17 homolog A; heparan sulfate proteoglycan 2; annexin A2; matrix metalloproteinase 10; G protein-coupled receptor; matrix metalloproteinase 14; solute carrier family 29, member 1; CD59 antigen p18-20; KIAA 1870 protein; plexin B2; lectin, galactoside-binding, soluble, 8; integrin beta 4 binding protein; acetyl LDL receptor; laminin, gamma 3; macrophage migration inhibitory factor; gap junction protein, alpha 1, 43 kD; aquaporin 1; protease, serine, 11; collagen, type IV, alpha 2; apolipoprotein D; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; regulator of G-protein signaling 12; prosaposin; laminin, alpha 4; lectin, galactoside-binding, soluble, 3 binding protein; glycoporphin C; endothelin receptor type B; biglycan; transmembrane 4 superfamily member 2; lysyl oxidase-like 2; TEK tyrosine kinase, endothelial; insulin receptor; cell membrane glycoprotein, 110000M(r); jagged 1; plasmalemma vesicle associated protein; TEM13, Thy-1 cell surface antigen; coagulation factor II (thrombin) receptor-like 3; dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); likely ortholog of rat vacuole membrane protein 1; nerve growth factor receptor (TNFR superfamily, member 16); degenerative spermatocyte homolog, lipid desaturase (Drosophila); TEM1, endosialin; heme oxygenase (decycling) 1; G protein-coupled receptor; C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 9; matrix metalloproteinase 14 (membrane-inserted); solute carrier family 29 (nucleoside transporters), member 1; likely ortholog of mouse embryonic epithelial gene 1; major histocompatibility complex, class I, C; likely ortholog of mouse fibronectin type III repeat containing protein 1; sprouty homolog 4 (Drosophila); KIAA0620 protein; coagulation factor III (thromboplastin, tissue factor); aquaporin 1 (channel-forming integral protein, 28kDa); major histocompatibility complex, class I, B; Lysosomal-associated multispansing membrane protein-5; endothelin receptor type B; insulin receptor; complement component 1, q subcomponent, receptor 1; brain-specific angiogenesis inhibitor 1; EGF-TM7 latrophilin-related protein; sema domain; integrin, alpha 5; likely ortholog of mouse fibronectin type III; Lutheran blood group (Auberger b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16) and complement component 1, q subcomponent, receptor 1; whereby immune destruction of cells of the glioma is triggered.

15. The method of clause 14 wherein the antibody is conjugated to a diagnostic or therapeutic reagent.
16. The method of clause 14 wherein the glioma is multidrug-sensitive.
17. The method of clause 15 wherein the reagent is a chemotherapeutic agent.
18. The method of clause 15 wherein the reagent is a cytotoxin.
19. The method of clause 15 wherein the reagent is a non-radioactive label.
20. The method of clause 15 wherein the reagent is a radioactive compound.
21. The method of clause 14 wherein the glioma is in a human.
22. A method of identifying a test compound as a potential anti-cancer or anti-glioma drug, comprising the step of:

contacting a test compound with a cell which expresses at least one gene selected from the group consisting of signal sequence receptor, delta (translocon-associated protein delta); DC2 protein; KIAA0404 protein; symplekin; Huntingtin interacting protein I; plasmalemma vesicle associated protein; KIAA0726 gene product; latexin protein; transforming growth factor, beta 1; hypothetical protein FLJ22215; Rag C protein; hypothetical protein FLJ23471; N-myristoyltransferase 1; hypothetical protein dJ1181N3.1; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonectin); Hs 111988; Hs 112238; laminin, alpha 5; protective protein for beta-galactosidase (galactosialidosis); Melanoma associated gene; Melanoma associated gene; E3 ubiquitin ligase SMURF1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; gene predicted from cDNA with a complete coding sequence; Thy-1 I cell surface

antigen; Hs 127824; GTP binding protein 2; Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918); cutaneous T-cell lymphoma-associated tumor antigen se20-4; differentially expressed nucleolar TGF-beta1 target protein (DENTT); dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); smoothelin; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); putative translation initiation factor; retinoic acid induced 14; matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase); Lutheran blood group (Auberger b antigen included); stanniocalcin 2; nuclear factor (erythroid-derived 2)-like 2; protein tyrosine phosphatase, non-receptor type 1; integrin, alpha 10; collagen, type VI, alpha 2; chromosome 21 open reading frame 25; CDC37 (cell division cycle 37, *S. cerevisiae*, homolog); Hs 16450; Rho guanine nucleotide exchange factor (GEF) 7; creatine kinase, brain; hypothetical protein FLJ10297; hypothetical protein FLJ10350; TNF-induced protein; tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein); cofilin 1 (non-muscle); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); v-ets avian erythroblastosis virus E26 oncogene homolog 1; protease, cysteine, 1 (legumain); ribosomal protein L13; chromosome 22 open reading frame 5; zinc finger protein 144 (Mel-18); degenerative spermatocyte (homolog *Drosophila*); lipid desaturase; eukaryotic translation initiation factor 2C, 2; mitochondrial ribosomal protein L45; prostate tumor over expressed gene 1; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a); glioma endothelial marker 1 precursor; NS1-binding protein; ribosomal protein L38; tuftelin-interacting protein; HLA class II region expressed gene KE2; translocase of inner mitochondrial membrane 17 homolog A (yeast); sudD (suppressor of bimD6, *Aspergillus nidulans*) homolog; heparan sulfate proteoglycan 2 (perlecan); SEC24 (*S. cerevisiae*) related gene family, member A; NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase); DNA segment on chromosome X and Y (unique) 155 expressed sequence; annexin A2; Homo sapiens clone 24670 mRNA sequence; hypothetical protein; matrix metalloproteinase 10 (stromelysin 2); KIAA1049 protein; G protein-coupled receptor; hypothetical protein FLJ20401; matrix metalloproteinase 14 (membrane-inserted); KIAA0470 gene product; solute carrier family 29 (nucleoside transporters), member 1; stanniocalcin 1; stanniocalcin 1; stanniocalcin 1; tumor suppressor deleted in oral cancer-related 1; tumor suppressor deleted in oral cancer-related 1; apolipoprotein C-I; glutathione peroxidase 4 (phospholipid hydroperoxidase); Hs 272106; transcription factor binding to IGHM enhancer 3; hypothetical protein DKFZp762A227; hypothetical protein FLJ22362; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); PRO0628 protein; melanoma-associated antigen recognised by cytotoxic T lymphocytes; LOC88745; Homo sapiens beta-1,3-galactosyltransferase-6 (B3GALT6) mRNA, complete cds; sprouty (*Drosophila*) homolog 4; sprouty (*Drosophila*) homolog 4; Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone DKFZp434E1515); coactosin-like protein; hypothetical protein FLJ21865; Hs296234; KIAA0685 gene product; hypothetical protein FLJ10980; ribosomal protein L10; ribosomal protein S19; Hs 299251; Huntingtin interacting protein K; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 50374; Hs 311780; Hs 212191; v-akt murine thymoma viral oncogene homolog 2; Hs 328774; transducin-like enhancer of split 2, homolog of *Drosophila* E(sp1); KIAA1870 protein; ribosomal protein L10a; peptidylprolyl isomerase A (cyclophilin A); Hs 344224; hypothetical protein FLJ23239; hypothetical protein DKFZp761H221; KIAA1887 protein; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 701679; Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453; Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035904; hypothetical protein LOC57333; myosin ID; plexin B2; lectin, galactoside-binding, soluble, 8 (galectin 8); double ring-finger protein, Dorfin; DKFZp434B168 protein; LIM domain binding 2; integrin beta 4 binding protein; synaptopodin; Hs 54828; insulin induced gene 1; acetyl LDL receptor; SREC; excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); hypothetical protein FLJ22329; schwannomin-interacting protein 1; PTEN induced putative kinase 1; myosin X; Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97; golgi phosphoprotein 1; splicing factor, arginine/serine-rich 6; laminin, gamma 3; cysteine-rich protein 2; U6 snRNA-associated Sm-like protein LSM7; hypothetical protein FLJ10707; Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene, clone IMAGE:3342825, mRNA, partial cds; macrophage migration inhibitory factor (glycosylation-inhibiting factor); ubiquinol-cytochrome c reductase hinge protein; gap junction protein, alpha 1, 43kD (connexin 43); dihydropyrimidinase-like 3; aquaporin 1 (channel-forming integral protein, 28kD); protein expressed in thyroid; macrophage myristoylated alanine-rich C kinase substrate; procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI); protease, serine, 11 (IGF binding); 24-dehydrocholesterol reductase; collagen, type IV, alpha 2; profilin 1; apolipoprotein D; hyaluronoglucosaminidase 2; hypothetical protein FLJ22678; quiescin Q6; ras homolog gene family, member A; ras homolog gene family, member A; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; uridine phosphorylase; KIAA0638 protein; B7 homolog 3; lamin A/C; lamin A/C; lamin A/C; regulator of G-protein signalling 12; proteasome (prosome, macropain) 26S subunit, non-ATPase, 8; Homo sapiens,

Similar to RIKEN cDNA 5730528L13 gene, clone MGC:17337 IMAGE:4213591, mRNA, complete cds; prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy); laminin, alpha 4; transcription elongation factor A (SII), 1; lectin, galactoside-binding, soluble, 3 binding protein; ribosomal protein S16; glycoporphin C (Gerbich blood group); endothelin receptor type B; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; small nuclear ribonucleoprotein polypeptide B"; transmembrane 4 superfamily member 2; TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD; lysyl oxidase-like 2; SRY (sex determining region Y)-box 4; SOX4 SRY (sex determining region Y)-box 4; SRY (sex determining region Y)-box 4; actin related protein 2/3 complex, subunit 2 (34 kD); Homo sapiens cDNA: FLJ23507 fis, clone LNG03128; hypothetical protein FLJ12442; Fas (TNFRSF6)-associated via death domain; mitogen-activated protein kinase kinase kinase 11; TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); insulin receptor; cell membrane glycoprotein, 110000M(r) (surface antigen); Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926; jagged 1 (Alagille syndrome); KIAA0304 gene product; pre-B-cell leukemia transcription factor 2; Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864; p53-induced protein; complement component 1, q subcomponent, receptor 1; complement component 1, q subcomponent, receptor 1; apolipoprotein E; chemokine (C-C motif) ligand 3; coagulation factor II (thrombin) receptor-like 3; coagulation factor III (thromboplastin, tissue factor); collagen, type I, alpha 1; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 9; cystatin C (amyloid angiopathy and cerebral hemorrhage); endoplasmic reticulum associated protein 140 kDa; ESTs; ESTs; ESTs, Highly similar to hypothetical protein FLJ10350 [Homo sapiens] [H.sapiens]; ESTs, Highly similar to ITB1_HUMAN Integrin beta-1 precursor (Fibronectin receptor beta subunit) (CD29) (Integrin VLA-4 beta subunit) [H.sapiens]; ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]; ESTs, Weakly similar to T17346 hypothetical protein DKFZp586O1624.1 - human (fragment) [H.sapiens]; ESTs, Weakly similar to T21371 hypothetical protein F25H8.3 - Caenorhabditis elegans [C.elegans]; eukaryotic translation initiation factor 4A, isoform 1; heme oxygenase (decycling) 1; Hermansky-Pudlak syndrome 4; Homo sapiens cDNA FLJ34888 fis, clone NT2NE2017332; Homo sapiens cDNA FLJ39848 fis, clone SPLEN2014669; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059; Homo sapiens, clone IMAGE:4845226, mRNA; hypothetical protein FLJ22329; hypothetical protein FLJ32205; hypothetical protein MGC4677; inhibin, beta B (activin AB beta polypeptide); insulin-like growth factor binding protein 5; junction plakoglobin; KIAA0620 protein; KIAA0943 protein; likely ortholog of rat vacuole membrane protein 1; Lysosomal-associated multispansing membrane protein-5; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; matrix Gla protein; matrix metalloproteinase 1 (interstitial collagenase); microtubule-associated protein 1 light chain 3 beta; nerve growth factor receptor (TNFR superfamily, member 16); ribosomal protein S9; ring finger protein 40; S100 calcium binding protein, beta (neural); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B; SPARC-like 1 (mast9, hevin); tumor necrosis factor, alpha-induced protein 3; UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5; von Willebrand factor; v-akt murine thymoma vial oncogene homolog 2; cyclin-dependent kinase (cdc2-like) 10; ortholog mouse myocytic induction/differentiation originator; brain-specific angiogenesis inhibitor 1; EGF-TM7 latrophilin-related protein; sema domain; integrin, alpha 5; likely ortholog of mouse fibronectin type III; Lutheran blood group (Auberger b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16); insulin-like growth factor binding protein; leukemia inhibitory factor; protein tyrosine phosphatase, nonreceptor type I; and Homo sapiens, clone IMAGE:3908182, mRNA, partial cds;

monitoring an expression product of the at least one gene; and

identifying the test compound as a potential anti-cancer drug if it decreases the expression of the at least one gene.

23. The method of clause 22 wherein the cell is a human cell.

24. The method of clause 22 wherein the cell is a glioma cell.

25. The method of clause 22 wherein the cell is a human glioma cell.

26. The method of clause 22 wherein the expression product is RNA.

27. The method of clause 22 wherein the expression product is protein.

28. The method of clause 22 wherein the cell overexpresses the at least one gene relative to a normal cell of the same tissue.

29. The method of clause 22 wherein expression of at least two of said genes is monitored.

30. The method of clause 22 wherein expression of at least three of said genes is monitored.

31. The method of clause 22 wherein expression of at least four of said genes is monitored.

32. The method of clause 22 wherein the test compound is identified if the decrease in expression is at least 50 %.

33. The method of clause 22 wherein the test compound is identified if the decrease in expression is at least 80 %.
34. The method of clause 22 wherein the decrease in expression is at least 90 %.
35. The method of clause 22 wherein the test compound is identified as an anti-glioma drug.
36. A method to aid in diagnosing glioma, comprising the steps of:

detecting an mRNA of at least one gene in a first brain tissue sample suspected of being neoplastic wherein said at least one gene is identified by a tag selected from the group consisting of SEQ ID NO: 1-32; and comparing expression of the at least one gene in the first brain tissue sample with expression of the at least one gene in a second brain tissue sample which is normal, wherein increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample identifies the first brain tissue sample as likely to be neoplastic.

37. The method of clause 36 wherein the increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is at least two-fold higher.
38. The method of clause 36 wherein the increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is at least five-fold higher.
39. The method of clause 36 wherein the increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is at least ten-fold higher.
40. The method of clause 36 wherein the first and second tissue samples are from a human.
41. The method of clause 36 wherein the first and second tissue samples are from the same human.
42. The method of clause 36 wherein the step of detecting is performed using a Western blot.
43. The method of clause 36 wherein the step of detecting is performed using an immunoassay.
44. The method of clause 36 wherein the step of detecting is performed using an immunohistochemical assay.
45. The method of clause 36 wherein the step of detecting is performed using SAGE.
46. The method of clause 36 wherein the step of detecting is performed using hybridization to a microarray.
47. A method of identifying a test compound as a potential anti-cancer or anti-glioma drug, comprising the step of:

contacting a test compound with a cell which expresses an mRNA of at least one gene identified by a tag selected from the group consisting of SEQ ID NO: 1-32;

monitoring an mRNA of the at least one gene; and

identifying the test compound as a potential anti-cancer drug if it decreases the expression of the at least one gene.

48. The method of clause 47 wherein the cell is a human cell.
49. The method of clause 47 wherein the cell is a glioma cell.
50. The method of clause 47 wherein the cell is a human glioma cell.
51. The method of clause 47 wherein the expression product is RNA.
52. The method of clause 47 wherein the expression product is protein.
53. The method of clause 47 wherein the cell overexpresses the at least one gene relative to a normal cell of the same tissue.
54. The method of clause 47 wherein expression of at least two of said genes is monitored.
55. The method of clause 47 wherein expression of at least three of said genes is monitored.
56. The method of clause 47 wherein expression of at least four of said genes is monitored.
57. The method of clause 47 wherein the test compound is identified if the decrease in expression is at least 50 %.
58. The method of clause 47 wherein the test compound is identified if the decrease in expression is at least 80 %.
59. The method of clause 47 wherein the decrease in expression is at least 90 %.
60. The method of clause 47 wherein the test compound is identified as an anti-glioma drug.
61. A method to induce an immune response to glioma, comprising:

administering to a mammal a protein or nucleic acid encoding a protein selected from the group consisting of:

signal sequence receptor, delta (translocon-associated protein delta); DC2 protein; KIAA0404 protein; symplekin; Huntingtin interacting protein I; plasmalemma vesicle associated protein; KIAA0726 gene product; latexin protein; transforming growth factor, beta 1; hypothetical protein FLJ22215; Rag C protein; hypothetical protein FLJ23471; N-myristoyltransferase 1; hypothetical protein dJ1181N3.1; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonectin); Hs 111988; Hs 112238; laminin, alpha 5; protective protein for beta-galactosidase (galactosialidosis); Melanoma associated gene; Melanoma associated gene; E3 ubiquitin ligase SMURF1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; collagen, type IV, alpha

1; insulin-like growth factor binding protein 7; gene predicted from cDNA with a complete coding sequence; Thy-1 cell surface antigen; Hs 127824; GTP binding protein 2; Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918); cutaneous T-cell lymphoma-associated tumor antigen se20-4; differentially expressed nucleolar TGF-beta target protein (DENTT); dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); smoothelin; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); putative translation initiation factor; retinoic acid induced 14; matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase); Lutheran blood group (Auberger b antigen included); stanniocalcin 2; nuclear factor (erythroid-derived 2)-like 2; protein tyrosine phosphatase, non-receptor type 1; integrin, alpha 10; collagen, type VI, alpha 2; chromosome 21 open reading frame 25; CDC37 (cell division cycle 37, *S. cerevisiae*, homolog); Hs 16450; Rho guanine nucleotide exchange factor (GEF) 7; creatine kinase, brain; hypothetical protein FLJ10297; hypothetical protein FLJ10350; TNF-induced protein; tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein); cofilin 1 (non-muscle); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); v-ets avian erythroblastosis virus E26 oncogene homolog 1; protease, cysteine, 1 (legumain); ribosomal protein L13; chromosome 22 open reading frame 5; zinc finger protein 144 (Mel-18); degenerative spermatocyte (homolog *Drosophila*; lipid desaturase); eukaryotic translation initiation factor 2C, 2; mitochondrial ribosomal protein L45; prostate tumor over expressed gene 1; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a); glioma endothelial marker 1 precursor; NS1-binding protein; ribosomal protein L38; tuftelin-interacting protein; HLA class II region expressed gene KE2; translocase of inner mitochondrial membrane 17 homolog A (yeast); sudD (suppressor of bimD6, *Aspergillus nidulans*) homolog; heparan sulfate proteoglycan 2 (perlecan); SEC24 (*S. cerevisiae*) related gene family, member A; NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase); DNA segment on chromosome X and Y (unique) 155 expressed sequence; annexin A2; Homo sapiens clone 24670 mRNA sequence; hypothetical protein; matrix metalloproteinase 10 (stromelysin 2); KIAA1049 protein; G protein-coupled receptor; hypothetical protein FLJ20401; matrix metalloproteinase 14 (membrane-inserted); KIAA0470 gene product; solute carrier family 29 (nucleoside transporters), member 1; stanniocalcin 1; stanniocalcin 1; stanniocalcin 1; tumor suppressor deleted in oral cancer-related 1; tumor suppressor deleted in oral cancer-related 1; apolipoprotein C-I; glutathione peroxidase 4 (phospholipid hydroperoxidase); Hs 272106; transcription factor binding to IGHM enhancer 3; hypothetical protein DKFZp762A227; hypothetical protein FLJ22362; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); PRO0628 protein; melanoma-associated antigen recognised by cytotoxic T lymphocytes; LOC88745; Homo sapiens beta-1,3-galactosyltransferase-6 (B3GALT6) mRNA, complete cds; sprouty (*Drosophila*) homolog 4; sprouty (*Drosophila*) homolog 4; Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone DKFZp434E1515); coactosin-like protein; hypothetical protein FLJ21865; Hs296234; KIAA0685 gene product; hypothetical protein FLJ10980; ribosomal protein L10; ribosomal protein S19; Hs 299251; Huntingtin interacting protein K; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 50374; Hs 311780; Hs 212191; v-akt murine thymoma viral oncogene homolog 2; Hs 328774; transducin-like enhancer of split 2, homolog of *Drosophila* E(sp1); KIAA1870 protein; ribosomal protein L10a; peptidylprolyl isomerase A (cyclophilin A); Hs 344224; hypothetical protein FLJ23239; hypothetical protein DKFZp761H221; KIAA1887 protein; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 701679; Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453; Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035904; hypothetical protein LOC57333; myosin ID; plexin B2; lectin, galactoside-binding, soluble, 8 (galectin 8); double ring-finger protein, Dorfin; DKFZP434B168 protein; LIM domain binding 2; integrin beta 4 binding protein; synaptopodin; Hs 54828; insulin induced gene 1; acetyl LDL receptor; SREC; excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); hypothetical protein FLJ22329; schwannomin-interacting protein 1; PTEN induced putative kinase 1; myosin X; Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97; golgi phosphoprotein 1; splicing factor, arginine/serine-rich 6; laminin, gamma 3; cysteine-rich protein 2; U6 snRNA-associated Sm-like protein LSm7; hypothetical protein FLJ10707; Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene, clone IMAGE:3342825, mRNA, partial cds; macrophage migration inhibitory factor (glycosylation-inhibiting factor); ubiquinol-cytochrome c reductase hinge protein; gap junction protein, alpha 1, 43kD (connexin 43); dihydropyrimidinase-like 3; aquaporin 1 (channel-forming integral protein, 28kD); protein expressed in thyroid; macrophage myristoylated alanine-rich C kinase substrate; procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI); protease, serine, 11 (IGF binding); 24-dehydrocholesterol reductase; collagen, type IV, alpha 2; profilin 1; apolipoprotein D; hyaluronoglucosaminidase 2; hypothetical protein FLJ22678; qui-

escin Q6; ras homolog gene family, member A; ras homolog gene family, member A; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; uridine phosphorylase; KIAA0638 protein; B7 homolog 3; lamin A/C; lamin A/C; lamin A/C; regulator of G-protein signalling 12; proteasome (prosome, macropain) 26S subunit, non-ATPase, 8; Homo sapiens, Similar to RIKEN cDNA 5730528L13 gene, clone MGC:17337 IMAGE:4213591, mRNA, complete cds; prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy); laminin, alpha 4; transcription elongation factor A (SII), 1; lectin, galactoside-binding, soluble, 3 binding protein; ribosomal protein S16; glycophorin C (Gerbich blood group); endothelin receptor type B; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; small nuclear ribonucleoprotein polypeptide B"; transmembrane 4 superfamily member 2; TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD; lysyl oxidase-like 2; SRY (sex determining region Y)-box 4; SOX4 SRY (sex determining region Y)-box 4; SRY (sex determining region Y)-box 4; actin related protein 2/3 complex, subunit 2 (34 kD); Homo sapiens cDNA: FLJ23507 fis, clone LNG03128; hypothetical protein FLJ12442; Fas (TNFRSF6)-associated via death domain; mitogen-activated protein kinase kinase kinase 11; TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); insulin receptor; cell membrane glycoprotein, 110000M(r) (surface antigen); Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926; jagged 1 (Alagille syndrome); KIAA0304 gene product; pre-B-cell leukemia transcription factor 2; Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864; p53-induced protein; complement component 1, q subcomponent, receptor 1; complement component 1, q subcomponent, receptor 1; apolipoprotein E; chemokine (C-C motif) ligand 3; coagulation factor II (thrombin) receptor-like 3; coagulation factor III (thromboplastin, tissue factor); collagen, type I, alpha 1; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 9; cystatin C (amyloid angiopathy and cerebral hemorrhage); endoplasmic reticulum associated protein 140 kDa; ESTs; ESTs; ESTs, Highly similar to hypothetical protein FLJ10350 [Homo sapiens] [H.sapiens]; ESTs, Highly similar to ITB1_HUMAN Integrin beta-1 precursor (Fibronectin receptor beta subunit) (CD29) (Integrin VLA-4 beta subunit) [H.sapiens]; ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]; ESTs, Weakly similar to T17346 hypothetical protein DKFZp586O1624.1 - human (fragment) [H.sapiens]; ESTs, Weakly similar to T21371 hypothetical protein F25H8.3 - Caenorhabditis elegans [C.elegans]; eukaryotic translation initiation factor 4A, isoform 1; heme oxygenase (decycling) 1; Hermansky-Pudlak syndrome 4; Homo sapiens cDNA FLJ34888 fis, clone NT2NE2017332; Homo sapiens cDNA FLJ39848 fis, clone SPLEN2014669; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059; Homo sapiens, clone IMAGE:4845226, mRNA; hypothetical protein FLJ22329; hypothetical protein FLJ32205; hypothetical protein MGC4677; inhibin, beta B (activin AB beta polypeptide); insulin-like growth factor binding protein 5; junction plakoglobin; KIAA0620 protein; KIAA0943 protein; likely ortholog of rat vacuole membrane protein 1; Lysosomal-associated multispinning membrane protein-5; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; matrix Gla protein; matrix metalloproteinase 1 (interstitial collagenase); microtubule-associated protein 1 light chain 3 beta; nerve growth factor receptor (TNFR superfamily, member 16); ribosomal protein S9; ring finger protein 40; 5100 calcium binding protein, beta (neural); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B; SPARC-like 1 (mast9, hevin); tumor necrosis factor, alpha-induced protein 3; UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5; von Willebrand factor; v-akt murine thymoma viral oncogene homolog 2; cyclin-dependent kinase (cdc2-like) 10; ortholog mouse myocytic induction/differentiation originator; brain-specific angiogenesis inhibitor 1; EGF-TM7 latrophilin-related protein; sema domain; integrin, alpha 5; likely ortholog of mouse fibronectin type III; Lutheran blood group (Auberger b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16); insulin-like growth factor binding protein; leukemia inhibitory factor; protein tyrosine phosphatase, nonreceptor type I; and Homo sapiens, clone IMAGE:3908182, mRNA, partial cds, whereby an immune response to the protein is induced.

62. The method of clause 61 wherein a protein is administered.

63. The method of clause 61 wherein a nucleic acid is administered.

64. The method of clause 63 wherein the nucleic acid is administered intramuscularly.

65. The method of clause 62 further comprising administering an immune adjuvant to the mammal.

66. The method of clause 61 wherein the mammal has a glioma.

67. The method of clause 61 wherein the mammal has had a glioma surgically removed.

EP 2 236 614 A2

SEQUENCE LISTING

5 <110> Genzyme Corporation
 The Johns Hopkins University
 <120> BRAIN ENDOTHELIAL EXPRESSION PATTERNS
 <130> 003482.00010
 10 <140> PCT/US03/25614
 <141> 2003-08-15
 <150> US 60/403,390
 <151> 2002-08-15
 15 <150> US 60/458,978
 <151> 2003-04-01
 <160> 869
 <170> FastSEQ for windows Version 4.0
 20 <210> 1
 <211> 10
 <212> DNA
 <213> Homo sapiens
 25 <400> 1
 aaaccattct 10
 <210> 2
 <211> 10
 <212> DNA
 30 <213> Homo sapiens
 <400> 2
 aaggcagggga 10
 <210> 3
 <211> 10
 35 <212> DNA
 <213> Homo sapiens
 <400> 3
 acacagcaag 10
 40 <210> 4
 <211> 10
 <212> DNA
 <213> Homo sapiens
 45 <400> 4
 agctggagtc 10
 <210> 5
 <211> 10
 <212> DNA
 <213> Homo sapiens
 50 <400> 5
 agctggcacc 10
 <210> 6
 <211> 10
 55 <212> DNA
 <213> Homo sapiens

	<400> 6 ataaatgagg	10
5	<210> 7 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 7 caagcacccc	10
	<210> 8 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 8 cactaccac	10
20	<210> 9 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 9 cactactcac	10
25	<210> 10 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 10 cccacctcca	10
	<210> 11 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 11 cccgctctt	10
40	<210> 12 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 12 cctcagatgt	10
45	<210> 13 <211> 10 <212> DNA <213> Homo sapiens	
50	<400> 13 cgctactcac	10
	<210> 14 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 14 ctaagacctc	10
	<210> 15 <211> 10	

	<212> DNA	
	<213> Homo sapiens	
5	<400> 15 ctaagacttc	10
	<210> 16	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
10	<400> 16 gagtgggtgc	10
	<210> 17	
	<211> 10	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 17 gggacagctg	10
	<210> 18	
20	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 18 gggttggtt	10
25	<210> 19	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 19 gtaagtgtac	10
	<210> 20	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 20 gtaagtgtac	10
	<210> 21	
40	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 21 gtaggggtaa	10
45	<210> 22	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 22 taaccactgc	10
	<210> 23	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	
	<400> 23 tactgctcgg	10

5	<210> 24		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 24		10
	tcaggctgaa		
	<210> 25		
	<211> 10		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 25		10
	tccatacacc		
20	<210> 26		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 26		10
	tcctttttaa		
	<210> 27		
	<211> 10		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 27		10
	tgattaaggt		
35	<210> 28		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 28		10
	tggtatcaca		
	<210> 29		
	<211> 10		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 29		10
	tggtgtatgc		
50	<210> 30		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 30		10
	tgtcactggg		
	<210> 31		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 31		10
	tgtgggaggc		
	<210> 32		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		

	<400> 32 tttaacggcc	10
5	<210> 33 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 33 gctctctatg	10
	<210> 34 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 34 agaatgaaac	10
20	<210> 35 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 35 aagtggaata	10
25	<210> 36 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 36 gatgacgact	10
	<210> 37 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 37 ccctttcaca	10
40	<210> 38 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 38 tcctggggca	10
45	<210> 39 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 39 tctattgatg	10
50	<210> 40 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 40 ggggctgtat	10
	<210> 41	

	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 41 cccaggacac	10
	<210> 42	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 42 ggagctgctg	10
	<210> 43	
	<211> 10	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 43 tggacagcag	10
20	<210> 44	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 44 tctgggaaca	10
	<210> 45	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 45 cctgtgtatg	10
	<210> 46	
	<211> 10	
35	<212> DNA	
	<213> Homo sapiens	
	<400> 46 ggcaagaaga	10
40	<210> 47	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 47 aaatgcttgg	10
	<210> 48	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 48 ctaaaaacct	10
	<210> 49	
	<211> 10	
55	<212> DNA	
	<213> Homo sapiens	
	<400> 49	

	gagcattgca	10
	<210> 50	
	<211> 10	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 50	
	ggtggacacg	10
10	<210> 51	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 51	
15	gctcctgagc	10
	<210> 52	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 52	
	aagaagtgga	10
	<210> 53	
	<211> 10	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 53	
	tgggaagtgg	10
	<210> 54	
	<211> 10	
30	<212> DNA	
	<213> Homo sapiens	
	<400> 54	
	actcgctctg	10
35	<210> 55	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
40	<400> 55	
	tttcagggga	10
	<210> 56	
	<211> 10	
	<212> DNA	
45	<213> Homo sapiens	
	<400> 56	
	acaacgtcca	10
	<210> 57	
	<211> 10	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 57	
	gtctcagtgc	10
55	<210> 58	
	<211> 10	
	<212> DNA	

	<213> Homo sapiens	
	<400> 58 ccccctgccc	10
5	<210> 59 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 59 agaaaccacg	10
	<210> 60 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 60 gaccgcagga	10
	<210> 61 <211> 10 <212> DNA <213> Homo sapiens	
20	<400> 61 gtgctacttc	10
	<210> 62 <211> 10 <212> DNA <213> Homo sapiens	
25	<400> 62 gataactaca	10
	<210> 63 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 63 tggctgtgac	10
	<210> 64 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 64 gagtgagacc	10
	<210> 65 <211> 10 <212> DNA <213> Homo sapiens	
40	<400> 65 gagtggtac	10
	<210> 66 <211> 10 <212> DNA <213> Homo sapiens	
45	<400> 66 gactcagga	10
	<210> 67 <211> 10 <212> DNA <213> Homo sapiens	
50	<400> 67 gactcagga	10
	<210> 68 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 68 gactcagga	10

	<210> 67	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 67	
	gttatatgcc	10
	<210> 68	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 68	
	gaggcgctgc	10
	<210> 69	
	<211> 10	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 69	
	gagctctgag	10
20	<210> 70	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 70	
	gccagccagt	10
	<210> 71	
	<211> 10	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 71	
	atggcaacag	10
	<210> 72	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 72	
	aaggagttac	10
40	<210> 73	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 73	
45	tcccacaagg	10
	<210> 74	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 74	
	taaatcccca	10
	<210> 75	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 75 cccgc ccccg	10
5	<210> 76 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 76 cccgaggcag	10
	<210> 77 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 77 ctacgtgatg	10
20	<210> 78 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 78 atgggtttgc	10
25	<210> 79 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 79 ggcattgtct	10
	<210> 80 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 80 gtgctaagcg	10
40	<210> 81 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 81 accgtttgca	10
45	<210> 82 <211> 10 <212> DNA <213> Homo sapiens	
50	<400> 82 cagcgctgca	10
	<210> 83 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 83 gaagacactt	10
	<210> 84 <211> 10	

	<212> DNA	
	<213> Homo sapiens	
5	<400> 84 cgctgggcgt	10
	<210> 85	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
10	<400> 85 caccctgat	10
	<210> 86	
	<211> 10	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 86 gccccctgc	10
	<210> 87	
20	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 87 ccccctgccc	10
25	<210> 88	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 88 agcataaaaa	10
	<210> 89	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 89 gggctggacg	10
	<210> 90	
40	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 90 ctgccaactt	10
45	<210> 91	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 91 aagtggatag	10
	<210> 92	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
55	<400> 92 cgtactgagc	10

	<210> 93	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 93	
	ccgcttactc	10
	<210> 94	
	<211> 10	
10	<212> DNA	
	<213> Homo sapiens	
	<400> 94	
	ggggcttctg	10
15	<210> 95	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 95	
20	cccgtccgga	10
	<210> 96	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 96	
	agttccacca	10
	<210> 97	
	<211> 10	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 97	
	ggcctccagc	10
35	<210> 98	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 98	
40	ggaggctgag	10
	<210> 99	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 99	
	cagaggcgtc	10
	<210> 100	
	<211> 10	
	<212> DNA	
50	<213> Homo sapiens	
	<400> 100	
	gaccagcctt	10
	<210> 101	
55	<211> 10	
	<212> DNA	
	<213> Homo sapiens	

	<400> 101 gaggatggtg	10
5	<210> 102 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 102 tcgtcgcaga	10
	<210> 103 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 103 ggggctgccc	10
20	<210> 104 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 104 ctgtacatac	10
25	<210> 105 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 105 gcgacgaggc	10
	<210> 106 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 106 gccaagtga	10
40	<210> 107 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 107 aagataaact	10
45	<210> 108 <211> 10 <212> DNA <213> Homo sapiens	
50	<400> 108 gagagtgtac	10
	<210> 109 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 109 ccactgcact	10
	<210> 110	

	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 110 ccaccctcac	10
	<210> 111	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 111 cagaccattg	10
	<210> 112	
	<211> 10	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 112 gggagctgcg	10
20	<210> 113	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 113 gggatttctg	10
25	<210> 114	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 114 cttccagcta	10
	<210> 115	
	<211> 10	
35	<212> DNA	
	<213> Homo sapiens	
	<400> 115 cagaaacaga	10
40	<210> 116	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 116 tctgtgctca	10
45	<210> 117	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 117 tgcaataggt	10
	<210> 118	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	
	<400> 118	

	atggccaact	10
	<210> 119	
	<211> 10	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 119	
	tcacacagtg	10
	<210> 120	
10	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 120	
15	ggcttaggat	10
	<210> 121	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 121	
	gggaggggtg	10
	<210> 122	
	<211> 10	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 122	
	gaagtagaag	10
	<210> 123	
30	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 123	
	caccctgtac	10
35	<210> 124	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
40	<400> 124	
	atgtttacaa	10
	<210> 125	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 125	
	caactgggtc	10
	<210> 126	
	<211> 10	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 126	
	gtaatgacag	10
55	<210> 127	
	<211> 10	
	<212> DNA	

	<213> Homo sapiens	
	<400> 127 acctgccgac	10
5	<210> 128 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 128 tgatgcgcgc	10
	<210> 129 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 129 tggccccagg	10
	<210> 130 <211> 10 <212> DNA <213> Homo sapiens	
20	<400> 130 gcctgctggg	10
	<210> 131 <211> 10 <212> DNA <213> Homo sapiens	
25	<400> 131 tgctgtggt	10
	<210> 132 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 132 gagggatac	10
	<210> 133 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 133 ggagccagct	10
	<210> 134 <211> 10 <212> DNA <213> Homo sapiens	
40	<400> 134 gagcctcagg	10
	<210> 135 <211> 10 <212> DNA <213> Homo sapiens	
45	<400> 135 tacttcacat	10
50		
55		

	<210> 136		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
5	<400> 136		
	taatcccagc		10
	<210> 137		
	<211> 10		
	<212> DNA		
10	<213> Homo sapiens		
	<400> 137		
	caccttccag		10
	<210> 138		
	<211> 10		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 138		
	gagtctgttc		10
20	<210> 139		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 139		
	ggattttggt		10
	<210> 140		
	<211> 10		
	<212> DNA		
30	<213> Homo sapiens		
	<400> 140		
	tgctgtagt		10
	<210> 141		
	<211> 10		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 141		
	ttacaaacag		10
40	<210> 142		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
45	<400> 142		
	tcttctttca		10
	<210> 143		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 143		
	agcacatttg		10
	<210> 144		
	<211> 10		
	<212> DNA		
55	<213> Homo sapiens		

EP 2 236 614 A2

	<400> 144 cagggctcgc	10
5	<210> 145 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 145 gctgggtccca	10
	<210> 146 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 146 tccacgccct	10
20	<210> 147 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 147 ttgcaatagc	10
25	<210> 148 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 148 agggcttcca	10
	<210> 149 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 149 ctgggttaat	10
40	<210> 150 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 150 aacctgggag	10
45	<210> 151 <211> 10 <212> DNA <213> Homo sapiens	
50	<400> 151 ggcaacgtgg	10
	<210> 152 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 152 ggatgcgag	10
	<210> 153 <211> 10	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 153 cacctgtagt		10
	<210> 154		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 154 gtggtgggcg		10
	<210> 155		
	<211> 10		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 155 gcagggtggg		10
	<210> 156		
20	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 156 caagcatccc		10
25	<210> 157		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 157 tgggggccga		10
	<210> 158		
	<211> 10		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 158 tcagtgtatt		10
	<210> 159		
40	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 159 ggcaagcccc		10
45	<210> 160		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 160 cctagctgga		10
	<210> 161		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 161 gcaaaaccct		10

5	<210> 162		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 162		
	gctgggttcct		10
	<210> 163		
	<211> 10		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 163		
	gcacctcagc		10
20	<210> 164		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 164		
	accagctgtc		10
	<210> 165		
	<211> 10		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 165		
	tttgaatcag		10
35	<210> 166		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 166		
	agactagggg		10
	<210> 167		
	<211> 10		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 167		
	agctcagtga		10
50	<210> 168		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 168		
	ggccaacatt		10
	<210> 169		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 169		
	tttgtgggca		10
	<210> 170		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		

	<400> 170 attgtagaca	10
5	<210> 171 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 171 ccctaggttg	10
	<210> 172 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 172 aaatcaccaa	10
20	<210> 173 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 173 ggctgcagtc	10
25	<210> 174 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 174 gtggcaggcg	10
	<210> 175 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 175 taaaggcaca	10
40	<210> 176 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 176 ggctcctggc	10
45	<210> 177 <211> 10 <212> DNA <213> Homo sapiens	
50	<400> 177 atattaggaa	10
	<210> 178 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 178 gcttcagtgg	10
	<210> 179	

	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 179 tgattaaaac	10
	<210> 180	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 180 agccaccacg	10
	<210> 181	
	<211> 10	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 181 ggcggctgca	10
20	<210> 182	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 182 tgtttggggg	10
	<210> 183	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 183 cctgcctcgt	10
	<210> 184	
	<211> 10	
35	<212> DNA	
	<213> Homo sapiens	
	<400> 184 aggcctgggc	10
40	<210> 185	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 185 caaaactggt	10
	<210> 186	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 186 gagaggacat	10
	<210> 187	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	
	<400> 187	

	gagttaggca	10
	<210> 188	
	<211> 10	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 188	
	ccgtagtgcc	10
	<210> 189	
10	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 189	
15	cataaacggg	10
	<210> 190	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 190	
	tccctggcag	10
	<210> 191	
	<211> 10	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 191	
	gaggccatcc	10
	<210> 192	
30	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 192	
	ttgcctggga	10
35	<210> 193	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 193	
40	ctgtcagcgg	10
	<210> 194	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 194	
	aacgcggcca	10
	<210> 195	
	<211> 10	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 195	
	ggtttggtt	10
55	<210> 196	
	<211> 10	
	<212> DNA	

	<213> Homo sapiens	
	<400> 196 gatttttgtg	10
5	<210> 197 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 197 ggctgcccctg	10
	<210> 198 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 198 atggcaacag	10
	<210> 199 <211> 10 <212> DNA <213> Homo sapiens	
20	<400> 199 cgctgtgggg	10
25	<210> 200 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 200 ggcagccaga	10
	<210> 201 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 201 agagcaaacc	10
	<210> 202 <211> 10 <212> DNA <213> Homo sapiens	
40	<400> 202 tttccctcaa	10
	<210> 203 <211> 10 <212> DNA <213> Homo sapiens	
45	<400> 203 tccccgtggc	10
50	<210> 204 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 204 ttctcccaaa	10

	<210> 205	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 205 ggctgggggc	10
	<210> 206	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 206 ccctaccctg	10
	<210> 207	
	<211> 10	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 207 taggaccctg	10
20	<210> 208	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 208 gtttttgctt	10
	<210> 209	
	<211> 10	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 209 cttgattccc	10
	<210> 210	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 210 gcttggtcc	10
40	<210> 211	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 211 ggtggcactc	10
	<210> 212	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 212 acctgtgacc	10
	<210> 213	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 213 actgaggaaa	10
5	<210> 214 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 214 tgcagcgcct	10
	<210> 215 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 215 ctgggggggaa	10
20	<210> 216 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 216 gtgctattct	10
25	<210> 217 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 217 ggaggggggct	10
	<210> 218 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 218 gtgcctgaga	10
40	<210> 219 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 219 tcacagggtc	10
45	<210> 220 <211> 10 <212> DNA <213> Homo sapiens	
50	<400> 220 gggctccctg	10
	<210> 221 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 221 gccccaggta	10
	<210> 222 <211> 10	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 222 gaaagtggct		10
	<210> 223		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 223 tccctggctg		10
	<210> 224		
	<211> 10		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 224 acagagcaca		10
	<210> 225		
20	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 225 ctttgcactc		10
25	<210> 226		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 226 atgctccctg		10
	<210> 227		
	<211> 10		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 227 ccgtccaagg		10
	<210> 228		
40	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 228 gggcccctg		10
45	<210> 229		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 229 cttatgctgc		10
	<210> 230		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 230 ggttattttg		10

5	<210> 231		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 231		
	gcctgtccct		10
	<210> 232		
	<211> 10		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 232		
	aagatgaggg		10
20	<210> 233		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 233		
	ccaacaagaa		10
	<210> 234		
	<211> 10		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 234		
	aaggatgcgg		10
35	<210> 235		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 235		
	tgtcatcaca		10
	<210> 236		
	<211> 10		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 236		
	caggcttttt		10
50	<210> 237		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 237		
	tcaagttcac		10
	<210> 238		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 238		
	tccctgggca		10
	<210> 239		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		

	<400> 239 caggagttca	10
5	<210> 240 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 240 caggtggttc	10
	<210> 241 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 241 gccccacatcc	10
20	<210> 242 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 242 gctgggggtgg	10
25	<210> 243 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 243 gacctcctgc	10
	<210> 244 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 244 agtgaataaa	10
40	<210> 245 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 245 aaggttcttc	10
45	<210> 246 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 246 agcctggact	10
50	<210> 247 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 247 caaccagat	10
	<210> 248	

	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
5	<400> 248		10
	tgcttctgcc		
	<210> 249		
	<211> 10		
	<212> DNA		
10	<213> Homo sapiens		
	<400> 249		10
	caggtgacaa		
	<210> 250		
	<211> 10		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 250		10
	ggccgggggc		
20	<210> 251		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 251		10
25	gtgcgctagg		
	<210> 252		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 252		10
	aggctgtcca		
	<210> 253		
	<211> 10		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 253		10
	tgttatgtcc		
	<210> 254		
	<211> 10		
	<212> DNA		
40	<213> Homo sapiens		
	<400> 254		10
45	tttcccaaac		
	<210> 255		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 255		10
	ggggatgggg		
	<210> 256		
	<211> 17		
	<212> DNA		
55	<213> Homo sapiens		
	<400> 256		

	aaaccattct cctccgc	17
	<210> 257	
	<211> 17	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 257	
	aaggcagga gggaggg	17
	<210> 258	
10	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 258	
15	acacagcaag acgagaa	17
	<210> 259	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 259	
	agctggagtc ctaggca	17
	<210> 260	
	<211> 17	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 260	
	agctggcacc agagccc	17
	<210> 261	
30	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 261	
	ataaatgagg taaggtc	17
35	<210> 262	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 262	
40	caagcacccc cgttcca	17
	<210> 263	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 263	
	cactaccac cagacgc	17
	<210> 264	
	<211> 17	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 264	
	cactactcac caggcgc	17
55	<210> 265	
	<211> 17	
	<212> DNA	

	<213> Homo sapiens	
	<400> 265	
	cccacctcca gtccagc	17
5	<210> 266	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
10	<400> 266	
	cccgctctt cacgggc	17
	<210> 267	
	<211> 17	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 267	
	cctcagatgt ttgaaaa	17
	<210> 268	
	<211> 17	
20	<212> DNA	
	<213> Homo sapiens	
	<400> 268	
	cgctactcac cagacgc	17
25	<210> 269	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 269	
	ctaagacctc accagtc	17
	<210> 270	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
35	<400> 270	
	ctaagacttc accggtc	17
	<210> 271	
	<211> 17	
40	<212> DNA	
	<213> Homo sapiens	
	<400> 271	
	gagtgggtgc agcctcc	17
45	<210> 272	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 272	
	gggacagctg tctgtgg	17
50	<210> 273	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
55	<400> 273	
	gggttggtt gaaacca	17

	<210> 274	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 274	
	gtaagtgtac tggaagt	17
	<210> 275	
	<211> 17	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 275	
	gtaagtgtac tggtaag	17
	<210> 276	
	<211> 17	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 276	
	gtaggggtaa aaggagg	17
20	<210> 277	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 277	
	taaccactgc actttcc	17
	<210> 278	
	<211> 17	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 278	
	tactgctcgg aggtcgg	17
	<210> 279	
	<211> 17	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 279	
	tcaggctgaa gtcaggc	17
40	<210> 280	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 280	
	tccatacacc tatcccc	17
	<210> 281	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 281	
	tcctttttaa acaaaac	17
	<210> 282	
	<211> 17	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 282 tgattaaggt cggcgct	17
5	<210> 283 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 283 tggtatcaca caagggg	17
10	<210> 284 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 284 tggtgtatgc atcgggg	17
	<210> 285 <211> 17 <212> DNA <213> Homo sapiens	
20	<400> 285 tgtcactggg caggcgg	17
25	<210> 286 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 286 tgtgggaggc tgatggg	17
30	<210> 287 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 287 tttaacggcc gcggtac	17
	<210> 288 <211> 17 <212> DNA <213> Homo sapiens	
40	<400> 288 gctctctatg ctgacgt	17
45	<210> 289 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 289 agaatgaaac tgccggg	17
50	<210> 290 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 290 aagtggaata aactgcc	17
	<210> 291 <211> 17	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 291 gatgacgact cggggct	17	
	<210> 292		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 292 ccctttcaca cacactt	17	
	<210> 293		
	<211> 17		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 293 tcctggggca ggggcgg	17	
	<210> 294		
20	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 294 tctattgatg tgtatgc	17	
25	<210> 295		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 295 ggggctgtat ttaagga	17	
	<210> 296		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 296 cccaggacac cagctgg	17	
	<210> 297		
40	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 297 ggagctgctg cttgtgg	17	
45	<210> 298		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 298 tggacagcag ggacctg	17	
	<210> 299		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 299 tctgggaaca gggacgg	17	

5	<210> 300		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 300		
	cctgtgtatg tgtgtaa		17
	<210> 301		
	<211> 17		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 301		
	ggcaagaaga agatcgc		17
20	<210> 302		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 302		
	aaatgcttgg aggtgaa		17
	<210> 303		
	<211> 17		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 303		
	ctaaaaacct tatgaca		17
35	<210> 304		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 304		
	gagcattgca ccacccg		17
	<210> 305		
	<211> 17		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 305		
	ggtggacacg gatctgc		17
50	<210> 306		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 306		
	gctcctgagc cccggcc		17
	<210> 307		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 307		
	aagaagtgga gattgtc		17
	<210> 308		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		

	<400> 308 tgggaagtgg gctcctt	17
5	<210> 309 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 309 actcgctctg tggaggt	17
	<210> 310 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 310 tttcagggga gggggaa	17
20	<210> 311 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 311 acaacgtcca gctggtg	17
25	<210> 312 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 312 gtctcagtgc tgaggcg	17
	<210> 313 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 313 ccccctgccc ctctgcc	17
40	<210> 314 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 314 agaaaccacg gaaatgg	17
45	<210> 315 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 315 gaccgcagga gggcaga	17
50	<210> 316 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 316 gtgctacttc ttcttct	17
	<210> 317	

	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
5	<400> 317 gataactaca ttacctg		17
	<210> 318		
	<211> 17		
10	<212> DNA		
	<213> Homo sapiens		
	<400> 318 tggctgtgac tgtgact		17
	<210> 319		
15	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 319 gagtgaagacc caggagc		17
20	<210> 320		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 320 gagtggctac ccgccgc		17
	<210> 321		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 321 gactcagga tttgttg		17
	<210> 322		
35	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 322 gttatatgcc cgggaga		17
40	<210> 323		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
45	<400> 323 gaggcgctgc tgccacc		17
	<210> 324		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 324 gagctctgag atcaccc		17
	<210> 325		
55	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 325		

	gccagccagt ggcaagc	17
	<210> 326	
	<211> 17	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 326	
	atggcaacag atctgga	17
10	<210> 327	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 327	
15	aaggagttac actagtc	17
	<210> 328	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 328	
	tcccacaagg ctgcttg	17
	<210> 329	
	<211> 17	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 329	
	taaatcccca ctgggac	17
	<210> 330	
30	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 330	
	cccgcccccg ccttccc	17
35	<210> 331	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 331	
40	cccgaggcag agtcggg	17
	<210> 332	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 332	
	ctacgtgatg aagatgg	17
	<210> 333	
	<211> 17	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 333	
	atgggtttgc attttag	17
55	<210> 334	
	<211> 17	
	<212> DNA	

	<213> Homo sapiens	
	<400> 334	
	ggcattgtct ctgtttc	17
5	<210> 335	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
10	<400> 335	
	gtgctaagcg ggcccgg	17
	<210> 336	
	<211> 17	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 336	
	accgtttgca ttcgaaa	17
	<210> 337	
	<211> 17	
20	<212> DNA	
	<213> Homo sapiens	
	<400> 337	
	cagcgctgca ttgactc	17
25	<210> 338	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 338	
	gaagacactt ggtttga	17
	<210> 339	
	<211> 17	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 339	
	cgctgggcgt ctgggac	17
	<210> 340	
	<211> 17	
40	<212> DNA	
	<213> Homo sapiens	
	<400> 340	
	caccctgat gttcgcc	17
45	<210> 341	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 341	
	gccccctgc cccgtgc	17
	<210> 342	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
55	<400> 342	
	ccccctgccc tgcctg	17

	<210> 343	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 343	
	agcataaaaa tgcgtgc	17
	<210> 344	
	<211> 17	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 344	
	gggctggacg gctgcgt	17
	<210> 345	
	<211> 17	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 345	
	ctgccaactt ctaaccg	17
20	<210> 346	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 346	
	aagtggatag atacttc	17
	<210> 347	
	<211> 17	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 347	
	cgtactgagc gctttgg	17
	<210> 348	
	<211> 17	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 348	
	ccgcttactc tgttggg	17
40	<210> 349	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 349	
	ggggcttctg tagcccc	17
	<210> 350	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 350	
	cccgtccgga acgtcta	17
	<210> 351	
	<211> 17	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 351 agttccacca gaaagcc	17
5	<210> 352 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 352 ggcctccagc caccac	17
	<210> 353 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 353 ggaggctgag gtgggag	17
20	<210> 354 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 354 cagaggcgtc cgcaggt	17
25	<210> 355 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 355 gaccagcctt cagatgg	17
	<210> 356 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 356 gaggatggtg tcctgag	17
40	<210> 357 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 357 tcgtcgaga aggcgct	17
45	<210> 358 <211> 17 <212> DNA <213> Homo sapiens	
50	<400> 358 ggggctgccc agctgga	17
	<210> 359 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 359 ctgtacatac tttttgg	17
	<210> 360 <211> 17	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 360 gcgacgaggc gcgctgg	17	
	<210> 361		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 361 gccaagtga ctgtggc	17	
	<210> 362		
	<211> 17		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 362 aagataaact ctgggcc	17	
	<210> 363		
20	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 363 gagagtgtac tggcact	17	
25	<210> 364		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 364 ccactgcact ccggcct	17	
	<210> 365		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 365 ccaccctcac acacaca	17	
	<210> 366		
40	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 366 cagaccattg tttgatc	17	
45	<210> 367		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 367 gggagctgcg ccaacgg	17	
	<210> 368		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 368 gggatttctg tgtctgc	17	

5	<210> 369		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 369		
	cttccagcta acaggtc		17
10	<210> 370		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 370		
	cagaaacaga ctggggg		17
15	<210> 371		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 371		
20	tctgtgctca ggaagag		17
25	<210> 372		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 372		
	tgcaataggt gagagaa		17
30	<210> 373		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 373		
	atggccaact tccacct		17
35	<210> 374		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 374		
40	tcacacagtg cctgtcg		17
45	<210> 375		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 375		
	ggcttaggat gtgaatg		17
50	<210> 376		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 376		
	gggaggggtg ggggtgg		17
55	<210> 377		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		

	<400> 377 gaagtagaag gtaagga	17
5	<210> 378 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 378 caccctgtac agttgcc	17
	<210> 379 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 379 atgtttacaa gatggcg	17
20	<210> 380 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 380 caaactggtc taggtca	17
25	<210> 381 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 381 gtaatgacag atgcaag	17
	<210> 382 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 382 acctgccgac agtggttg	17
40	<210> 383 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 383 tgatgcgcgc tttgttg	17
45	<210> 384 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 384 tggtcccagg tgccacc	17
50	<210> 385 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 385 gcctgctggg cttggct	17
	<210> 386	

	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
5	<400> 386		
	tgctgtggt cccagct		17
	<210> 387		
	<211> 17		
	<212> DNA		
10	<213> Homo sapiens		
	<400> 387		
	gaggtatac tgagggg		17
	<210> 388		
	<211> 17		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 388		
	ggagccagct gacctgc		17
20	<210> 389		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 389		
25	gagcctcagg tgctccc		17
	<210> 390		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 390		
	tacttcacat acagtgc		17
	<210> 391		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 391		
	taatcccagc actttgg		17
	<210> 392		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 392		
	caccttccag cccgggg		17
45	<210> 393		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 393		
	gagtctgttc gtgactc		17
	<210> 394		
	<211> 17		
	<212> DNA		
55	<213> Homo sapiens		
	<400> 394		

	ggatttttggc ctctgtc	17
	<210> 395	
	<211> 17	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 395	
	tgctgtagt cctagtt	17
10	<210> 396	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 396	
15	ttacaaacag aaaagct	17
	<210> 397	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 397	
	tcttctttca gaatggg	17
	<210> 398	
	<211> 17	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 398	
	agcacatttg atatagc	17
	<210> 399	
30	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 399	
	cagggctcgc gtgcggg	17
35	<210> 400	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 400	
40	gctggtccca gggccag	17
	<210> 401	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 401	
	tccacgccct tcctggc	17
	<210> 402	
	<211> 17	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 402	
	ttgcaatagc aaaaccc	17
55	<210> 403	
	<211> 17	
	<212> DNA	

	<213> Homo sapiens	
	<400> 403 agggcttcca atgtgct	17
5	<210> 404 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 404 ctgggttaat aaattgc	17
	<210> 405 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 405 aacctgggag gtggagg	17
	<210> 406 <211> 17 <212> DNA <213> Homo sapiens	
20	<400> 406 ggcaacgtgg tagaggc	17
	<210> 407 <211> 17 <212> DNA <213> Homo sapiens	
25	<400> 407 ggatgcgcag gggaggc	17
	<210> 408 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 408 cacctgtagt cctagct	17
	<210> 409 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 409 gtggtgggag cctgtag	17
	<210> 410 <211> 17 <212> DNA <213> Homo sapiens	
40	<400> 410 gcagggtggg gaggggt	17
	<210> 411 <211> 17 <212> DNA <213> Homo sapiens	
45	<400> 411 caagcatccc cgttcca	17
50		
55		

	<210> 412	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 412	
	tgggggccga tgggcag	17
	<210> 413	
	<211> 17	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 413	
	tcagtgtatt aaaaccc	17
	<210> 414	
	<211> 17	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 414	
	ggcaagcccc agcgcct	17
20	<210> 415	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 415	
	cctagctgga ttgcaga	17
	<210> 416	
	<211> 17	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 416	
	gcaaaaccct gctctcc	17
	<210> 417	
	<211> 17	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 417	
	gctggttcct gagtggc	17
40	<210> 418	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 418	
	gcacctcagc caggggt	17
	<210> 419	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 419	
	accagctgtc caggggc	17
	<210> 420	
	<211> 17	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 420 tttgaatcag tgctaga	17
5	<210> 421 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 421 agactagggg ccggagc	17
10	<210> 422 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 422 agctcagtga gaagggc	17
	<210> 423 <211> 17 <212> DNA <213> Homo sapiens	
20	<400> 423 ggccaacatt tggtcca	17
25	<210> 424 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 424 tttgtgggca gtcaggc	17
30	<210> 425 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 425 attgtagaca atgaggg	17
	<210> 426 <211> 17 <212> DNA <213> Homo sapiens	
40	<400> 426 ccctaggttg ggcccct	17
45	<210> 427 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 427 aatcaccaa tcaaggc	17
50	<210> 428 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 428 ggctgcagtc ttcttcc	17
55	<210> 429 <211> 17	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 429 gtggcaggcg cctgtag	17	
	<210> 430		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 430 taaaggcaca gtggctc	17	
	<210> 431		
	<211> 17		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 431 ggctcctggc tctggac	17	
	<210> 432		
20	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 432 atattaggaa gtcgggg	17	
25	<210> 433		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 433 gcttcagtgg gggagag	17	
	<210> 434		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 434 tgattaaaac aagttgc	17	
	<210> 435		
40	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 435 agccaccacg cctggtc	17	
45	<210> 436		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 436 ggcggctgca gagcctg	17	
	<210> 437		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 437 tgtttggggg cttttag	17	

5	<210> 438		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 438		
	cctgcctcgt agtgaag		17
	<210> 439		
	<211> 17		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 439		
	aggcctgggc ctctgcg		17
20	<210> 440		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 440		
	caaaactggt tgttggc		17
	<210> 441		
	<211> 17		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 441		
	gagaggacat tggaggg		17
35	<210> 442		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 442		
	gagttaggca cttcctg		17
	<210> 443		
	<211> 17		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 443		
	ccgtagtgcc tttatgg		17
50	<210> 444		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 444		
	cataaacggg cacaccc		17
	<210> 445		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 445		
	tccctggcag agggctt		17
	<210> 446		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		

	<400> 446 gaggccatcc ccaaccc	17
5	<210> 447 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 447 ttgcctggga tgctggt	17
	<210> 448 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 448 ctgtcagcgg ctgcccc	17
20	<210> 449 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 449 aacgcggcca atgtggg	17
25	<210> 450 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 450 ggtttggtt aggctgg	17
	<210> 451 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 451 gattttgtg gtgtggg	17
40	<210> 452 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 452 ggctgccctg ggcagcc	17
45	<210> 453 <211> 17 <212> DNA <213> Homo sapiens	
50	<400> 453 atggcaacag aaaccaa	17
	<210> 454 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 454 cgctgtgggg tgcagac	17
	<210> 455	

	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 455 ggcagccaga gctccaa	17
	<210> 456	
	<211> 17	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 456 agagcaaacc gtagtcc	17
	<210> 457	
	<211> 17	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 457 tttccctcaa agactct	17
20	<210> 458	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 458 tccccgtggc tgtgggg	17
	<210> 459	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 459 tttctccaaa taccggt	17
	<210> 460	
	<211> 17	
35	<212> DNA	
	<213> Homo sapiens	
	<400> 460 ggctgggggc cagggct	17
40	<210> 461	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 461 ccctaccctg ttacctt	17
	<210> 462	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 462 taggaccctg caggggg	17
	<210> 463	
	<211> 17	
	<212> DNA	
55	<213> Homo sapiens	
	<400> 463	

	gtttttgctt cagcggc	17
	<210> 464	
	<211> 17	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 464	
	cttgattccc acgctac	17
	<210> 465	
10	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 465	
15	gcttggtccc caaaggg	17
	<210> 466	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 466	
	ggtggcactc agtctct	17
	<210> 467	
	<211> 17	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 467	
	acctgtgacc agcactg	17
	<210> 468	
30	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 468	
	actgaggaaa ggagctc	17
35	<210> 469	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 469	
40	tgcagcgctt gcggcct	17
	<210> 470	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 470	
	ctggggggaa gggactg	17
	<210> 471	
	<211> 17	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 471	
	gtgctattct ggggctg	17
55	<210> 472	
	<211> 17	
	<212> DNA	

	<213> Homo sapiens	
	<400> 472	
	ggagggggct tgaagcc	17
5	<210> 473	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
10	<400> 473	
	gtgcctgaga ggcaggc	17
	<210> 474	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
15	<400> 474	
	tcacagggctc cccgggg	17
	<210> 475	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 475	
	gggctccctg gccctgg	17
	<210> 476	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 476	
	gccccaggta gggggac	17
30	<210> 477	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
35	<400> 477	
	gaaagtggct gtcctgg	17
	<210> 478	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
40	<400> 478	
	tccctggctg ttgaggc	17
	<210> 479	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 479	
	acagagcaca gctgccc	17
50	<210> 480	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
55	<400> 480	
	ctttgcactc tcctttg	17

	<210> 481	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 481	
	atgctccctg aggagct	17
	<210> 482	
	<211> 17	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 482	
	ccgtccaagg gtccgct	17
	<210> 483	
	<211> 17	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 483	
	gggcccctg ggcagtg	17
20	<210> 484	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 484	
	cttatgctgc tgggtgcc	17
	<210> 485	
	<211> 17	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 485	
	ggttattttg gagtgtgta	17
	<210> 486	
	<211> 17	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 486	
	gcctgtccct ccaagac	17
40	<210> 487	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 487	
	aagatgaggg ggcaggc	17
	<210> 488	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 488	
	ccaacaagaa tgcattg	17
	<210> 489	
	<211> 17	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 489 aaggatgcgg tgatggc	17
5	<210> 490 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 490 tgtcatcaca gacactt	17
10	<210> 491 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 491 caggcttttt ggcttcc	17
	<210> 492 <211> 17 <212> DNA <213> Homo sapiens	
20	<400> 492 tcaagttcac tgcctgt	17
	<210> 493 <211> 17 <212> DNA <213> Homo sapiens	
25	<400> 493 tccctgggca gcttcag	17
30	<210> 494 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 494 caggagttca aagaagg	17
35	<210> 495 <211> 17 <212> DNA <213> Homo sapiens	
40	<400> 495 caggtgggttc tgccatc	17
	<210> 496 <211> 17 <212> DNA <213> Homo sapiens	
45	<400> 496 gcccacatcc gctgagg	17
	<210> 497 <211> 17 <212> DNA <213> Homo sapiens	
50	<400> 497 gctgggggtgg ggggtggg	17
55	<210> 498 <211> 17	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 498 gacctcctgc cctgggg	17	
	<210> 499		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 499 agtgaataaa tgtcttg	17	
	<210> 500		
	<211> 17		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 500 aaggttcttc tcaaggg	17	
	<210> 501		
20	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 501 agcctggact gagccac	17	
25	<210> 502		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 502 caaccagat tgggggtg	17	
	<210> 503		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 503 tgcttctgcc accctgc	17	
	<210> 504		
40	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 504 caggtgacaa gggccct	17	
45	<210> 505		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 505 ggccgggggc agttctc	17	
	<210> 506		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 506 gtgcgctagg gccccgg	17	

5	<210> 507		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 507		
	aggctgtcca ggctctg		17
	<210> 508		
	<211> 17		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 508		
	tggtatgtcc attttgc		17
20	<210> 509		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 509		
	tttcccaaac tgtgagg		17
	<210> 510		
	<211> 17		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 510		
	ggggatgggg tactgcc		17
35	<210> 511		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 511		
	gtctcagtgc		10
	<210> 512		
	<211> 10		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 512		
	cttatgctgc		10
50	<210> 513		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 513		
	ccaccctcac		10
	<210> 514		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 514		
	gtgctacttc		10
	<210> 515		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		

	<400> 515 gagtgagacc	10
5	<210> 516 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 516 atggcaacag	10
	<210> 517 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 517 tcacacagtg	10
20	<210> 518 <211> 9 <212> DNA <213> Homo sapiens	
	<400> 518 gaccgcagg	9
25	<210> 519 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 519 gggaggggtg	10
	<210> 520 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 520 ccctaccctg	10
40	<210> 521 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 521 ttctcccaaa	10
45	<210> 522 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 522 ggatgcgag	10
50	<210> 523 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 523 gtgctaagcg	10
	<210> 524	

	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 524 cccaggacac	10
	<210> 525	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 525 tagttggaaa	10
	<210> 526	
	<211> 10	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 526 aagggcgcg	10
20	<210> 527	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 527 agctgtgcca	10
	<210> 528	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 528 acaaaatcaa	10
	<210> 529	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 529 gcctgcagtc	10
40	<210> 530	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 530 accaggtcca	10
	<210> 531	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 531 ggctaattat	10
	<210> 532	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	
	<400> 532	

	tttaaatagc	10
	<210> 533	
	<211> 10	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 533	
	cagttcatta	10
	<210> 534	
10	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 534	
15	ctgccgtgac	10
	<210> 535	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 535	
	ttttaactta	10
	<210> 536	
	<211> 10	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 536	
	tagaaaccgg	10
	<210> 537	
30	<211> 9	
	<212> DNA	
	<213> Homo sapiens	
	<400> 537	
	cttcttgcc	9
35	<210> 538	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
40	<400> 538	
	tagaaaaaat	10
	<210> 539	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 539	
	gtgctacttc	10
	<210> 540	
	<211> 10	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 540	
	gagtgagacc	10
55	<210> 541	
	<211> 10	
	<212> DNA	

	<213> Homo sapiens	
	<400> 541 tcacacagtg	10
5	<210> 542 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 542 gaccgcagga	10
	<210> 543 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 543 gggaggggtg	10
	<210> 544 <211> 10 <212> DNA <213> Homo sapiens	
20	<400> 544 ggggctgccc	10
	<210> 545 <211> 10 <212> DNA <213> Homo sapiens	
25	<400> 545 ttctccaaa	10
30	<210> 546 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 546 ccacagggga	10
	<210> 547 <211> 10 <212> DNA <213> Homo sapiens	
40	<400> 547 tcaagttcac	10
	<210> 548 <211> 10 <212> DNA <213> Homo sapiens	
45	<400> 548 accaaaaacc	10
50	<210> 549 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 549 gatcaggcca	10

	<210> 550		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
5	<400> 550		
	agaaaccacg		10
	<210> 551		
	<211> 10		
	<212> DNA		
10	<213> Homo sapiens		
	<400> 551		
	aaggttcttc		10
	<210> 552		
	<211> 10		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 552		
	ccctttcaca		10
20	<210> 553		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 553		
	agactagggg		10
	<210> 554		
	<211> 10		
	<212> DNA		
30	<213> Homo sapiens		
	<400> 554		
	cataaacggg		10
	<210> 555		
	<211> 10		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 555		
	ggccaacatt		10
40	<210> 556		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
45	<400> 556		
	gtacgtccca		10
	<210> 557		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 557		
	gcaatttaac		10
	<210> 558		
	<211> 10		
	<212> DNA		
55	<213> Homo sapiens		

	<400> 558 aggtgcgggg	10
5	<210> 559 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 559 tttggggctg	10
	<210> 560 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 560 caccctgtac	10
20	<210> 561 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 561 gggtgggcgt	10
25	<210> 562 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 562 gtacgtccca ccctgtc	17
	<210> 563 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 563 gcaatttaac cacattt	17
40	<210> 564 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 564 aggtgcgggg ggcagac	17
45	<210> 565 <211> 17 <212> DNA <213> Homo sapiens	
50	<400> 565 tttggggctg gcctcac	17
	<210> 566 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 566 caccctgtac agttgcc	17
	<210> 567 <211> 17	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 567 gggtgggcgt gcagggga	17	
	<210> 568		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 568 actcagcccg gctgatg	17	
	<210> 569		
	<211> 17		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 569 gctctctatg ctgacgt	17	
	<210> 570		
20	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 570 agaatgaaac tgccggg	17	
25	<210> 571		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 571 aagtggaata aactgcc	17	
	<210> 572		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 572 tttgaatcag tgctaga	17	
	<210> 573		
40	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 573 ttctgctctt gtgccct	17	
45	<210> 574		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 574 tggaagtgg gctcctt	17	
	<210> 575		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 575 tgggcccggtg tctggcc	17	

5	<210> 576		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 576		
	acaacgtcca gctggtg		17
	<210> 577		
	<211> 17		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 577		
	ccccctgccc ctctgcc		17
20	<210> 578		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 578		
	gtctatgcct cccagga		17
	<210> 579		
	<211> 17		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 579		
	ggctggagcc gctttgg		17
35	<210> 580		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 580		
	catacctcct gccccgc		17
	<210> 581		
	<211> 17		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 581		
	tgctgcacc aggagac		17
50	<210> 582		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 582		
	ttccttgtaa tcaaaga		17
	<210> 583		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 583		
	tggcggcaga ggcagag		17
	<210> 584		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		

	<400> 584 ccacgtggct ggctggg	17
5	<210> 585 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 585 ctggaggctg cctcggg	17
	<210> 586 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 586 atggcaacag atctgga	17
20	<210> 587 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 587 ggtcccctac ccttccc	17
25	<210> 588 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 588 cccgcccccg ccttccc	17
	<210> 589 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 589 cccgaggcag agtcggg	17
40	<210> 590 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 590 ctacgtgatg aagatgg	17
45	<210> 591 <211> 17 <212> DNA <213> Homo sapiens	
50	<400> 591 atggggtttgc atttttag	17
	<210> 592 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 592 atggaagtct gcgtaac	17
	<210> 593	

	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 593 tggacagcag ggacctg	17
	<210> 594	
	<211> 17	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 594 tcatagaaac cttgatt	17
	<210> 595	
	<211> 17	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 595 cagcgctgca ttgactc	17
20	<210> 596	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 596 ctgggtgccc cagcctg	17
	<210> 597	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 597 cgaccccacg ccacccc	17
	<210> 598	
	<211> 17	
35	<212> DNA	
	<213> Homo sapiens	
	<400> 598 cgctgggcgt ctgggac	17
40	<210> 599	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 599 attagtcaga aactgcc	17
	<210> 600	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 600 gatagcacag ttgtcag	17
	<210> 601	
	<211> 17	
55	<212> DNA	
	<213> Homo sapiens	
	<400> 601	

	cgtactgagc gctttgg	17
	<210> 602	
	<211> 17	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 602	
	ggggcttctg tagcccc	17
10	<210> 603	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 603	
15	cccgtccgga acgtcta	17
	<210> 604	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 604	
	ccagtggccc ggagctg	17
	<210> 605	
	<211> 17	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 605	
	actgtactcc agcctag	17
	<210> 606	
30	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 606	
	agctccagac ccccagc	17
35	<210> 607	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 607	
40	gactcgcaga caccggg	17
	<210> 608	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 608	
	ggcctccagc cacccac	17
	<210> 609	
	<211> 17	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 609	
	gaccagcctt cagatgg	17
55	<210> 610	
	<211> 17	
	<212> DNA	

	<213> Homo sapiens	
	<400> 610 gccccaggg gcaggac	17
5	<210> 611 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 611 gaggatggtg tcctgag	17
	<210> 612 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 612 aagatcaaga tcattgc	17
	<210> 613 <211> 17 <212> DNA <213> Homo sapiens	
20	<400> 613 agcacagggc cgggggg	17
25	<210> 614 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 614 gccaaagtga ctgtggc	17
	<210> 615 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 615 cgtgggtggg gagggag	17
	<210> 616 <211> 17 <212> DNA <213> Homo sapiens	
40	<400> 616 ctcccctatg gactggc	17
	<210> 617 <211> 17 <212> DNA <213> Homo sapiens	
45	<400> 617 agtatgagga aatctct	17
50	<210> 618 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 618 gcccccttcc tcccttg	17

	<210> 619	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 619	
	gggatttctg tgtctgc	17
	<210> 620	
	<211> 17	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 620	
	cttccagcta acaggtc	17
	<210> 621	
	<211> 17	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 621	
	gccttggggtg acaaatt	17
20	<210> 622	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 622	
	gcctcccgcc acggggc	17
	<210> 623	
	<211> 17	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 623	
	gtgtgggggg ctggggg	17
	<210> 624	
	<211> 17	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 624	
	gactcttcag tctggag	17
40	<210> 625	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 625	
45	gccacacca ccgcccc	17
	<210> 626	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 626	
	ccagggcaac agaatga	17
	<210> 627	
	<211> 17	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 627 caccctgtac agttgcc	17
5	<210> 628 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 628 gacgaatatg aatgtca	17
	<210> 629 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 629 caaactgggtc taggtca	17
20	<210> 630 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 630 gtaatgacag atgcaag	17
25	<210> 631 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 631 tggtcccagg tgccacc	17
	<210> 632 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 632 aacacaatca tatgatg	17
40	<210> 633 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 633 gaggggtatac tgagggg	17
45	<210> 634 <211> 17 <212> DNA <213> Homo sapiens	
50	<400> 634 ggagccagct gacctgc	17
	<210> 635 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 635 gagcctcagg tgctccc	17
	<210> 636 <211> 17	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 636 tacttcacat acagtgc		17
	<210> 637		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 637 cggtgggacc accctgc		17
	<210> 638		
	<211> 17		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 638 ggagaaacag ctgctga		17
	<210> 639		
20	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 639 gctcaggtct gccgggg		17
25	<210> 640		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 640 tctgcactga gaaactg		17
	<210> 641		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 641 tccacgccct tcctggc		17
	<210> 642		
40	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 642 ttgcaatagc aaaaccc		17
45	<210> 643		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 643 tccaaatcga tgtggat		17
	<210> 644		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 644 agggcttcca atgtgct		17

5	<210> 645		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 645		
	aacctgggag	gtggagg	17
	<210> 646		
	<211> 17		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 646		
	ggccaacatt	tggtcca	17
20	<210> 647		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 647		
	ggggctggag	gggggca	17
	<210> 648		
	<211> 17		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 648		
	ggatgcgag	gggaggc	17
35	<210> 649		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 649		
	gaagacactt	ggtttga	17
	<210> 650		
	<211> 17		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 650		
	gagagaagag	tgatctg	17
50	<210> 651		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 651		
	gcagggtggg	gaggggt	17
	<210> 652		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 652		
	tcagtgtatt	aaaaccc	17
	<210> 653		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		

	<400> 653 atactataat tgtgaga	17
5	<210> 654 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 654 gctggttcct gagtggc	17
	<210> 655 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 655 agccactgcg cccggcc	17
20	<210> 656 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 656 agactagggg ccggagc	17
25	<210> 657 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 657 gggacagctg tctgtgg	17
	<210> 658 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 658 aaccaggag gcggagc	17
40	<210> 659 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 659 cagcctgagg ctcttgg	17
45	<210> 660 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 660 cctcccctgc acctggg	17
50	<210> 661 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 661 gcttcagtgg gggagag	17
	<210> 662	

	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 662	
	tgtttggggg ctttttag	17
	<210> 663	
	<211> 17	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 663	
	ttttaaatta ggttttg	17
	<210> 664	
	<211> 17	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 664	
	atctcaaaga tacacag	17
20	<210> 665	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 665	
25	tttgtgggca gtcaggc	17
	<210> 666	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 666	
	attgtagaca atgaggg	17
	<210> 667	
	<211> 17	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 667	
	gcaaaaccct gctctcc	17
	<210> 668	
40	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 668	
45	gtctcagtgc tgaggcg	17
	<210> 669	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 669	
	agccactgtg cccggcc	17
	<210> 670	
	<211> 17	
	<212> DNA	
55	<213> Homo sapiens	
	<400> 670	

	tgattaaggt cggcgct	17
	<210> 671	
	<211> 17	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 671	
	ttacaaacag aaaagct	17
	<210> 672	
10	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 672	
15	tttattattg ttcaata	17
	<210> 673	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 673	
	cgggcctcag gtggcag	17
	<210> 674	
	<211> 17	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 674	
	taaaggcaca gtggctc	17
	<210> 675	
30	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 675	
	atattaggaa gtcgggg	17
35	<210> 676	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 676	
40	tgattaaaac aagttgc	17
	<210> 677	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 677	
	ttgtgcacgc atcagtg	17
	<210> 678	
	<211> 17	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 678	
	cctgcctcgt agtgaag	17
55	<210> 679	
	<211> 17	
	<212> DNA	

	<213> Homo sapiens	
	<400> 679	
	caaaactggt tgttggc	17
5	<210> 680	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
10	<400> 680	
	taggaaagta aaatgga	17
	<210> 681	
	<211> 17	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 681	
	ctccatcggc tgtgagg	17
	<210> 682	
	<211> 17	
20	<212> DNA	
	<213> Homo sapiens	
	<400> 682	
	caagcatccc cgttcca	17
25	<210> 683	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 683	
	gagttaggca cttcctg	17
	<210> 684	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
35	<400> 684	
	cataaacggg cacaccc	17
	<210> 685	
	<211> 17	
40	<212> DNA	
	<213> Homo sapiens	
	<400> 685	
	ttgcctggga tgctggt	17
45	<210> 686	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
	<400> 686	
	aacgcggcca atgtggg	17
50	<210> 687	
	<211> 17	
	<212> DNA	
	<213> Homo sapiens	
55	<400> 687	
	ggtttggtt aggctgg	17

	<210> 688		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
5	<400> 688		
	gatttttgtg gtgtggg		17
	<210> 689		
	<211> 17		
	<212> DNA		
10	<213> Homo sapiens		
	<400> 689		
	ggctgccctg ggcagcc		17
	<210> 690		
	<211> 17		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 690		
	atggcaacag aaaccaa		17
20	<210> 691		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 691		
	agagcaaacc gtagtcc		17
	<210> 692		
	<211> 17		
	<212> DNA		
30	<213> Homo sapiens		
	<400> 692		
	tgcaacttcaa gaaaatg		17
	<210> 693		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 693		
	ccctaccctg ttacctt		17
40	<210> 694		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
45	<400> 694		
	ggaaaaatgt tggaatg		17
	<210> 695		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 695		
	gtttttgctt cagcggc		17
	<210> 696		
	<211> 17		
	<212> DNA		
55	<213> Homo sapiens		

	<400> 696 gaggacccaa caggagg	17
5	<210> 697 <211> 17 <212> DNA <213> Homo sapiens	
10	<400> 697 actgaggaaa ggagctc	17
	<210> 698 <211> 17 <212> DNA <213> Homo sapiens	
15	<400> 698 tgcagcgcct gcggcct	17
20	<210> 699 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 699 ctggggggaa gggactg	17
25	<210> 700 <211> 17 <212> DNA <213> Homo sapiens	
30	<400> 700 gtgcctgaga ggcaggc	17
	<210> 701 <211> 17 <212> DNA <213> Homo sapiens	
35	<400> 701 tcacagggtc cccgggg	17
40	<210> 702 <211> 17 <212> DNA <213> Homo sapiens	
	<400> 702 ggagggggct tgaagcc	17
45	<210> 703 <211> 17 <212> DNA <213> Homo sapiens	
50	<400> 703 ggaggaattc atcttca	17
	<210> 704 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 704 gaaagtggct gtcctgg	17
	<210> 705 <211> 17	

	<212> DNA		
	<213> Homo sapiens		
5	<400> 705 tccctggctg ttgaggc	17	
	<210> 706		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 706 aagatgaggg ggcaggc	17	
	<210> 707		
	<211> 17		
	<212> DNA		
15	<213> Homo sapiens		
	<400> 707 ccaacaagaa tgcattg	17	
	<210> 708		
20	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 708 aaggatgcgg tgatggc	17	
25	<210> 709		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
30	<400> 709 tgcagtcact ggtgtca	17	
	<210> 710		
	<211> 17		
	<212> DNA		
35	<213> Homo sapiens		
	<400> 710 gccgtgtaga ccctaac	17	
	<210> 711		
40	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
	<400> 711 caggcttttt ggcttcc	17	
45	<210> 712		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
50	<400> 712 tccctgggca gcttcag	17	
	<210> 713		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 713 gagcgcagcg agctagc	17	

5	<210> 714		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 714		
	caggtgggttc tgccatc		17
	<210> 715		
	<211> 17		
15	<212> DNA		
	<213> Homo sapiens		
	<400> 715		
	gcccacatcc gctgagg		17
20	<210> 716		
	<211> 17		
	<212> DNA		
	<213> Homo sapiens		
25	<400> 716		
	aaggttcttc tcaaggg		17
	<210> 717		
	<211> 10		
30	<212> DNA		
	<213> Homo sapiens		
	<400> 717		
	actcagcccg		10
35	<210> 718		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
40	<400> 718		
	gctctctatg		10
	<210> 719		
	<211> 10		
45	<212> DNA		
	<213> Homo sapiens		
	<400> 719		
	agaatgaaac		10
50	<210> 720		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
55	<400> 720		
	aagtggaata		10
	<210> 721		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 721		
	tttgaatcag		10
	<210> 722		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		

	<400> 722 ttctgctctt	10
5	<210> 723 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 723 tggaagtgg	10
	<210> 724 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 724 tgggcccgtg	10
	<210> 725 <211> 10 <212> DNA <213> Homo sapiens	
20	<400> 725 acaacgtcca	10
	<210> 726 <211> 10 <212> DNA <213> Homo sapiens	
25	<400> 726 ccccctgccc	10
	<210> 727 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 727 gtctatgcct	10
	<210> 728 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 728 ggctggagcc	10
	<210> 729 <211> 10 <212> DNA <213> Homo sapiens	
40	<400> 729 catacctcct	10
	<210> 730 <211> 10 <212> DNA <213> Homo sapiens	
45	<400> 730 tgctgcacc	10
	<210> 731	
50		
55		

	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 731 ttccttgtaa	10
	<210> 732	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 732 tggcggcaga	10
	<210> 733	
	<211> 10	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 733 ccacgtggct	10
20	<210> 734	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 734 ctggaggctg	10
	<210> 735	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 735 atggcaacag	10
	<210> 736	
	<211> 10	
35	<212> DNA	
	<213> Homo sapiens	
	<400> 736 ggtcccctac	10
40	<210> 737	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 737 cccgcccccg	10
	<210> 738	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 738 cccgaggcag	10
	<210> 739	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	
	<400> 739	

	ctacgtgatg	10
	<210> 740	
	<211> 10	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 740	
	atgggtttgc	10
	<210> 741	
10	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 741	
15	atggaagtct	10
	<210> 742	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 742	
	tggacagcag	10
	<210> 743	
	<211> 10	
	<212> DNA	
25	<213> Homo sapiens	
	<400> 743	
	tcatagaaac	10
	<210> 744	
30	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 744	
	cagcgctgca	10
35	<210> 745	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
40	<400> 745	
	ctgggtgccc	10
	<210> 746	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 746	
	cgacccacg	10
	<210> 747	
	<211> 10	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 747	
	cgctgggcgt	10
55	<210> 748	
	<211> 10	
	<212> DNA	

	<213> Homo sapiens	
	<400> 748 attagtcaga	10
5	<210> 749 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 749 gatagcacag	10
	<210> 750 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 750 cgtactgagc	10
	<210> 751 <211> 10 <212> DNA <213> Homo sapiens	
20	<400> 751 ggggcttctg	10
	<210> 752 <211> 10 <212> DNA <213> Homo sapiens	
25	<400> 752 cccgtccgga	10
	<210> 753 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 753 ccagtggccc	10
	<210> 754 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 754 actgtactcc	10
	<210> 755 <211> 10 <212> DNA <213> Homo sapiens	
40	<400> 755 agctccagac	10
	<210> 756 <211> 10 <212> DNA <213> Homo sapiens	
45	<400> 756 gactcgcaga	10
50		
55		

	<210> 757	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 757 ggcctccagc	10
	<210> 758	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 758 gaccagcctt	10
	<210> 759	
	<211> 10	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 759 gccccaggg	10
20	<210> 760	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 760 gaggatggtg	10
	<210> 761	
	<211> 10	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 761 aagatcaaga	10
	<210> 762	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 762 agcacagggt	10
40	<210> 763	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 763 gccaagtga	10
	<210> 764	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 764 cgtgggtggg	10
	<210> 765	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 765 ctcccctatg	10
5	<210> 766 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 766 agtatgagga	10
	<210> 767 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 767 gcccccttcc	10
20	<210> 768 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 768 gggatttctg	10
25	<210> 769 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 769 cttccagcta	10
	<210> 770 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 770 gccttggggtg	10
40	<210> 771 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 771 gcctcccgcc	10
45	<210> 772 <211> 10 <212> DNA <213> Homo sapiens	
50	<400> 772 gtgtgggggg	10
	<210> 773 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 773 gactcttcag	10
	<210> 774 <211> 10	

	<212> DNA	
	<213> Homo sapiens	
5	<400> 774 gccacaccca	10
	<210> 775	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
10	<400> 775 ccagggcaac	10
	<210> 776	
	<211> 10	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 776 caccctgtac	10
	<210> 777	
20	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 777 gacgaatatg	10
25	<210> 778	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 778 caaactggtc	10
	<210> 779	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 779 gtaatgacag	10
	<210> 780	
40	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 780 tggccccagg	10
45	<210> 781	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 781 aacacaatca	10
50	<210> 782	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
55	<400> 782 gagggtatac	10

5	<210> 783		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 783		
	ggagccagct		10
10	<210> 784		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 784		
	gagcctcagg		10
15	<210> 785		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 785		
20	tacttcacat		10
25	<210> 786		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 786		
	cggtgggacc		10
30	<210> 787		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 787		
	ggagaaacag		10
35	<210> 788		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 788		
40	gctcaggtct		10
45	<210> 789		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 789		
	tctgcactga		10
50	<210> 790		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		
	<400> 790		
	tccacgccct		10
55	<210> 791		
	<211> 10		
	<212> DNA		
	<213> Homo sapiens		

	<400> 791 ttgcaatagc	10
5	<210> 792 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 792 tccaaatcga	10
	<210> 793 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 793 agggcttcca	10
20	<210> 794 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 794 aacctgggag	10
25	<210> 795 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 795 ggccaacatt	10
	<210> 796 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 796 ggggctggag	10
40	<210> 797 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 797 ggatgcgag	10
45	<210> 798 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 798 gaagacactt	10
50	<210> 799 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 799 gagagaagag	10
	<210> 800	

	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 800 gcagggtggg	10
	<210> 801	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 801 tcagtgtatt	10
	<210> 802	
	<211> 10	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 802 atactataat	10
20	<210> 803	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 803 gctggttcct	10
	<210> 804	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 804 agccactgcg	10
	<210> 805	
	<211> 10	
35	<212> DNA	
	<213> Homo sapiens	
	<400> 805 agactagggg	10
40	<210> 806	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 806 gggacagctg	10
	<210> 807	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 807 aaccaggag	10
	<210> 808	
	<211> 10	
55	<212> DNA	
	<213> Homo sapiens	
	<400> 808	

	cagcctgagg	10
	<210> 809	
	<211> 10	
5	<212> DNA	
	<213> Homo sapiens	
	<400> 809	
	cctcccctgc	10
10	<210> 810	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 810	
15	gcttcagtgg	10
	<210> 811	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
20	<400> 811	
	tgtttggggg	10
	<210> 812	
	<211> 10	
25	<212> DNA	
	<213> Homo sapiens	
	<400> 812	
	ttttaaatta	10
30	<210> 813	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 813	
	atctcaaaga	10
35	<210> 814	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
40	<400> 814	
	tttgtgggca	10
	<210> 815	
	<211> 10	
	<212> DNA	
45	<213> Homo sapiens	
	<400> 815	
	attgtagaca	10
	<210> 816	
	<211> 10	
50	<212> DNA	
	<213> Homo sapiens	
	<400> 816	
	gcaaaaccct	10
55	<210> 817	
	<211> 10	
	<212> DNA	

	<213> Homo sapiens	
	<400> 817 gtctcagtgc	10
5	<210> 818 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 818 agccactgtg	10
	<210> 819 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 819 tgattaaggt	10
	<210> 820 <211> 10 <212> DNA <213> Homo sapiens	
20	<400> 820 ttacaaacag	10
	<210> 821 <211> 10 <212> DNA <213> Homo sapiens	
25	<400> 821 tttattattg	10
30	<210> 822 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 822 cgggcctcag	10
	<210> 823 <211> 10 <212> DNA <213> Homo sapiens	
40	<400> 823 taaaggcaca	10
	<210> 824 <211> 10 <212> DNA <213> Homo sapiens	
45	<400> 824 atattaggaa	10
50	<210> 825 <211> 10 <212> DNA <213> Homo sapiens	
55	<400> 825 tgattaaaac	10

	<210> 826	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
5	<400> 826 ttgtgcacgc	10
	<210> 827	
	<211> 10	
	<212> DNA	
10	<213> Homo sapiens	
	<400> 827 cctgcctcgt	10
	<210> 828	
	<211> 10	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 828 caaaactggt	10
20	<210> 829	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 829 taggaaagta	10
	<210> 830	
	<211> 10	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 830 ctccatcggc	10
	<210> 831	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 831 caagcatccc	10
40	<210> 832	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 832 gagttaggca	10
	<210> 833	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 833 cataaacggg	10
	<210> 834	
	<211> 10	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 834 ttgcctggga	10
5	<210> 835 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 835 aacgcggcca	10
10	<210> 836 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 836 ggtttgctt	10
	<210> 837 <211> 10 <212> DNA <213> Homo sapiens	
20	<400> 837 gattttgtg	10
	<210> 838 <211> 10 <212> DNA <213> Homo sapiens	
25	<400> 838 ggctgccctg	10
	<210> 839 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 839 atggcaacag	10
	<210> 840 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 840 agagcaaacc	10
	<210> 841 <211> 10 <212> DNA <213> Homo sapiens	
40	<400> 841 tgcacttcaa	10
	<210> 842 <211> 10 <212> DNA <213> Homo sapiens	
45	<400> 842 ccctaccctg	10
	<210> 843 <211> 10	
50		
55		

	<212> DNA	
	<213> Homo sapiens	
5	<400> 843 ggaaaaatgt	10
	<210> 844	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
10	<400> 844 gtttttgctt	10
	<210> 845	
	<211> 10	
	<212> DNA	
15	<213> Homo sapiens	
	<400> 845 gaggacccaa	10
	<210> 846	
20	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 846 actgaggaaa	10
25	<210> 847	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
30	<400> 847 tgcagcgcct	10
	<210> 848	
	<211> 10	
	<212> DNA	
35	<213> Homo sapiens	
	<400> 848 ctggggggaa	10
	<210> 849	
40	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 849 gtgcctgaga	10
45	<210> 850	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
50	<400> 850 tcacagggtc	10
	<210> 851	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
55	<400> 851 ggagggggct	10

	<210> 852	
	<211> 10	
	<212> DNA	
5	<213> Homo sapiens	
	<400> 852	
	ggaggaattc	10
	<210> 853	
	<211> 10	
10	<212> DNA	
	<213> Homo sapiens	
	<400> 853	
	gaaagtggct	10
15	<210> 854	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 854	
20	tccctggctg	10
	<210> 855	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
25	<400> 855	
	aagatgaggg	10
	<210> 856	
	<211> 10	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 856	
	ccaacaagaa	10
	<210> 857	
35	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
	<400> 857	
	aaggatgcgg	10
40	<210> 858	
	<211> 10	
	<212> DNA	
	<213> Homo sapiens	
45	<400> 858	
	tcagtcact	10
	<210> 859	
	<211> 10	
	<212> DNA	
50	<213> Homo sapiens	
	<400> 859	
	gccgtgtaga	10
	<210> 860	
55	<211> 10	
	<212> DNA	
	<213> Homo sapiens	

	<400> 860 caggcttttt	10
5	<210> 861 <211> 10 <212> DNA <213> Homo sapiens	
10	<400> 861 tccctgggca	10
	<210> 862 <211> 10 <212> DNA <213> Homo sapiens	
15	<400> 862 gagcgagcg	10
20	<210> 863 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 863 caggtggttc	10
25	<210> 864 <211> 10 <212> DNA <213> Homo sapiens	
30	<400> 864 gcccacatcc	10
	<210> 865 <211> 10 <212> DNA <213> Homo sapiens	
35	<400> 865 aaggttcttc	10
40	<210> 866 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 866 ggctaattat	10
45	<210> 867 <211> 10 <212> DNA <213> Homo sapiens	
	<400> 867 caaaaataaa	10
50	<210> 868 <211> 17 <212> DNA <213> Homo sapiens	
55	<400> 868 ggctaattat catcaat	17
	<210> 869	

<211> 16
 <212> DNA
 <213> Homo sapiens

<400> 869
 caaaaataaa agccga

16

Claims

1. A method to aid in diagnosing glioma, comprising the steps of:

detecting an expression product of at least one gene in a first brain tissue sample suspected of being neoplastic wherein said at least one gene is plasmalemma vesicle associated protein and
 comparing expression of the at least one gene in the first brain tissue sample with expression of the at least one gene in a second brain tissue sample which is normal, wherein increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample identifies the first brain tissue sample as likely to be neoplastic.

2. An antibody, optionally conjugated to a diagnostic or therapeutic reagent, which specifically binds to an extracellular epitope of plasmalemma vesicle associated protein for use in treating a glioma, especially whereby immune destruction of cells of the glioma is triggered.

3. A method of identifying a test compound as a potential anti-cancer or anti-glioma drug, comprising the step of:

contacting a test compound with a cell which expresses plasmalemma vesicle associated protein monitoring an expression product of the plasmalemma vesicle associated protein; and
 identifying the test compound as a potential anti-cancer drug if it decreases the expression of the plasmalemma vesicle associated protein.

4. A method to aid in diagnosing glioma, comprising the steps of:

detecting an mRNA of at least one gene in a first brain tissue sample suspected of being neoplastic wherein said at least one gene is identified by a tag selected from the group consisting of SEQ ID NO: 1-32; and
 comparing expression of the at least one gene in the first brain tissue sample with expression of the at least one gene in a second brain tissue sample which is normal, wherein increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample identifies the first brain tissue sample as likely to be neoplastic.

5. A method of identifying a test compound as a potential anti-cancer or anti-glioma drug, comprising the step of:

contacting a test compound with a cell which expresses an mRNA of at least one gene identified by a tag selected from the group consisting of SEQ ID NO: 1-32;
 monitoring an mRNA of the at least one gene; and
 identifying the test compound as a potential anti-cancer drug if it decreases the expression of the at least one gene.

6. Plasmalemma vesicle associated protein or a nucleic acid encoding plasmalemma vesicle associated protein for use in inducing an immune response to a glioma.

7. The method of claim 1 or 4 wherein the increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is at least two-fold higher; preferably at least five-fold higher; more preferably at least ten-fold higher.

8. The method of claim 1, 2 or 5 wherein the expression product is RNA or protein.

9. The method of claim 1 or 3 wherein the first and second tissue samples are from a human, especially from the same human.
10. The antibody of claim 2 wherein the antibody is conjugated to a diagnostic or therapeutic reagent.
11. The antibody of claim 2 wherein the glioma is multidrug-sensitive, and/or wherein the glioma is in a human.
12. The antibody of claim 2 wherein the reagent is a chemotherapeutic agent; or a cytotoxin; or a non-radioactive label; or a radioactive compound.
13. The method of claim 2 or 5 wherein the cell is a human cell and/or a glioma cell,
14. The method of claim 2 or 5 wherein the cell overexpresses the at least one gene relative to a normal cell of the same tissue.
15. The method of claim 2 or 5 wherein expression of at least one, preferably at least two, more preferably three additional genes selected from the group consisting of signal sequence receptor, delta (translocon-associated protein delta); DC2 protein; KIAA0404 protein; symplekin; Huntingtin interacting protein I; plasmalemma vesicle associated protein; KIAA0726 gene product; latexin protein; transforming growth factor, beta 1; hypothetical protein FLJ22215; Rag C protein; hypothetical protein FLJ23471; N-myristoyltransferase 1; hypothetical protein dJ1181N3.1; ribosomal protein L27; secreted protein, acidic, cysteine-rich (osteonectin); Hs 111988; Hs 112238; laminin, alpha 5; protective protein for beta-galactosidase (galactosialidosis); Melanoma associated gene; Melanoma associated gene; E3 ubiquitin ligase SMURF1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; collagen, type IV, alpha 1; insulin-like growth factor binding protein 7; gene predicted from cDNA with a complete coding sequence; Thy-1 cell surface antigen; Hs 127824; GTP binding protein 2; Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918); cutaneous T-cell lymphoma-associated tumor antigen se20-4; differentially expressed nucleolar TGF-beta1 target protein (DENTT); dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive); smoothelin; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); putative translation initiation factor; retinoic acid induced 14; matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase); Lutheran blood group (Auberger b antigen included); stanniocalcin 2; nuclear factor (erythroid-derived 2)-like 2; protein tyrosine phosphatase, non-receptor type 1; integrin, alpha 10; collagen, type VI, alpha 2; chromosome 21 open reading frame 25; CDC37 (cell division cycle 37, *S. cerevisiae*, homolog); Hs 16450; Rho guanine nucleotide exchange factor (GEF) 7; creatine kinase, brain; hypothetical protein FLJ10297; hypothetical protein FLJ10350; TNF-induced protein; tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein); cofilin 1 (non-muscle); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated); v-ets avian erythroblastosis virus E26 oncogene homolog 1; protease, cysteine, 1 (legumain); ribosomal protein L13; chromosome 22 open reading frame 5; zinc finger protein 144 (Mel-18); degenerative spermatocyte (homolog *Drosophila*; lipid desaturase); eukaryotic translation initiation factor 2C, 2; mitochondrial ribosomal protein L45; prostate tumor over expressed gene 1; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a); glioma endothelial marker 1 precursor; NS1-binding protein; ribosomal protein L38; tuftelin-interacting protein; HLA class II region expressed gene KE2; translocase of inner mitochondrial membrane 17 homolog A (yeast); sudD (suppressor of bimD6, *Aspergillus nidulans*) homolog; heparan sulfate proteoglycan 2 (perlecan); SEC24 (*S. cerevisiae*) related gene family, member A; NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase); DNA segment on chromosome X and Y (unique) 155 expressed sequence; annexin A2; Homo sapiens clone 24670 mRNA sequence; hypothetical protein; matrix metalloproteinase 10 (stromelysin 2); KIAA1049 protein; G protein-coupled receptor; hypothetical protein FLJ20401; matrix metalloproteinase 14 (membrane-inserted); KIAA0470 gene product; solute carrier family 29 (nucleoside transporters), member 1; stanniocalcin 1; stanniocalcin 1; stanniocalcin 1; tumor suppressor deleted in oral cancer-related 1; tumor suppressor deleted in oral cancer-related 1; apolipoprotein C-I; glutathione peroxidase 4 (phospholipid hydroperoxidase); Hs 272106; transcription factor binding to IGHM enhancer 3; hypothetical protein DKFZp762A227; hypothetical protein FLJ22362; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); PRO0628 protein; melanoma-associated antigen recognised by cytotoxic T lymphocytes; LOC88745; Homo sapiens beta-1,3-galactosyltransferase-6 (B3GALT6) mRNA, complete cds; sprouty (*Drosophila*) homolog 4; sprouty (*Drosophila*) homolog 4; Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone DKFZp434E1515); coactosin-like protein; hypothetical protein FLJ21865; Hs296234; KIAA0685 gene product; hypothetical protein FLJ10980; ribosomal protein L10; ribosomal protein S19; Hs 299251; Huntingtin interacting protein K; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 50374; Hs 311780; Hs 212191; v-akt murine thymoma viral oncogene homolog 2; Hs 328774; transducin-like enhancer of split 2, homolog of *Drosophila*

E(sp1); KIAA1870 protein; ribosomal protein L10a; peptidylprolyl isomerase A (cyclophilin A); Hs 344224; hypothetical protein FLJ23239; hypothetical protein DKFZp761H221; KIAA1887 protein; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 701679; Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453; Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035904; hypothetical protein LOC57333; myosin ID; plexin B2; lectin, galactoside-binding, soluble, 8 (galectin 8); double ring-finger protein, Dorfin; DKFZP434B168 protein; LIM domain binding 2; integrin beta 4 binding protein; synaptopodin; Hs 54828; insulin induced gene 1; acetyl LDL receptor; SREC; excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); hypothetical protein FLJ22329; schwannomin-interacting protein 1; PTEN induced putative kinase 1; myosin X; Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97; golgi phosphoprotein 1; splicing factor, arginine/serine-rich 6; laminin, gamma 3; cysteine-rich protein 2; U6 snRNA-associated Sm-like protein LSm7; hypothetical protein FLJ10707; Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene, clone IMAGE:3342825, mRNA, partial cds; macrophage migration inhibitory factor (glycosylation-inhibiting factor); ubiquinol-cytochrome c reductase hinge protein; gap junction protein, alpha 1, 43kD (connexin 43); dihydropyrimidinase-like 3; aquaporin 1 (channel-forming integral protein, 28kD); protein expressed in thyroid; macrophage myristoylated alanine-rich C kinase substrate; procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI); protease, serine, 11 (IGF binding); 24-dehydrocholesterol reductase; collagen, type IV, alpha 2; profilin 1; apolipoprotein D; hyaluronoglucosaminidase 2; hypothetical protein FLJ22678; quiescin Q6; ras homolog gene family, member A; ras homolog gene family, member A; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; uridine phosphorylase; KIAA0638 protein; B7 homolog 3; lamin A/C; lamin A/C; regulator of G-protein signalling 12; proteasome (prosome, macropain) 26S subunit, non-ATPase, 8; Homo sapiens, Similar to RIKEN cDNA 5730528L13 gene, clone MGC: 17337 IMAGE:4213591, mRNA, complete cds; prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy); laminin, alpha 4; transcription elongation factor A (SII), 1; lectin, galactoside-binding, soluble, 3 binding protein; ribosomal protein S16; glycophorin C (Gerbich blood group); endothelin receptor type B; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; biglycan; small nuclear ribonucleoprotein polypeptide B"; transmembrane 4 superfamily member 2; TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD; lysyl oxidase-like 2; SRY (sex determining region Y)-box 4; SOX4 SRY (sex determining region Y)-box 4; SRY (sex determining region Y)-box 4; actin related protein 2/3 complex, subunit 2 (34 kD); Homo sapiens cDNA: FLJ23507 fis, clone LNG03128; hypothetical protein FLJ12442; Fas (TNFRSF6)-associated via death domain; mitogen-activated protein kinase kinase kinase 11; TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); insulin receptor; cell membrane glycoprotein, 110000M(r) (surface antigen); Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926; jagged 1 (Alagille syndrome); KIAA0304 gene product; pre-B-cell leukemia transcription factor 2; Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864; p53-induced protein; complement component 1, q subcomponent, receptor 1; complement component 1, q subcomponent, receptor 1; apolipoprotein E; chemokine (C-C motif) ligand 3; coagulation factor II (thrombin) receptor-like 3; coagulation factor III (thromboplastin, tissue factor); collagen, type I, alpha 1; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 9; cystatin C (amyloid angiopathy and cerebral hemorrhage); endoplasmic reticulum associated protein 140 kDa; ESTs; ESTs; ESTs, Highly similar to hypothetical protein FLJ10350 [Homo sapiens] [H.sapiens]; ESTs, Highly similar to ITB1_HUMAN Integrin beta-1 precursor (Fibronectin receptor beta subunit) (CD29) (Integrin VLA-4 beta subunit) [H.sapiens]; ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]; ESTs, Weakly similar to T17346 hypothetical protein DKFZp586O1624.1 - human (fragment) [H.sapiens]; ESTs, Weakly similar to T21371 hypothetical protein F25H8.3 - Caenorhabditis elegans [C.elegans]; eukaryotic translation initiation factor 4A, isoform 1; heme oxygenase (decycling) 1; Hermansky-Pudlak syndrome 4; Homo sapiens cDNA FLJ34888 fis, clone NT2NE2017332; Homo sapiens cDNA FLJ39848 fis, clone SPLEN2014669; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059; Homo sapiens, clone IMAGE:4845226, mRNA; hypothetical protein FLJ22329; hypothetical protein FLJ32205; hypothetical protein MGC4677; inhibin, beta B (activin AB beta polypeptide); insulin-like growth factor binding protein 5; junction plakoglobin; KIAA0620 protein; KIAA0943 protein; likely ortholog of rat vacuole membrane protein 1; Lysosomal-associated multispinning membrane protein-5; major histocompatibility complex, class I, B; major histocompatibility complex, class I, C; matrix Gla protein; matrix metalloproteinase 1 (interstitial collagenase); microtubule-associated protein 1 light chain 3 beta; nerve growth factor receptor (TNFR superfamily, member 16); ribosomal protein S9; ring finger protein 40; S100 calcium binding protein, beta (neural); sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B; SPARC-like 1 (mast9, hevin); tumor necrosis factor, alpha-induced protein 3; UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 3; UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5; von Willebrand factor; v-akt murine thymoma vial oncogene homolog 2; cyclin-dependent kinase (cdc2-like) 10; ortholog mouse myocytic induction/differentiation originator; brain-specific angiogenesis in-

hibitor 1 ; EGF-TM7 latrophilin-related protein; sema domain ; integrin, alpha 5 ; likely ortholog of mouse fibronectin type III; Lutheran blood group (Aubergier b antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member 16); insulin-like growth factor binding protein; leukemia inhibitory factor; protein tyrosine phosphatase, nonreceptor type I; and Homo sapiens, clone IMAGE:3908182, mRNA, partial cds; is monitored.

- 5
16. The method of claim 2 or 5 wherein the test compound is identified if the decrease in expression is at least 50%, preferably at least 80%, more preferably at least 90%.
- 10
17. The method of claim 2 or 5 wherein the test compound is identified as an anti-glioma drug.
- 15
18. A nucleic acid encoding plasmalemma vesicle associated protein, according to claim 6, wherein the nucleic acid is for intramuscular administration.
- 20
19. Plasmalemma vesicle associated protein or a nucleic acid encoding plasmalemma vesicle associated protein, according to claim 6, wherein the plasmalemma vesicle associated protein or nucleic acid encoding the plasmalemma vesicle associated protein is for administration with an immune adjuvant.
- 25
20. Plasmalemma vesicle associated protein or a nucleic acid encoding plasmalemma vesicle associated protein, according to claim 6, wherein the plasmalemma vesicle associated protein or nucleic acid encoding the plasmalemma vesicle associated protein is for administration to a mammal, or a mammal from which a glioma has been surgically removed.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 60403390 B [0001]
- US 60458978 B [0001]
- US 61075181 B, Kucherlapati [0017]

Non-patent literature cited in the description

- **Bart, J. ; Groen, H. J. ; Hendrikse, N. H. ; van der Graaf, W. T. ; Vaalburg, W. ; de Vries, E. G.** The blood-brain barrier and oncology: new insights into function and modulation. *Cancer Treat Rev*, 2000, vol. 26, 449-62 [0004] [0005] [0061]
- **Vajkoczy, P. ; Menger, M. D.** Vascular microenvironment in gliomas. *J Neurooncol*, 2000, vol. 50, 99-108 [0005] [0061]
- **Bernsen, H. J. ; Rijken, P. F. ; Oostendorp, T. ; van der Kogel, A. J.** Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. *Br J Cancer*, 1995, vol. 71, 721-6 [0005] [0061]
- **Vick, N. A. ; Bigner, D. D.** Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. *J Neurol Sci*, 1972, vol. 17, 29-39 [0005] [0061]
- **Hobbs, S. K. ; Monsky, W. L. ; Yuan, F. ; Roberts, W. G. ; Griffith, L. ; Torchilin, V. P. ; Jain, R. K.** Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci U S A*, 1998, vol. 95, 4607-12 [0005] [0061]
- **Vajkoczy, P. ; Schilling, L. ; Ullrich, A. ; Schmiedek, P. ; Menger, M. D.** Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifuorescence microscopic approach in the athymic nude mouse. *J Cereb Blood Flow Metab*, 1998, vol. 18, 510-20 [0005] [0061]
- **Holash, J. ; Maisonpierre, P. C. ; Compton, D. ; Bolland, P. ; Alexander, C. R. ; Zagzag, D. ; Yancopoulos, G. D. ; Wiegand, S. J.** Vessel cooption, regression, and growth in tumors mediated by angiopeptides and VEGF. *Science*, 1999, vol. 284, 1994-8 [0005] [0061]
- **Guerin, C. ; Wolff, J. E. ; Laterra, J. ; Drewes, L. R. ; Brem, H. ; Goldstein, G. W.** Vascular differentiation and glucose transporter expression in rat gliomas: effects of steroids. *Ann Neurol*, 1992, vol. 31, 481-7 [0005] [0060] [0061]
- **St Croix, B. ; Rago, C. ; Velculescu, V. ; Traverso, G. ; Romans, K. E. ; Montgomery, E. ; Lal, A. ; Riggs, G. J. ; Lengauer, C. ; Vogelstein, B.** Genes expressed in human tumor endothelium. *Science*, 2000, vol. 289, 1197-202 [0006] [0041] [0043] [0061]
- **Nina D. Russel ; Jose R. F. Corvalan ; Michael L. Gallo ; C. Geoffrey Davis ; Liise-Anne Pirofski.** Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci. *Infection and Immunity*, April 2000, 1820-1826 [0017]
- **Michael L. Gallo ; Vladimir E. Ivanov ; Aya Jakobovits ; C. Geoffrey Davis.** The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans European. *Journal of Immunology*, 2000, vol. 30, 534-540 [0017]
- **Larry L. Green.** Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. *Journal of Immunological Methods*, 1999, vol. 231, 11-23 [0017]
- **Yang X-D ; Corvalan JRF ; Wang P ; Roy CM-N ; Davis CG.** Fully Human Anti-interleukin-8 Monoclonal Antibodies: Potential Therapeutics for the Treatment of Inflammatory Disease States. *Journal of Leukocyte Biology*, 1999, vol. 66, 401-410 [0017]
- **Yang X-D ; Jia X-C ; Corvalan JRF ; Wang P ; CG Davis ; Jakobovits A.** Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy. *Cancer Research*, 1999, vol. 59 (6), 1236-1243 [0017]
- **Jakobovits A.** Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci. *Advanced Drug Delivery Reviews*, 1998, vol. 31, 33-42 [0017]
- **Green L ; Jakobovits A.** Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. *J. Exp. Med.*, 1998, vol. 188 (3), 483-495 [0017]

- **Jakobovits A.** The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. *Exp. Opin. Invest. Drugs*, 1998, vol. 7 (4), 607-614 [0017]
- **Tsuda H ; Maynard-Currie K ; Reid L ; Yoshida T ; Edamura K ; Maeda N ; Smithies O ; Jakobovits A.** Inactivation of Mouse HPRT locus by a 203-bp retrotransposon insertion and a 55-kb gene-targeted deletion: establishment of new HPRT-Deficient mouse embryonic sGEM cell lines. *Genomics*, 1997, vol. 42, 413-421 [0017]
- **Sherman-Gold, R.** Monoclonal Antibodies: The Evolution from '80s Magic Bullets To Mature, Mainstream Applications as Clinical Therapeutics. *Genetic Engineering News*, August 1997, vol. 17 (14) [0017]
- **Mendez M ; Green L ; Corvalan J ; Jia X-C ; Maynard-Currie C ; Yang X-d ; Gallo M ; Louie D ; Lee D ; Erickson K.** Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. *Nature Genetics*, 1997, vol. 15, 146-156 [0017]
- **Jakobovits A.** Mice engineered with human immunoglobulin YACs: A new technology for production of fully human antibodies for autoimmunity therapy. *Weir's Handbook of Experimental Immunology, The Integrated Immune System*, 1996, vol. IV, 194.1-194.7 [0017]
- **Jakobovits A.** Production of fully human antibodies by transgenic mice. *Current Opinion in Biotechnology*, 1995, vol. 6 (5), 561-566 [0017]
- **Mendez M ; Abderrahim H ; Noguchi M ; David N ; Hardy M ; Green L ; Tsuda H ; Yeast S ; Maynard-Currie C ; Garza D.** Analysis of the structural integrity of YACs comprising human immunoglobulin genes in yeast and in embryonic sGEM cells. *Genomics*, 1995, vol. 26, 294-307 [0017]
- **Jakobovits A.** YAC Vectors: Humanizing the mouse genome. *Current Biology*, 1994, vol. 4 (8), 761-763 [0017]
- **Arbones M ; Ord D ; Ley K ; Ratech H ; Maynard-Curry K ; Otten G ; Capon D ; Tedder T.** Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. *Immunity*, 1994, vol. 1 (4), 247-260 [0017]
- **Green L ; Hardy M ; Maynard-Curry K ; Tsuda H ; Louie D ; Mendez M ; Abderrahim H ; Noguchi M ; Smith D ; Zeng Y.** Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. *Nature Genetics*, 1994, vol. 7 (1), 13-21 [0017]
- **Jakobovits A ; Moore A ; Green L ; Vergara G ; Maynard-Curry K ; Austin H ; Klapholz S.** Germ-line transmission and expression of a human-derived yeast artificial chromosome. *Nature*, 1993, vol. 362 (6417), 255-258 [0017]
- **Jakobovits A ; Vergara G ; Kennedy J ; Hales J ; McGuinness R ; Casentini-Borocz D ; Brenner D ; Otten G.** Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production. *Proceedings of the National Academy of Sciences USA*, 1993, vol. 90 (6), 2551-2555 [0017]
- **Schultz et al.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 5857-5864 [0022]
- **BaGEMan et al.** *Nucleic acids Res.*, 2000, vol. 28, 263-266 [0022]
- **Nielsen et al.** *Protein Engineering*, 1997, vol. 10, 1-6 [0022]
- **Jagla.** *Bioinformatics*, 2000, vol. 16, 245-250 [0022]
- **Nakai, K ; Horton, P.** *Trends in Biochem. Sci.*, 1999, vol. 24, 34-35 [0022]
- **Pasquier.** *Protein Eng.*, 1999, vol. 12, 381-385 [0022]
- **Sonnhammer et al.** *Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology*. CA: AAAI Press, 1998, 175-182 [0022]
- **Klein.** *Biochim. Biophys. Acta*, 1985, vol. 815, 468 [0022]
- **Nakai ; Kanehisa.** *Genomics*, 1992, vol. 14, 897-911 [0022]
- **Altschul.** *Nucleic Acid Res.*, 1997, vol. 25, 3389-3402 [0023]
- **BaGEMan.** *Nucleic Acids Res.*, 1999, vol. 27, 260-262 [0023]
- **Henikoff.** *Nucl. Acids Res.*, 2000, vol. 28, 228-230 [0023]
- **Ponting.** *Nucleic Acid Res.*, 1999, vol. 27, 229-232 [0023]
- **Chen, H. ; Centola, M. ; Altschul, S. F. ; Metzger, H.** Characterization of gene expression in resting and activated mast cells. *J Exp Med*, 1998, vol. 188, 1657-68 [0044] [0061]
- **Huminiecki, L. ; Bicknell, R.** In silico cloning of novel endothelial-specific genes. *Genome Res*, 2000, vol. 10, 1796-806 [0052] [0061]
- **Tamagnone, L. ; Artigiani, S. ; Chen, H. ; He, Z. ; Ming, G. I. ; Song, H. ; Chedotal, A. ; Winberg, M. L. ; Goodman, C. S. ; Poo, M.** Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. *Cell*, 1999, vol. 99, 71-80 [0057] [0061]
- **Bowers, D. C. ; Fan, S. ; Walter, K. A. ; Abounader, R. ; Williams, J. A. ; Rosen, E. M. ; Laterra, J.** Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. *Cancer Res*, 2000, vol. 60, 4277-83 [0057]
- **Lamszus, K. ; Laterra, J. ; Westphal, M. ; Rosen, E. M.** Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. *Int J Dev Neurosci*, 1999, vol. 17, 517-30 [0057] [0061]

- **Abounader, R. ; Lal, B. ; Luddy, C. ; Koe, G. ; Davidson, B. ; Rosen, E. M. ; Laterra, J.** In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. *Faseb J*, 2002, vol. 16, 108-10 [0057] [0061]
- **Shinoura, N. ; Shamraj, O. I. ; Hugenholtz, H. ; Zhu, J. G. ; McBlack, P. ; Warnick, R. ; Tew, J. J. ; Wani, M. A. ; Menon, A. G.** Identification and partial sequence of a cDNA that is differentially expressed in human brain tumors. *Cancer Lett*, 1995, vol. 89, 215-21 [0057] [0061]
- **Stan, R. V. ; Arden, K. C. ; Palade, G. E.** cDNA and protein sequence, genomic organization, and analysis of cis regulatory elements of mouse and human PLVAP genes. *Genomics*, 2001, vol. 72, 304-13 [0058] [0061]
- **Marx, J.** Caveolae: a once-elusive structure gets some respect. *Science*, 2001, vol. 294, 1862-5 [0058] [0061]
- **Smith, R. M. ; Jarret, L.** *Lab. Invest.*, 1988, vol. 58, 613-629 [0060] [0061]
- **Roberts, W. G. ; Palade, G. E.** Neovasculature induced by vascular endothelial growth factor is fenestrated. *Cancer Res*, 1997, vol. 57, 765-72 [0060] [0061]
- **Abounader, R. ; Lal, B. ; Luddy, C. ; Koe, G. ; Davidson, B. ; Rosen, E. M. ; Laterra, J.** In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. *Faseb J*, 2002, vol. 16, 108-10 [0061]
- **Bowers, D. C. ; Fan, S. ; Walter, K. A. ; Abounader, R. ; Williams, J. A., Rosen, E. M. ; Laterra, J.** Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT- dependent pathways. *Cancer Res*, 2000, vol. 60, 4277-83 [0061]

专利名称(译)	脑内皮细胞表达模式		
公开(公告)号	EP2236614A2	公开(公告)日	2010-10-06
申请号	EP2010168014	申请日	2003-08-15
[标]申请(专利权)人(译)	建新公司 约翰霍普金斯大学		
申请(专利权)人(译)	Genzyme公司 约翰·霍普金斯大学		
当前申请(专利权)人(译)	Genzyme公司 约翰·霍普金斯大学		
[标]发明人	MADDEN STEPHEN WANG CLARENCE COOK BRIAN LATTERA JOHN WALTER KEVIN		
发明人	MADDEN, STEPHEN WANG, CLARENCE COOK, BRIAN LATTERA, JOHN WALTER, KEVIN		
IPC分类号	C12Q1/00 C12Q1/68 C12Q1/70 G01N33/53 G01N33/567 G01N33/569 C12N5/09 G01N33/574		
CPC分类号	A61P25/00 A61P35/00 A61P37/04 C12N5/0693 C12Q1/6886 C12Q2600/112 C12Q2600/136 G01N33/57407 G01N33/57484 G01N2500/00		
优先权	60/403390 2002-08-15 US 60/458978 2003-04-01 US		
其他公开文献	EP2236614A3		
外部链接	Espacenet		

摘要(译)

为了更好地了解脑肿瘤血管生成，开发了分离脑内皮细胞（EC）和评估基因表达模式的新技术。当将来自正常和恶性结肠直肠组织的脑EC的转录物与来自非内皮细胞的转录物进行比较时，鉴定了主要在内皮中表达的基因。正常和肿瘤来源的内皮之间的比较揭示了在肿瘤相关的脑内皮中特异性升高的基因。这些结果证实，人脑中的肿瘤和正常内皮在分子水平上是不同的，并且对于未来抗血管生成疗法的发展具有重要意义。

```

SEQUENCE LISTING
<110> genzyme corporation
The Johns Hopkins university
<120> BRAIN ENDOTHELIAL EXPRESSION PATTERNS
<130> 003482.00010
<140> PCT/US03/25614
<141> 2003-08-15
<150> US 60/403,390
<151> 2002-08-15
<150> US 60/458,978
<151> 2003-04-01
<160> 869
<170> FastSEQ for windows version 4.0
<210> 1
<211> 10
<212> DNA
<213> Homo sapiens
<400> 1
aaaccattct 10
<210> 2
<211> 10
<212> DNA
<213> Homo sapiens
<400> 2
aaggcaggga 10
<210> 3
<211> 10
<212> DNA
<213> Homo sapiens
<400> 3
acacagcaag 10
<210> 4
<211> 10
<212> DNA
<213> Homo sapiens
<400> 4
agctgggtc 10
<210> 5
<211> 10
<212> DNA
<213> Homo sapiens
<400> 5
agctggcacc 10
<210> 6
<211> 10
<212> DNA
<213> Homo sapiens

```